var title_f4_1_4112="Normal optic disc";
var content_f4_1_4112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The normal optic disc",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 277px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The margins are distinct, the rim has a pinkish color, and there is a central pale cup (arrows). This optic disc has a cup:disc ratio of 0.2.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl C Golnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_1_4112=[""].join("\n");
var outline_f4_1_4112=null;
var title_f4_1_4113="Geographic tongue";
var content_f4_1_4113=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Geographic tongue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 300px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEsAQoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDhNUQRyRY85bgjAVRuwCc8A456cH1rL1PeiKkZPnzHo/8AD+A+n0q7cSpJM+CWAJbco659j26DPtWNLI19cySzSBWjwueSW9fXtx17GkrWN5ajoUSAIsYQsgAB67gOp+h/HtVHUJWLkbV3EYOOMdP/AK1asUZtrTeu1cxno33cev6Vzwk3IxZiSW4IrmmzeCsNZiqAAYJ6+9JCY9wLEhOSQOaST5pNq/Nxmnxx5H3cgE5IrJbGth6btm3BIzxx/n2p+Cu7Lc9CKdHGZEPJypGPepUwrksGyOASKkfmPt4HmkZESRnYbgAM9Bz/ACJp0JXABI5Axx2pwIBJBAJ7/wCfxqFtrztkDygOPU1SJbLiqvmMseCDzuPb3zV2JsxIJefLTIKEd+ep/D1rN+0NJMkaqByM4Hbv/SrECsoHDg9Qf8/jVoh6mhAHaZWQlDHyHDEDOOWJ+ueeKuwzbbeN3lV2J6MhHU89eTnimWNuZY2RoiCFZ1wCSf8ADp1q7DpkcjRrAsgyw3naDgj8+O1aLYkqSzSy7VzFGpYAqBgDB4B9f51BJdXKySRmSSQYwQzFgw/HHGSTmt640KYRbGQhS20YAwfoOoPIHp9etN1DRWVbfBiRZSWJVssQcAZwfbHb3HQ0g0OckugkS5V0QHLLjv79uneknu8zqdu3nkjrn/8AVVo6e0aqMqEYYZg2M+/sKa9osUojZV3dME5J44/DmouVYx5JueGO8LwQMYz9PwqvcSKzKGLE7Tksa2pbdHJkOAo4K5xt+nTNZ11Dw6KAVTk8gAZNJsaRTLoYyd3O3jjp/wDXqIlSAW/i9T0qV7JmjJQgADrnOM1CIyzKGBzzyRkAVJWpFIuHDHbzk4U8D/PpUbJ8pABK9MCpdpDMozlTkk9TURZnUbsZAxgd6B3IJAVJJBGecUzaV+btjgelTzRlQGAK/XvUJ3bWLYA9TVITGoQfvHI6A1btZCCBxkevpVLfgbl65weelPVhv3NnavJyeop2FdGn5u5dwXG0Eg45Hamm4ZJdwOA4+ZGGcnGAajtZFLkkDI6c9KbMCyyMzM2ehzWkHYzmkzVtbkN94hUPVe7H/OOKsrM64RkjXsSp5z9On41h2zcop2Hrk9xkc1dCBowQcgDAVj1/+vTqChqi5JckIyRSZkOAccZH+RUPls3OVOee1MmVHZArA7Rhj0/z3pCCScD8lFcsr9DoWxevr1/Lyxi87++G9R044qja5ZSVdjkbnT146fqf1qldncyY4JIJGc8ev/1quovl4LYUp0AHUeprrlL3TlS1HXbqI8jr0OeP89+ayGIU5xnJxV++lYoofsOtZ7jIOevXINc/W5utB0eYwGBz261MVDcx5Oeff0/wqBF+fO3IqTaEAdC390/TNJjRajLblH8Kj0x+H86eQVfDcHJyF5x3/wA/jTVchduAMHJB70loomk3SFcY+9mpQ7kjFmKt8rEtwAfXtzVqxtBKjys+Xj/Ie+fz4qN4YxlVb5gc5Hr7U5I5XiULvKh8E9v89K1hHQiT7Fq1tVZ48xMdwxvL44+v07VYjiMXMLAgfKGCsc+w45/lVcNhYxw0iMVwvTr6961bVpHijVJMjcFZME4PrW8YJGfMSi5YGGSTznJXA3qFAPqMH0ra8PzSGVlCLLIH8xVCFhk8Dg4yfpmoDNb/AGR2vlMaA7dqJkj/AOuTx3rqbS1tY4FuEtr25d2CQ9iR3+Xpj6+tacpDkS6bazeRE7WcpZd5mRYgFbng4IJwD79vwrT1PTIbbTP3U9rMMYMiSKrhic4Dd8ZHH16Vp6jpsdsIhGsds0DLIqSMkgUsBx0yw4yRWTdwrFcX0Ud1eidSzFFsPlOT9/mPGOQB061TinuZqTPMfEl2FMkCxvvbBVuTjqPToetYRllW4QgT+YpBGc10Gq6Wn2yNvL1BssFbzSsZyPvccYFZGpRiG/CrH8ytjb5m7cCM5znrgiudwsdEZGdOzOw4JPQcdKimZTMxfIUqBmlZ2ilkyrAIeuex/wD10gk3yAqoGSCPz/8ArVnY0uMlMkUAAbGTUSXEqOysAysMMSM55qa5d3ALAhfTtVeR1aRjGhVOMKxyaErgM3CRichSeAG5AqJzwrKy4HTnnNPmiDRoVyMHP51W2bTGTg45x2pcoXJpX3gLnIB67eTVWTALbuSewPT6U9ZQUKt8p6g5/OoZj83Hft/9ely2EMc/KOmAcdeaYGyx7A+o4PpUiKHDELkBen+P5VFk8qxBQc81oiCzZufMwPlz6mrRlk3hhgjoB19v8KoW4G/AKkbumf0q+6BUY5yAOvrSvZj3RHgpJt6ZGCR69f5VaikLIMDcwGPmOMVTdgVDHdjjvUyEcnaCD6Dirl7yRMNGXTcGQgkrwe46/jTd8v8ACBjtzVdGUPj1qQq2eDx9K5pbnQhsbZu5ijABEwVzu4zn/CrrSPHGqu7FTgYx6c8f59aoWe3MjNkgt9MirIOEbeSz+nSt5tnPFFa5VpCyLGzEcAA5zjr/ACqiMA5C7mxxVy4laJFkV9jMMEIcHBGD/Wq8xBUHBAOM85A45/pUJF81hwJG3HGckj0//XzUpLxqVONoP4VCpJJ3DOCB9adIwCck4796hoq6H+Zh/m598dfSoYVnF6SJP3ZGCOm6hWLphT8pP5+1W4kOwHB6Ef5/KtIrlJepctUdgqZJzlQh796uQySIPJVmCKC2AMbSP8iq4lje3iUAhuBuPGKIruNIxIXG4nBA9M9zVpdhSaLau4gDBzGc8EHvUcWo3EG1E8zcX+YKev8An1rLvdYhiVxKUaRvmAOc7s9cCm6PFqOvXYXT4WjUkHdnbz64FXrFXZK952idteeI2050Z4xAkjBwGGd23gg57c/qKtR+Pdto8lv5CFm2hl4bB6jj3PX68V03hj4LXmoWqS61qMkSHJVQCxGT2yfWuut/gL4dEQEtzfSv8zM2VGBg4x+OCatSbXumT5V8TOFb4nT381qL+SIhvlkkHAVcYUY68DP555zVm48dWeoQgXl9Zi4bAM3lS5PUctu6YA9O1S+KvhLY6G6zuJLu2ZWyvnFBuKkAkryMHB/CvK9N0KHT9TaLULSa8X5C0Jb5nUsOBkHBPY4J6H2JGctmaKlGSvE37nVraK5eSHULVpk5Big3DPtubk9Tn1xWNeao87B57uWXdkMqBVGO3AGO1eifC/wJIqSx3FlYPDfxEmN40maONiCpL9VYFQQOCOpHNe26f4L0aDe0tjbytLgy4jCh+c84qdZbClJU9z40urmFGYrJcE5ydxxnt0/KoUvrUEiSdkUDjMnII9ifpX2JrPw10G/ik8i1WBz3CgivAvip8OxpYkKwhVALKwXgj2pcri9TSDjUVovU86juS43pIzL2xhh+lTgTmIzEKFJ27mJGfpmuXt7VSSI9ySA9VODV03d7AqxtIZo16BjzVcqMuaS3NOaRXb93FIGHXjO0D3H0piyARcEMxB461Wh1eJmAmjET+rd8+9XTGsqx+UgbPVx1596nkKUyoFDsgQcseucfr/Wo7pXt5pY5DGX3Yyjhx+BHBHvVyS0ETbRKvmY5XGMewPeqMyHKqVyMdalq25VyNRgtkjBGSCaCSXUkkgnGaTlWCkjkdTTnA2qUYDjIA/h//XRYljI2zOSFCAtnC8AVsAKbSUA9gc+3+cVjw7UYbz7mr8av5ThSRz09amRUWODJt4GMjaQFohO1M78c7eT/ADpgBYcKSD0GaarEucHJHGKvSxPUtHnBH3V+Wmeb/tH/AL6pYwUHzcBv4qQSKBjZ+hrnZ0J6E9hEQoJ68kbvTP8A+urBfAwwIDjOen4fSoYFAQNn5duOe5/zmnSy5iLFflXjHp9K0nuYx2KUy7cAfMTxwc4qtGN6/LjcDjJNTXMmxzgYUYAC9Bgdf51EMqrYXhj0BpiuS7yFZzk5Hc1X85mI54zzzUknmS4hhQttXcwx0A6n6daigVQBuztJ+YjnFNR6jTNG0iyS6KxVBk7RWnOYVEJhuFElwcvEVGFAPA3dOcDnjrzWEtwPN+XKL655H4/nU14BNCi21uWlK85Py4/vN7+1XGPcUn0QX12lu0kckhZR8qoOfwqgnn3RwN0UZ/gU8n6mqhQ28refkzE8sf6Ves7hexzn3q/QztrqMngjgiYoiqcY4FfQ37O3h6Ke3F7KgKIoIyO9fPl+26FgByBX1b+zNC83w1iupI9glndEz3CcZ/PNQ1zNFSlyQaR6sABgD8AKcOnenBQrHOeKXditG2jkSM/VbOO+spYpM8qdpA/i7V8zePbrWNK8V6jNb3c1td3QQSNB8hbEgI6dOQDx6V9T7A/btXzx8Z77T4/GV3AXQXFnFG0gb1IDDP4EVE31OrCO8uVo9Y+GmlJpXhi0Xy9txIodznHBA4rrwpPPAH0rL8I3lvq3hvTtStMG3uYEkQj0I6fzFbRBB6YFNaIwm+aTbIhuHYGuV+J+mRaj4RvWkQboEMmQOgHWutIPpT7iyjvLWa2uUDwzI0bqejKRgindtCi+WSaPz1t41aaUqQQZDtPtmpL2EL1ABH60t9HFpHiDUdP5/wBEupYBk4+4xXp+FFzKLmFmjxkdSSBULyO1pNGbKmYWJAKjse1aOi6dfBo3sEZ84LRKevuPf2rW8J+Fb3xFfra2MbSx5wWC9fX6Cvp74b/DKz0C2Et8oluyB7gU05N2REuWKvI+UNVtbmznK3CPGx7OMEVDFIjxAE7pCeeOK+ovjt4X0+bwzd3yxRxzwRllcDGPr7c18nKsm1pDGy7G2uQMqD7Gh32ZMGpK6JJ0y+MnA9BS27DaRkENjAIxikkcngDHSq7ZRgc4A5JpDZajAR+ikk8nHAq3GO5GT1A/p+tVw3mISqADbzjufX9ani+6CMe7Z/z7VLCIM3ylYnK8Hr606MqZv3f3SAT2zQfmGBtKZyQacVBIbGQV7DA49KOhVtUSOTyuPmUYwO9GD2I/Ol6EOAxzz60mc87RWBui3agmNd6sS2Npz29TUfzFTvfsSQB/n2ptvkkrGxLr1H+f88UkhWNI9o5PVie/+cVrLcwWxUnJyWJAPR/pTWPBZCC3XbnH5UNlhl8DbzjPBqOQuIhuP3uOlNCZXScpch1G4jpkZx+dLI4iGUPBPr0qGIlHLDHtkdav+GrOLWfElnYzuFSV8YXjOP8A9VaWFeyJ/CFidd8SWVg5bY57dh1/x4r6z074YaA+lxxm2WNivLqOc461xlv8IdPt76y1jRb42k8GJW3t8jkc4PoTjFe16CwutMglQkqyg8Vp7Oz94551bpcrPnjxp8G7pXZ7GMzRg5UrwwFeOeJtCuPD84j1KGWIgnaZF2k/4199SiK2glmumSOCNC7ySHCoo5JJPQAZ5r4W+OXjeDxx41kuNNDDSrVfItiwwZBnJkx2yenfAGaXI49SlW5tGji5b8bdsSnHYsc19X/soeNtKu/BqeGbu6ig1aymkaKKRwpnjc7gVz1IJYEDJ6HvXyFjikxzTuKV2fpzLBuzt45ApptQQBu5+lfnVbeN/FdrDBFb+JdbihgIMUa30oRCOmF3YFbmofGL4g37Wxn8U36m3+55G2HP+9sA3/8AAs0aMizPv2KAIPmwa+F/2m5Ub41eIPJfIC26vg8ZEEfFZzfGj4htZtanxReeWy7SQkYfHs+3cD7g5rgLiaW6uJZ7mV5p5WLySSMWZ2JySSeSSe9FkCufdf7NOpWuqfB3REt5Veaz8y2nQHJjcSMQD9VZT9DXpjRRgksegycnHFfmrouu6voUskmiarf6bJIArtZ3DwlgOgJUjNRarql/q9615q19dX12wAaa5laVyB0BZiTRZAfoz4n8SaD4WsRfeINStbC34CmV+X9lUZLH6A8V5V42/aP8I6Xpcw8MSy6xqbKRCogeOFH7Fy4Ukey5z0yM5r4voxRogJbqea7upri5kaWeZzJI7HJZickn3Jo2yxBJVDKpJ2t2JFImBnNBHp+VK5aj1PqX9lvx3pF1aDw5qjW9rq6sTbsQEF0voDwN49O4/GvoqWP5iAK/M9GeJ1eNirqQysDggjvX0p8Kf2hfscVvpvjWSe5iCBFvAuZFP+3z8w9+v1qk0tCWm3dnufi7SLPXLb+zdSZhbTcsqjJfGDt9s461558TfDekaR4HvrawsooysJKBFwd54B+vSuI+L3xguLzxBp83gy5uLeztEJkeRNonY44x12gD9awtV+NEWqmwhvrOZBG++5yQQ5A4A/HFSpRldF8k4pNnmE1vc24WO9GJQcZPBqHZlsOOo4wa1vHOvW+sX8UtvtVAMgL1z71iW0u8jHQHioaSemxve6L8RKQgBsZ4IOMU9MKBhd2eG/D/ACKrhvn2hcg9RirsK/KNowxwDzxUMEiSLPG/nvgdOO5phZ2kBG7A5HtUiqrAg5GOnpQPlUbSfwPSpuV1JdudmSME846ioG3hj+5c89R3p5c4B6Huf8/jTgxIHEY/4DWNzoS0LMC+ZMqxoAz4A46moriKR3OCFPTB7+/61JCqtuGcsT1B9/8APNJO4VSH2+cANoPXAzn+f6Vt1OYzw20AMQwA61WuVyAM8+1WWC+YA3A9R19xUUrBsFVIIP0zVIkqT4VQpPTtitzw1a28ONSaeOKe2IkQM2Mkdv51y2pSZkCKenPFUpZJX273ZsdMk8VsvMiTtofQesfGZYfDYj0VHGoSjB3JlY/c56/Stz4Q/HHS9J0L7J43muI7iMkpcxwl1kBPQqo4I+mK+ZjeSNAYyBk/xd6gALYLEn6mm5SbTZHLC1oo9l+N/wAa7rxwJNI0JZrLw8D84fiW6IOQXx0XIyF/E+g8YVTTwmB71IEAjyTg9h60nIcaZGelIOtOamE4pDehMgUg+tMkA9KZvIppYmmS5IOKKbS5pkXD+VApKKBDwaUYzTVRieASanSzuT0gkx/u0nYuKk+gwCn4rX0rQLu+cIiqhJwN5xzXVzfDbVI7MSOih+pGenpUu/RHSoJbs8/cKyrtUhu5zxULIAK3NR0W509sTrjtWcIsvggUlK2gSpXVyGGSVI2RHZUbqKZ5eTnrVxYirbNhTv8AN1Nbnh3RDqExLg7F5NLm10HGldamJa2EkgLLGWUdQBShVjbYp7Eg+/8AnNevWuk21ra7YouCO461wWvaYsGou0I+Ujp9aqz3G4q2hkswKBh25FaMJDQgYXAH61lx5EckXdefwrX0xf3K5IJAxkisZ6IS3H+Xh1TaTt4P1pqZznBVlPJzxU7BYz+8LKCeAvQUwbQSApJP6VnfuWkOKBmPzDH1pAVA58z8KVyNpIIHqDUWR/dFZm97Ei7lcMcgZ9ePf+VPuQRGw4YNwGA5J/z3p2GZtzHOD0od8x4YcNj5iOV/Ct9zlZnS8NnIJP8AKoXd9gPTA9aszrtQhMDC8gj86zZ5AYdq5JJwCTWkURfUzo42uJztGcmi/tXt3UMMZrrfCeliQ+a6jA55FXdY0WO81WCLcAjDAx64/wDrVau2W4K1jz5Vpw4r1HS/hXc3twytdQW0KqZGklbooxnH9488L3pvxB8BaLoGm6NJpWry3d9PaiS7hZVZUl3AEZGNowTwcngf3uB3EopNJbnmaKCODlvQV0ei+G5L+EOSQv04pumacVZ/MUrHjDkDP4AflXXpLem1jhsYjaInsN5+uRwaIq7uy+XlOW1fwutjGczZbGelcrc27xHJVtn97HBr1EaCbj97fSzyz5xhjkAfSpX8MQCLiPcDyBIc49vQdDWjS6ETgpaHkFKASeK9OHhu3mZxDaxsuAW8pSefyqlFoMkZZraN4u+OgFIy9gzjLTSry6kCxwkd8v8AL/Ouj03wghXff3Iz2jiGfrk1vWOgzWY8yV5zITxxu4/zmuji0m4aON2kdZGGVXA24/A0JrdlKkkcnF4T0lkXEkm9eTngMPy4PWt2x8H6OpA8pGGBksSSa2La31EQhDGkeRhgpClgP51oJBOikTfJHtBARgMH1xnk8Um0aKKRS0/w5pUXypDBtJIHABH1NX10yAx/NBkH5FZeo/8ArVYtYcoDHDGc87jwSfX2q7AkMb754kLfwgjgUr22LOY1Hw7CFf7GjrMT9+PnHtt6Gq/hvWL/AE/UDpurkmyYFElkONjf3fYe3au0MtuqFbchXPGelc7q9pu3RsN6t1DCk5uJSjzKzE8SaHDqMWEGWIzwOtebXfhu5t5jtQ7QeeK9K8MXzSO2nXQYTW/3SerJ2x9Old4wg1WWzjmtrZEtoRGvlR4Lj1Y9z71LSm7oIydPSx89v4YeCO3uwwkVvlkVsgxc4GfXNbOjYtXWNVC5617DrvhvT1tp0JSRGQ+XsXG1vfNeR6mDBNgLgg7SSc8iqcbK4KXMdCbkLb5LA4rivEEiyyhwMndxXSeSWsEcyEuw5GMev+Fc/qVsJ5okjByPQetWtrkdTlZV26hIuTkg81r6Wpe3eMMqJj73v9ag1i2EeqEAH7p6c9qtaXJGthKgQlmwR/8AXrmq7CSsxwAxuXLvnJz6f5zTo4dwKsAG7DPrUm791tCAkZO7P9KekQ2ckGRulc8paG0VqVZ0Plj0PJ56VW5HcVZuvmlCZzxgnFRKj4GAcUJ6FvUt5C4AG6Ptg80jpmNjnJPOSMZ9hShz5iMh2N9ePxpkYLq25i23jA/h+n861Rzvcr3vMTnB68dwo/zisjy9zxr13HNbN3CBDJ5bMVGSSfesu0O2WAKNzF8D8v8A61bw1Mup3GmBLTT0I4YiptHYT6xBnnLH8KWa3JsUGQDt9ar+GhjWYi3QHbzWiTUjbdXPZYrdTaZxkgZrINlB/aFrc3MCyypIrCJ4Q6HB+64PBU1v25K2PQHA/pXI2OtSzXsrPDJHEjFIXY/K+Dzj9PWrk1oZJbow/iDZW2m3lqscIiNy7zEQrtRTnpjsoyeKh06zM0aSdQ2Tnk5Hp9PrzVPxpetqevwRyMVETYA6g5xXT2SbY1EeNxHGe3FDZcbpK4ltafKu4LGg6AkE/n3NV3sI2kRlysJbJZnyzN6/T6VqeXG7tgHK9ST1qEW8t9K6xMIYI+Gcj26D3xUMpMxI4xHfzpZP+4IOcnJB47dP6V0WlaJBNZiUbVGclpBkn6frzTNOs4VJeAAByUPHJ5xn/wCvXWWml2QiWN42kkHJlBI+b/D2FStWU7JGLB4bsZJGCKJnRtykPjB+gqaTSI7gqZoVgbGA6dT/APW5rp4raJp4zdSKyIMD+Ege3v19qdHbwxnEO/eD67uKCLnJr4ftvsyxPaRmZXLPMAc+w/r+VUjob/aHSGMA4xuJ4/Ku/kDLAQhkJJ+ZSfvCqjQwnMruVBXAAXnjsKmWuhSkce2lyxBQPlOMcNkGnwxXFrJ81uZEz1Azz610Mll8++JgykDI+8fp9MUqRR/8tUZeOGHApXaAxZmtpRv+y7c8ZRelUZY4gh+QqCO44/WuknhQsGjRQV9OMiq8tstwDuQ49u//ANahu44qx59rNjJHdW11Auy4gcOjdQ3tx+WK7Twffw3t3JImVRjgggZX1HsetVdR00KSYsmM/wAOeV/xFYuhXZ0jxM1vKQLa4XevHRhUQnZmko8yPUtV02C6a/Flcg28EPmq8mFz045x714Vrds8lxO20YWTI9+K9U8V6uur3gaFTHG0aoEU/dwP88Vzt9ovk6cJwgcE5Yd8etbRa6kRi0jzQXc250J4AxgduajtShvUeWMjy8ksGxn0GPz5rd1HTVUmSIAqeprnbhhHeiMk88DApXcdOhbipK6JbnT5JJTctGxVIvMbaM9Sox9cHpWPp9wrTyC3Xhj8uR1969Nk0lrX4ajUhlpmkeRY2GVKHCj/ANAJ/KvMIY2G07THjv0rnm0ZLdmlIpS3hYRxgHPIOWBzzn8+lPjUgEoTyMk0zkFCDiNh8hccn1NWYoF2bUIAA9efeuWbsbU11KE4+fOTn19adhhx5UnH+1Us0JWQu4yvT069qZ5ZHRzjt8povoXa5ENxV1I7cYHWnxIoTdLx6DHJ/Cl2dDvYAj8qblApAb5cdSO/rz+NdK1ORkdxgwSMV2jbwecZrIgdzG8ir80Eiudo4xnH+Fak2DvwVjyo3BiNp/z6Ve8HWwn1WW0a0E/2kPGUXjPGc/hjOK3gzKTtqOa8neNYl42mtnRrYsRLj7vzfXHNZNpHNHfzWdxEVkixyT74/wAOa9E8P6cv2QzMu2M4AyOtb01d3Zu2rKxqtrSwaaAw5C5zXAR6nNFC7SIoAZpEUAYTdjv3+6DjpnPrU2uTzXWqPbB/3MR2Kqnqff161NPpX/EtImQK2CdwHWonNXsUoK12c7p8v2jUJZnYn95kH04/nXbaT5shIUHngkVy3hqwRQ5Y5G8kDtmu+02Dd5aQRliRk9QKaZEiYfu4jGq8e3ekWIRQM0kp2kEbF6fX/wCvWktmsR/eldw52gVDcQiSRIBgKQWYjqaJMSV2VPC6JNeMsSKsaHCyMcgt3/xya7i2WPY53BAzkjPQe/8A+uuX0e3zObh2JDAoqRgBAvrj1wPxrrbSBCFEgyuMcjOOlTE1qqxIrW6yCPLk4zkLgH8aWSFWQ7TyOQSSMf41aMaGUsw3E8KP4R/9f3qvJEZFdpDkDopOOP8AGjUxI3GXfYm1mPY8CnxW0qf8sw6lsnI6VFGZUUbEkYKw4UcD/wCtWnCJSF3ALu5HoKAehlXumJNIZbcmF87iy5Gfw/CqeJYWMUrMQDg7D6V0gjBZtuCTjGU4z/nvXP69ZXJVrix2uA2515Dfh/hWclYuDu7Me0MTocNuTHJI5FMto4iMBxt9SapadfJInlzMVlA5QjDD69/xqxJNbshdGAkj4zj+ft71N1uacrWjK2rxSR2/mRjeF6+przjxWY/tthcozLiUKwPVc9f55r1IsWVWfGP51wXi6yFxftGCgjKjafX6/TPasZu2qN6S7jdOnMd55MxLMCMHtiuse6jWIxSLwR371x4lWx/s24KmSWVcMh5Lcc11FvoGsaysb21ssKovAmbFa03zRuTJRWrdkcX4giWyu3CH93J0Hv6Vw2qwMdaiiKspzgjHNdz4rSTT7h7LWYXhuAOOMj6g9xWF4ItW1rxhAsy+cIGG/wBTnp/WtZNODaEvdfken+Oof7O+HWn2tqmyQxK29myjJtGcceueK8btrRi5dYvOVVDSOBuEY9SOwyRye+K9S+LtwxtYrOB28iNiyRqcbc9j7cZri7S2vNOs5CyIpuoACByCGO4fToOvQ1wTncxijn5mUw+XGYz5Y5Zjyealj2LtYKMnsTmqxG9+D5gyRnA69/wpzw7nGcgKOc96zmzaCLckgZCMfKRk8dDVHHuaflgCvmYUc+9RHGen8qhstIglmSGHfICFPHXNMh53OGCqgzhTnr9aWVlMQ4IfGME1FF8g+dc7j3H8v8+td0dDiYi+XJPtO0O3Ocep7/Stzw1d/wBmeI7aRHACsAfLb5evOD9CayuWl2puboAcY/z3rWZZoBbTRhUjTHysQeM/l2P4VtF2Zk0a/iK3dfEKysWCsyRMGHIBGRk+uCBmu0hv45LNbbaNgxhQcYIFcV4ne2ksGksriNnaYxKgBzjG4vkjp0H/AOqvVPAdlpmqeBLO5FpGTgrMW+Z/MBIY/nzj0IreM+Vlc3LBNnk1jLGfEtzGfmKzEkZ6A/8A669DvWs7TQrueaPdKsDeWD0Bx/jWP4w8KR6VepqmkqscYUiWJR97nORWTe6m1xoN4rsDGYSQw689vrWF71NTdP2kLx6GT4ULG5SM/McZPqSa9LtT5WxR1PUAda868ExqmrNHNIrmNQd4Xgj1/kK9DRmRzM+4p/DnqT9K15hKNy1JIfOMW0EtycdT/wDWrP1JZwZH81VbHyBcjj/JrVjgEe6dzmUjAX+7Wfdubu8hgtELNvAbJxkZ6/TvUXujaEFc39Eh22Efmne4T5jjGT/Qda2rRgWG8gBTuyR0qIWn2aIr5nmDgZbjd/nrTrWQEHYWwPf7xx1qjnk+Ztoth/mAC4yR1J5pl27QqCsalyeW5IpEPmFGAXOOATyPf61omzcRbhuGT0Uj0/l79KPQnYo2biaBWZiR0G08e/061dVVU8AYB3DJyeO1RWsQdnIm24O1huXgntnuaXUIxYw+fcHgAZOC2B3IA6n2o9Q3dh7SlgVZQrdOvBp6okrfvFYA9wcZ/D1pktq32VHk3HcA3K4OPT+VMVdj4Py5AAwMZHt+dJha5Dqfh+3vYmUYXOOSBkfj2/Csu28NG0V5gA43EjAwy+mPbvg966SQEwleR25/nTIrnajIc5BxhuRWTikyozmlZM4Se1u0naPzDMh5OTgnnt2B781lazpx/s6WfA80ZyrDOBjr9fpXfXkcJkDlQVJyw6c1n6pDEmnXUT5aNkLdPUVlOOjOmNZ6GZ4C0dpdNhvrjy5jjZkgcEdf1rutMlT7QIsnbnLHtXmnwlkule50RpGwALiJOTlTweewzt4969ut9OhtLNIAg3Yyx9TWdGMna2yOPEq02pHnvxW8K2/iDQZZIEC31uC0TZ6+1eTfCLSJEW9uwD9pSU7kPZQMdfrnivc/Gl6mj6JeXk5JihQt9fb69BXiPhCO6hjXUIbgwuXZ92/kZPPHcZYDFVVqWuka4XmlBpvQr/EG+N1qVvaeW4khbBJOD16+x9vas9Yylo5CD5eCV4//AFUmqSPea86SvmSOQ8sMA4HX881r+QsUBDLsUjHoSff2rkk7m0UcFLDtuclCvOSQMY/+t0q9AAzN5p3LjOQOpq5e2xa6YpFu44DN/n+lRIhiUFlPzcjPOKVR6GlMx7pgjuwBC+gPWqvnf3ShHY5rV1OP90FRQe44xWX5y+pH0Wqg9BvRlaI5AIOCePm/wpyIRIzZJJwcKtRRAALgtjHO71qfDBlTBOepDf5/ya7epxFmOEtIWC89OvPPfPetqE7rQRyK0zpggEgj8/y4rNsyCrkqXIGNw4x7ZroNIDMdsLqgf5SrgEj6e3JHHNWn1M2YlzOF08WsgbzEZgw6KoOMEep656dBXdfBTWUt/E7aA8ipBqieYkZJ4lQdB9Vz/wB8iuH1b91q7xKyqDKNwOGPX3qrr81zp2uWusae/wBnuIJFntHGB908HA4+8DkdOtW3Z3HFc0eU+lPGHhm4itFkspWeE8sCPun1rxfxPoF3pNhNKqmS0lBDbWzsJIHIHQZIwa+gfDfjK28S+E7HUbONB9riDSJnPlSDhkPrg5/ya5DxrohnglkR0VihYZ4APUH61UqKbUkc9OtKm7M8V8ERTXF5bFZEZ3ASQA5IIOMH64/I163ehVREYLtXkDPJNebeDLeWARG5IzG7HCgDdzn8+tegGOd02oixsv3i3ceg/wA5rNS6HqRg9Gy00gNmzhinpnqeKm0CzgeWN9m09iOSfx/XFU4LTzI4hcM7qxPGenXGfb+ddJZRmKFFUL8gIHA/znmqitQqPlVkWLuNmkG99zAEjPAquMiJmfHPKoOM+wqyzNOrEYZTxnNIEzc87owmQTjgfWrZzIv6Vh2jJUu/ACqMk47D15rnvEes3M180EJa1JxtkiJ3IvIb5gOQcHjoO+a3rNY5Z/MVipiGW524Xvj37ZrCltIo7mREV1UEllc5wSeg9uR9TmlJu2hpSS5rso6SLl7izEatLKj7xvXcshx0wOnpnvjtWzd6vdw6kzXpumjRHj8mGIfK/HCgnCn37e9Mt/OU4g3RsRjKHpx2PY47ilkgaCQRtMCkgy+CWOc5+brzwPcilrYuTUpaorjxhqDpFHdQOsTy75CXDMFB4RTj7vHJxnt6V1mn3EV9ao+1o0ILMGPT+XGcVzlvbWpuUa7jdoF5IXG7249M4p+n+bNdQxzGN4mACsOCjA9PoPzpXfUU4Qa91WOmkEasMLtA75GD+P4VBdqqZJK7gcDHepCCIw20M49Ru5B549PaucuvEelxXNtbCYn7VKYkbk/OOoJ7H+tEmluYxi3sW5CC21j8o79v/wBVU9WQSDYuSGGMfga1I7fcxDqGBPAz1/8Ar0iIrSRhhkgEfXj+VRJXRadjkNLYaLqVjqBhYrBuSUIOWiPX69jj1FeuG/jNoLiFy0TKGV85DDqDXDXOmRM4kTdlugJP8qt6ZrVtpHhbWX1h9llp7YBxnKsPlUe5OQB71nB8l0Z4iPOudHH/ABa8RW+pf2bocD+YlxMJrgq38CkED2yf5Vz6JHa2ttNbyxKHEskkK8GPg4GPTAHNc/punR3sV7rcjS2Zf/VRKpIVSchWY9BjPqTV7xWp0nSoTJtlaU+X5yk85BxnPqDXNOTludipqlDlRiacvn6zG5X5s5DBeRXVX0TAGMyF2YjcGHc/yPvWJ4TVpL0y4jMhYnnJ6/0ArqNTjw7q3Pl5JdyAD9Kxd2yLnFyxP9omk4bsVX6/pVSYlsoVbKnIx0rWmjIUpkKhbbwc4qk0Z84lWwpUnIHWlM1gYl+SQ7HAOOBnp1rJ8w9gcfjWvfxKVY7jjbn3x07dKyMKOhP5VdOyWop7lO3KsFLcDORV1I1kBxkj6dTWdEygqoJwcZIHetON8IrHl92cEHivQaOJM0bHfGuQWCA49Dg8EY9PatfSw8U8Tn7rnhhjg+47/j0qjAG8+MoWwckjAIGe59fXFaqxgxuzyMfLbdgDkjvgentTa6ENlDxLbBJyERHPzL5oXJYk47denX0rB1CIXtvJKGO5FX73J442j39+O9dfrVur2BeJg5ZVUCMbc9enuep6Vzej7Pt0sMm0P5m45UMBjdyc8HoOO9NaoIuzudL8DfF0GgahLo2tSeXp91JvjlJ+WKUjHzexAAz2I9zXrXxNlGneHHuQ2zznFvEM/fZu+e3QnNfN2o2kMRE6oQu4gqeQy9Cc9znPpXbeF/EF/wCK20zQ9Ufz7PSgxidj8zhsABvXaBgH0Jqqc1yuMiqlBTmpx67m1oEEcOmRyTOmcEja3UDI/wA5rpLf/SyBDKVRsDa6FcZroLe0t4LZIYbdFjAxwOn1qK4to1Vl2jBzgAYOfWoUWju9rcWEbD5T5ZjyCx69q1VhPkdMHH5//W61ysqTQuASxjzypJ/HntXQ2tyHi3EMikbgMgk5+7n29q0hLUyqQdronsyIQwYMG55zwOx/nipNThdYSiIA0pUsQ3PUdPU+/QU1XPmH5PfPSr0k7bFEYjO3JcE4ViOi56j6im3oY7O5zcWpvDezLp0ReO3cK8pG5cg/qe55wKfBFJEi+axDN8/zY5B5H881kWU90k0lqNiB3YvHHuz97hffOc5PWuhtkWSNQg+bvnsf8PepTudElylqygllTdGrkKMjA6+p/wDr0XcZkaNAUzgHrVq0V1t8K43gYxkEnr+lLaQPNcCPDb2GF+XPzdACf681fQwvrczZYNisTkr1JPFbFlpscqWkkGRKCXcAcYA4z6d/rim38LyNNEl1GNg2QuG+TnOR0+uTxnnHFJpdncW9qJr7bMhKgCOXdgep55x7emKz6jcrxumaeHFqHRWiSQkcn7w6Hnv9PSsi60W3k3TQQqpEm9iQcA+p9+nNamoyQxtGYfmjUHhiVx/9fvVSxvY7kXUEMoKqwEgXpuwCB+TdPWm7PRmcbpXRHGzCE5ALI3GB1/yKVIfMl3LuCkcH15/lUEEzC8e1eIkFd4cHIIB/Q/zq7nCKVABBwMVDtYrYhfEbCR1RnUcKv+fpXl3xHtLiaORpJ3S281HeJThZCM4JHcjJ+ldrqeoywmFflR5GO9iR8oHb9Otcv4lsJby38sbGi2b0YEkuccg/h6VyVHfRHXRXK7s5/SNU/df2b5Rjtnfe0igkyjGFBGduBkkGsPx5eMzWtiCW8lw+VzjATjPvhvbAxU2hoJbQvGvlRo5wWz+7xz+XT0rD1O6Go+IDPuG1m3hcfKO364zWHNfVjqJX0O18JwmO3aZGCoVyBt57cVb1CRXjZlQomRgE5wcf54qroEoSw8yTGGO0jPT/AOvxV2ZI5FJOEd1wpPPPvSRzsxpFzFFKBvkPJPHXnn/61Y11PHtdNzZwScDoP85rob50t7gGeJnjRcYVtgXjjkZ781y05R0kK5EjE53cL/8AXofc2hsZc7ABlyB/CTkZGf8APSsppJNx24K54wKu3AYuQ23kZxjqP8ms8mQHG0cVrBETZQt89A2MHHHate3TfhELHtnPtz0rItGCqpY57bfStyxlwUJ5OcDHI47fyrtmrHJFmraFYY/NlJd1O0Db0zj9AR+ta9jNKxWRVXyzlSwPJB/yax1cZkiO5BIoO0ZIx9fTOOKtwOkiCMHaRyQTjkfzHHWmxGheLE8D+fLhhld4J6Y/U+9cbq4MFwXjIKuowRwACMe3/wBauqvDlF2kHdhWbOQOw/qawNagElk/7rmPG5mOMen8xU3sCRX1ZluEtjK6Am334U/e9vrwcmtL4UYg1+78pt4G0ZIxjvj+dYtqwMUbSgSJASwTH8JBB/mK3vhfAyatcjHmSjYH29R8oP6UK2rN6Uvese6RO8ibsAd+KYWk81GY/d4wR696SznWRAUOfl+Ueoqc4kViCvJwPU1tdNFvRlOQeZ5hXGSctjocf171DbAWV4AyMfNQSoCcZ+v5d60bS3YzFBGWJ6Y79/8AE1k3ISO+WQqZEIPVumP/AK/bpWbVmbQd9DpNm61ErkfMeV4yc85+lX7WFv7MkCBi0qABQoIJDDGfT1zWbEXa3ilmUhiMgHgsOcfh/T61vaOuLSdhzCECsz5Uk4+6uPr9eK1eqRy1NEcx4gsZdPv4b1yFkkZIwAR8wHXIPDYyOeR+NR6X5kBAm3dMAnkEDpj29+9WfEIZdZjkaNntnjAUsQwDDOQhH8IyODznt6yzGaaUC4URIkXmIgCjaCMjn0PHHJzUW1NE3yq50cqO1oRt2rG0W0H5ckgErwME4PXtg1GVitVnQrG5BM8bE4eQEEAeoG7JzxnAz1q5pFrFJpTrdSOjRx7hhiFxtyeB1wTn8vSue1NpVjhlSOPaoCkBQqkYH4k5DepJB7Vq9NTmiuZ8pqRafHHInmsXkUk+bb8OR0PbkckZ6Ed+lXMiKKckAu42fMoyMds9v61Wspo5NOQIUd+E2p1xkEZx35I5PbPWnyCU3CAhgBhAY/mDfT1PbIqNhtt7kGoL5wMe4FVQxgqOo55578mqOl2/2OOGCPgDCl5MsR0APqe1ady8vn7yVVWYqUU8jgj8P51VYFoJFjMnmlhjH3TjPP16UkluUr2sQXb+ZKqDIWOVvm2YLAZ5x2HfHWrRt/MXrgkDqe9U9RuX86Sa7KNKQOEPBGAOMf5zmsO81We4vnjLqqxsTlSe3p+XWq5NDaFOUloSXdqG1Ai5jEgjkztcghxnr+feo7v94HUxiPnIxTbm9Se7tXGPm+XI6Z6fnzT7tHeZcE7WGOnGa4WrNo0aatc8p1uSfSpNSt1ISOVWRVQdQwOTn8RXLxHzJV2kFyoAJbj6foOa7f4nxiH7NjJLZVgO2Mdj68fXFcNpcYe5jL54PBrlkrNrsN7XO70qNk04buQuQAeNzY/PFaW0YU5HBBzu79Px9MVRggMdtEYkUlzuIznGD6e9XJi1vCd5VS5zzwBn/wDVQmYswL6RnubgR7k3HB5+7z/PnrWPqUeyADzcqedxHX3+tbq23msZDuXbywyAD/8AXzVLxBFYLpkctrfxSTuf3tv5bo6/mMFfcHrTa10NFKyONv5FCBE+UMcN6is4HIBZhk8mpbpmMuRjIOckZFVjFCSSYXyfc10xjoYyepTtnyQMZzzjNbtow2hlVt6nLMDxj/8AVXM2rAPgAcYOCeldBYsrqBkkgdjXZNHLBnQ2bIoikDHbuxg8DB/pwKuOpguo2IVgfk5HfH6d+KzLFMFeGLMNp3nAOf8A9VaMqvIrBVJAHBGOCDnn1Pv/APqrMstXyr9lzCU2KQTn5se/15+uKxpZP3M+CWjLgkk9eOOv860IZdqBJAqxjksT39/btj1FZN6/luEVThmyQR14z/WokhxZkSny5JV3bkfkc5+tdp8ItRtTf3UM4QTJIdoU4ZtwA4/IVxd9F5kRO0/J0OelY+j3z6b4phuEJG75sg85APP1pwTaZpBrnSfXQ+o5rTyIIkXcsjNwR2zUumNtfDHJHfpms3wjrx1q2FvcENMFysg6H/69TTu9jdfvcL83TGQauMjp5Wm4y3N2+ym1gPl68DvWRrtuNX1hm0/zEtoIkJzxkDAywHGSxAwOOfrV2W4eWPAORjGG5x7VkXxms3yZJYXXATa2PlHOPp0Ptj8iXmFJNPTc37ZriREimP7wKI15AVV6gex5PpWtpjsYjGFR2BwVcrgAHlueOnSsLw9c2sysJIxGzqFV3LHy84G8jr0yavQSCGSWJBDIX/dxyMSFBBwGH1x39a0T5loZVI6uJVv/ANy/mNCUd4gikEkAAYyR03YB4HIzSuUNgPkK3K4LbyeF9APxPWk1mS5tL6KRp2lZlCrsYtGrAck56NyB3qYvbS2UUwS5Ryu24QtlWcHAbrnJ3dO30pdQ2imaum6gXtxJch28ojYYyA2On5ZIPel1aEyXRM1w0yYbyzKeUz82Plzk/wCNZEQayZ0dlaN0BChuvOQCR9M47Hir0t9KLW2kbDrvwrFeD7dOR1GPU+1UtiHHW6N+1eD+zoZILaNXBCeVkEZII59W6cnA59s1HIWg3EMRt4G45xnPT0wOMdqq2LSRxCGTI4Eisi89Pu//AFj9eaVmignfZkMq8YfcA3bn+nrTZnYkGEuIkjZ/MA+b5f73b6449qz9Z1aGDMUMQWYZIw38Pp+Hp706/wBRgtrdcBlkbhGLYZj3/rxXFXyX+oCaWLeqQnnfhSxJxkDsM+vPPTrUaXsb0qSk7yLEkzalH50xVXBKlAxwPTI9eM1Jp2mNM07LFuVIySxbGBkc/XkDFT6RYxad9ogvYxJdgHlG+Xdn73HBGPwrUiZAhEXcgnjGfxqXd7nRKpbSOxjrYvHN+75CneWJ5z/nFbdyEez3tnI+Y8ZqxHaiWAl2+fBGQKzNQLxIIkyGH6f55rC1jKU+do81+LU6hLQRkFmZh0ycdvp61x2hQPLIzAjA5OT1x2+taXxGvRc63Da4AVFJb3z0/rTtAieOOJANwDFtpz09Pr1rjqfEVPTQ6TSdhRVVQC3O4c7B6fWk1AsxCRszOTt6bvl9aQXTRw7Ytyg5YsRnGDz/AD61FYhZrzKKeF3fd6f40o7mTIY1FrDK+G3kkgsRggHp7DnNcT4kuQ83yFnCjlvX6f412mphdxyjbTzw2AnH+NeeaxcO80isq7Q2cj5Rn1+taRV2DehmrKxmVRkjH3cfjQUYkne1KgOxiCNxO7avAFMCyMM5TnnqK6VoY3MJZmV8HO7v7j61sadMsiheI2XqM/e/GsVSCMcliMDnpVmxnCSLvwQCCcH72fSuySujli7HdWm0T+ZEQ7FRkMpHXjj1HvxWjAwQD92C2cnDcHn9f6VjWNwJM+U5WbIKnGQf8K1vMPlRmRVcDDEoOhHGeO/1rF9jZEU0Uixs6uquxPCjp/k1DeoG8mZQ0giGD6HjuPb2q7cKhjICs5ySSDwP8arqDAnOWiBwcYbP+emahaqzH5mDMu9W3tsweQB/n3rltUVo1WZPvxtuBrt7uEpIYwFBVslQ27IxXP6pbidCjIVU5OQP8+1XTdnqKd2rndfDfU55BBJasvnMylQB8oGec/rXsGs4vbQEhhyG3Y4GD29TXzb8L7yZNWbT95TgsDnnAIOP6/nX0VcXyyRWzFssACy9hxRbllY7uf2sYzW4+3aby2LFjI2fyFMup5ZbR4WAbepjAlAIQZzlfQ5rWtChywfAIHfrRfRR+TJvIjVF4CjLMew29+cfSqavsJT11RUs9LuNPa1gaze5a8ZI03OOMjeMMORwc/hitAhbiUBT5GQuQ2W3kdT7euP8awYJSlmol8oTxyYRWbLqCeVx6n09BVqe/u7iCa4gspWhjQGa4ZNoQnI4x07DjmiLsXOEm7s3L1ba4jLXQKNEjyb4iWy7AFSFyAOFGSAOn0rn5delK3VmyrE8kweaMLggj0P5HHrzUOk6hBe6oLYsYi7kEuhGwHqCD05GMdifY1nrZGC685r37UzOylV5OAeOe/FDd1oEaSi2pHRwsk1mshWT7SrH5AQVZccH6g5JqW3nL26weWg+fJYt1PGB7Dg8fU1gy3sULOryFCo6Dv8AlU41hTbwNHJCzKxJi2kFQccFu/TOcYA4pprYXs2zsbcXFmHihdJ9hDZiUtkYGTz054x/9ao2vmsbWS9uHFu2TtUthsn27L+X6VxF942W0CARuWBAZRg88ZJHp154602411tek8q3tluAx3SxxDaAG7c555wKHNREsNPeS0Ld54murqVNtvvCNxIvJP8AgKf9rkvJUMrFzkM79CfUe5yetFjp+yHbLatAiHBU9QfQj1zWpLYwQQxPuXfKAVVTnaP9r0P8uKys27styhHSKJooyts7yo2xsbXTPynnAJ9Dz78VPHGmGdcckbeetVhOyw/Z1YlG5CD7pPQE/Tn86t2kYyuScDrjnJrQyei1LT3aadYyyyhyV5TBz3547np6Vy2p6ll3lkRl4JIPGPb610+oFFtmLKNx4XvivMfiVcppuk3NwZmW6ZRHGoOASf8A9eaxqIKNm7s8yuLx9T8RXl3IhaLzNi/QGulss+XDGSwZkLEg5wM9Paub8MxN9m3kBgxBOfm3V1FoweMySfL8wClUwCB2FcEt22W7tmnehGiyckEZwDtz/nrRBcPa2qjYVRiCrc9Bj+ecYqMyjKRkDAGc565/ya07wqukKrYLIhyhOCBnnj15AogZS3scz4jumAZ5HZQCT04P5dRzXn10Wu7t5SRtLclDW54o1R2naNsfLkxhT7fr3rBhnEUa84cglu5AP9a6acWtTKcr6CF1iZi/AAABBxx9KFZcD/SgPbyjxVWaRCrOTyThRt5NMWDKgkgHHPNdEYmbZkK+Mc+2RUillYMCvPB5qnE+1gd3erYYMcjJzwBiuxo5dzqdDvgHAEjCXjaMZrpbedAhXzFzkkoBjbk88+n14rzzSrloLhDuAxweOcH0rtdMut1uVOcH5t5zg9e3rWE42Nos2sqm0JKC8jZVM8gcg/40wx74ZcHCscAAc5z/APWFRSxbdxYhSMsGP8XT8vrzyKfaupOXVQDjOe4APP8A9b/CsJqxtF9ClqkBt7o+S5Hzblb1P1/E1h6oDHIu4shHCjH8/Q9a6K8wYFGTIXHO5u4H6VkaxGRLiQiR3Gdyjhjj9T149qdOQpRscnPK+kaza6lC5yrgnbwSO+PrzXq2i+Ll1SHzYZNzHqDzt+orzPWrdbiyk2ABozwM9a5/SdRn0u7EsDEZ4dexFdLjzE0a3spWezPqTwvrv2i5ME2cn5kx6V1M4NzAXjkRWDBdrnHXv7+49K8I8L60j6pp12N3DgEDo2e3tXvbYmSLfGh2r8x/vfX1rNqzsejNJWmupgXSXOnz3MQgl8+EqrNkZUbsDrjAPJ7GsmPVbk7IgysuR/tBOAc+3+IrS1tEEbqIYdj4BJTaBtPX/E1nW2mqfvsyyFi5AIxj046etQ072R0QceW8iy2m3F4kmo3QeZN/72QtjLHp3ye5qpNazf2hbyaHss5YUIYGRtsp9B6Hp6ACr+JjhI0aQKvAUZwo68frmoVurW9eFbyIssB+XymCkfjjn0703FMlSluZmlWl9d+YJAhuRKVaJRk56Yx0znjPGTVi+uhEgtrW33Sn5TKyYY4OCeen06Cqp+13l5qC6NI08Ay+5nEbOMgAYzyenHP6U3R/ItXuf7SEoudu2NNoOGz3zn0P6dqm/Q3t1f3D5LCCZXjgheWRASXC4AX147+5z6Vs6Fo8thJb3kV7B5U2x/ICdRzyc8eh75rHku3juVZICFj5dQM78f3vb2rqLC4S6LXEqBSxOI1Hyrn2HTr06VUYq5hWnO1uhuXFwtzPLM0cKlmLYQcD6D+lUdQmjlKiIAbf4Uzj8cnqfapLq5kf99KrHceXCBdxHsPwFQSIZIC4A25x1xmqauckVYkt2bC5yB6nj/JrUswUYO6F0B5XOM/j+VZsJQ8kZIGQDU17q1jp9iz3c6RRxpl3c9/6mjRBK8tEY/iTX/szurNhY16n1rwXxZrk3iDWPLSTfbxPhBn7x9as/Erxo2v6q0VkSsWNvHGR6ms7wzZGScOq/KnHTiuWrLlV2baJcqOo0Sx2wRoDtbaCUUd+f/rVuwlVVScbEfoDkFu/+FVLLeHG4bpAB86c7s9fwq406RqVkOwDDfN6fTv+PSvPb5nYlrlRPEUnvDGCwJG4sFxjoPz6VU8U3i25cK+8IuWJI4OOlSWbmLTpZ5Lj95Ix2EDrxxiuF8Xaw8sKW+3DcFgpyc+p/wAa6oQu+U5m7amRNcC81J5GclR0x0z0qtNJ1CZ3EdCOgqFfkAZAAzDr0wKr3N0FyGwWXgsTn8BXbGBzuRO0oVV8w4A6Y7VS/tADorY7cUtnbPqDk4xAvUkda3Nlovy+WnHHWnKai7BGDkrnFByGO4fWrcMzEqMYr0DXfDNvq4FxbMguHQSERgLl3chUA9gPavO721l02+kt5hlkYjIyAcHGRXpVaEqe+xxQqKWxYPILj35I4rotCv2Xy9pDSKcjIP5e9c1BJv5BGBzg1YtZTbz53MM+lc0o3RtF2Z6bBLFtA2KzbDuKnceef8inDfEQ4DAAjbk5znt9ea5bSNSKyY3AJtPOMkj/AD/OujimkkjYvs2tjgcjjqf8+tc0l0N4sulFVVLnjGTuHOOOnoPaqurQrNahVB3HLKM9OccfgO9WEGZIXuGCiQcc/l9KtXCbwHYnJXgnP4f0rma5Xc6E09zg3zHksQCCBg+lZGuafFOr3dkgTqWQdOvauw1PTQ24qpZycYAzispoHt3eNlBRhyScYPsT7/yrqpVEzCrTMbwTqJg1S3gkOU8wMoPqDnFfUsF8Lm2WZHBDqDtJOR7V8j6jC1hfiWE4w25T6GvcvBHilNX0SAAKk0S7GHuK0lHW50YWpePs5bo7W8uGlVwAWwCeeoFU7OVIzvPzZ/GqE7sxWRhwpyRgE0kF0pVEUhST34x71NrM7o2aNQ30sU0m3coddhKuRuB7HHb26Vaj1WJ2jaS2t2eKPYhK4UD0wOo5I/E1RgCbi8j7kGcZGM+n0prGNAT5m0nnaQABz09zRYUlHsMTSY2unlsrtbSCRk81Q3IOeSq5GQOvWqV7ujvZ3muvtEztgPtJMgP8R54OPr1qrqF5Fbozl2C9cZ6/Subk1S6eOVQHigAw5B5/xJ9qSj2NFNrVs6GU3sFywhEZQDPmIcgZ7fWur068320fmoFcDLNjkn1/SuE0a5RfKjKFIlIbP8bc8/Sun+1r5ZjhddxHXPT/AOvVxVjGo76HRrcBzvZecEKWzwP85pbieNl2g4PA57/hXPw3UgiEYkWQLxnOc/iaiu9RZBgbRuHQnipWupFknuaGsa59hhZY2zIegHJNeJ+PfG1zeCTToWG/IMkgOT9Aa6Px14jXTtPkXhriYFUwO/r9BXlmjadPqV6PvEk5ZiM5NDtFXkYzqO/JT6lrw/ZPPPvbLHr/APrr0vT7IQKkI58wAkL3/wA8VS0zT47EFEVNuPmPpjr1rYsBsRXLLnJKj1/zxXk1qjqSubwgoRsXUT7KAjLjcpHUewx/KqsqK15g/PFnGWPIB7fp9aPMV58kFk3ZTIIx/wDW5zVKa9FsVKSqJ4chRj73P69R7UUoGdSV9BNd1GOzgRcRkQZYNztJIxlfcZ615tPcme4kmdjubncBxn0rQ8RamtzLtT5uPm3nJLetc41yFh2KoOf1r0qNOyucNSfQnluVGc5A7DPp0p2l2Ul8+ZV+Qc59afo2ltezebODsHXArp8JaQkRoqpjB96KtXl92O46dPmd5Fe/eO2gWG2BXGFAHc0R+GdVkjVxtwwB6V0vg3SPPn/tPyRKEJEKsOAehYDuefwq4YbhCUfVArLwVx0PpXZg8JFw56j3OfE4hqXLDoc/8P766l1VbMRC4jdyxR+csVKgj6Zqf4h+GFWzjljhnSaItFGmMgRogLFsd9zVQ0KN9I1CW6mEkJUjLIMYHfFek6lq1lrXgzxBrM8ryW1hFHbxRFQn2qWaQZwWLYCgBjtwfevYmtPf2OG/vXifPBt7mBFlaGVI2+65UgHHoamglDjDfU17EdXsL6NreexhlvVVomkkUMhBwF2jHGOcV554r0BYNcvYtJXcsTOQiAgFFHLANhuxOCK4p4SUVeJtGtd2Zm2czQtlXAPBC5wa7DTNQhZxLIGLAE8c4J4AP61wEbsjMkv7uRezDGKv6fdGJw3J79a4pQvqjpjK2h6VFcRyeXEzOMZcHbkj3HtV+Kbe21txg+9g9hx1rktJ1SHYckkAEkEnByfb8K3bS8WSYFmRnLYDKMnb1LDPBH6/WuWUDeMzSuSrS9NueQqfNkn098/lWFqEBEL7S4XJ3DsSOma3FeIFkKgqygiQ+vU8cYGTUeoQu9ltaNgwONg5OT2JrFRcXobcyaPPNatTLasM5cZYeuf84qj4T1s6JfuZC6xOMMB/Cc9cV18tu435QOi8H+8D+Hf/AArkPEumCCQTW6sY3+Y8dK7IS6GErxfPHoeuWGtx3Nmm2T5X757fT+tQjW7OKYEyHecg5NeNafq11YgLHKxiBzs3cVf/ALfEpIkjZQe+7J/lWtkzeGKj1Pb7fxRo1qQt/OS7Djbzj/Gm6v4t0G6SAWURaeMZkd+Fc+vOMV4x/a1u8WJZQw/u7MH88VSm1G3Z/lVgnov/ANeocPM1eIp7na63rRuLlhAyKmeCckD8qNOHlRq0cyZY7izDB6/X9K4cavtZSIjxx9//AOtRNrUshz5aZ9TVJWRk8VF9TvjfsjtsniJU5yDjJ9q1bbW4o7dHWTDM210ySeO/45xXk6atOrZATHoM/wCNWZdcZ1GIcN3IPeiyBYuLZ6lL4kji3LGpyTwScVj6v4x8iErlN5445/IV5zNqNxMfvbc/3c1NpWlXmp3SpDGzsx6t3/Gk7RV2S8S5O0EXJpLzxDfq8m4oDtX2FegaTp0emWQRe33m6896j0fRotIDK5V5iDnA479D3HuKvynPLZU59eg/P9a8ytVlVdlsdFOKhq9yYxgeXtAJYcADr9f51JLLyjRAJhc84zjPU+/tVZ59rB8fKuEBI4bB/l1+tUrq7VYZX+6WcKSTnI64FZRphKoWri/+4pZRGq/KR8xx1J9+nSuU1/VnkhLSOqtjCgDGB6f1pdV1WMCQrtDbsZxjjvg1xt9ctdz/AClig+6Ca7aVHqzjqVe2417h3kOOSfXtWrpGltdSb5DnjOTTNI0tpnDH7vqa6gSR2cKxKQnciqrVbe7EVOn1Y9FjgtxGmFUdx3rNupxNcRxZYGRguR3pstzO+RbrIyk4YheBnius1fwPqcD6Q9jaxmCSRE3bsySSnr8vXFGGw7qyvLYqtXVKNlubdpdXVl4fFnp9ssEJAHnzHt/Pms06TeMdzXltk8nivQtP+HU89v5usREykGICWTag5wPkXr2705vhDeuxc6/HGWOSiWTbV9hz0r3FOCVkeRrucFqS6feI8Cxz3iwr57rAcrCBjcW4xg5x+X0rfkTQ/FWkx2SC2i8pR5QixGkahTwF7npluSTXG69ZLo/hzS/sUsw/tO3xdbnz5gyDg+2VB+tc1oV1MqTqr4WK2aRQBjkZHXrXU4+0as9hWsjp9L8JX9t4itYLG3n1R7SaFwGj/doTlyWPRVwuST2Br1LTPBNtc297d6nNJyHubjU9xRo425aGID+Ektl+421P4HsobO58MWcAKjW7Z72/l/5aTERgCPd2j56DGe5rgPjl4u1We/1fT1kWGzspokiii3BcFAfmGcHkk81hObba7foPyOK+KMvh66e0bQViE6kpNLvw0rD+IqemeOSf61wMUhjbDYI/PFewfBTw9pmpWxur62WeeSRo2Z+crjpj+vWuU+LOhWGi60v9nRGFJVDGMH5Qcdqyq0XKHtkaQmoy9mc9a3XlgHque3863rS+EYXEgULw21SR7f1ri4XZWwDweorSjleCRHQ5YcjdzXBKKaudUZNHoVnfrPcpdsXOVywUZKnsT69q1oJco/nYKggtvOQM9cdRnpx3/CvNrS7lWRmUgEDcDjv/AJNdBY6hOYvmKnDKRx0JPJrnlGzNoyub88cIYvv25XJCr93gjB9/aoBYxNDuypUnaCW4JwP0pizySyAyHIUg7egOR39arW8rXBBk+9u27gTnGaSK6FC68IWl4d0M/kTv/DncOvUDqao/8ILIQxF6AA+3mIj8TzxXX3Ur5cKxUMOQPYe/0qVZGkjeXcy4XhVY4AGcAc9qpTZPInqcKfA18G/10Yj7lkYEc8cYrRtvAcUYJvrqXG3dujTCjuAc9zg11tg8k2pQW7zOUlC7jxnk/wD1q0BM9sstvGcx71xuGSOvfr2pOswVJXOdtPCWnwRsRBDIm7GX+csPbPf6VdGgWdmqZtIFZm+ZAF5B6AH1/Eda3tQZ47a62ucCUqAQMD5c1T0iU3G1WVFG3aNo6ZHUZ7+9Y+0lvc05VYyJ/D2msSpsIYw7ZK7QxXpkZ4wOtZLeFNJ85QbeQE/9Njgc9x64xxXYSRKn2gZLbfm+bnJ3Dr+dZ+uytHHNMMEjB2n7ucHnH4U/bSB00ZVroemwvtFtEoQAh8Bjn3OfwxWjEUhWR3UBVzwB0GDjp2qDdmwilf5+T8p6fp9aptdyC1iBw28Bjnt06VErzLjZbF57v9421j+8UDlemP6cYqs1wsh3SbinU9OnbGP89apvOyRZ2q3lruAYZBPHX8zVC6nkichW/h49vYUlAbmzSu79FdQ67lAOVxgdP/1Vg6hfiMEx8FTyT0H4f561BqBKXqxhiQdxJJ571z17PJLKUY4ReAB/X1rqhSS1OadRjr+7a7mJAwmelT6bZtJIDgcetXfCemwalrVlaXO/ypnVWKnBwT2r3/RfCOixW0ypZIDE5RWPJwB3zWqhKp7sdDNzVKzlqeMqvkRqu5iMcgGtLwn4dvPE+spbQQyeVjc747ZwAPcnA/8A1V6i+iafa3FvHHbIylWPz89j3rv/AIaaba6xYzy3MZjCRSDy4CYlbHAJ285wT0PeiOB5HebuKWMurRRn+FPDWiT2kwuILFtNsHW3dlkXyRKP4j3I77j19q6tBZeG44U19YYIbQuseoXMiHKsB8xJwMt0C9TmoNRt4LbXtb0uC3ij0+w06N4YFGFywbJI714x4e8ZXusW9zfavZ6ffTpFMiC4iZ1UIfkwC2Mjs3UdiK71G6v0ONvXXc9t1bx/oenalYWNvb3mpTyhJEewtjJHsfO19/yrsznqT7VWu/FvjuK6mjg8BSzRK7Kkqaj8rqDww56HrXh3/Cx/Eutm7Rb7+zY4LaTy1sF8sKEXgDOcdBz196wPNu5PnfUtQZm5JNy/J/OiNDmV0U5NH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martha Ann Keels, DDS, PhD, Duke Pediatric Dentistry.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_1_4113=[""].join("\n");
var outline_f4_1_4113=null;
var title_f4_1_4114="Rx algorithm SVC synd";
var content_f4_1_4114=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 623px\">",
"   <div class=\"ttl\">",
"    Treatment algorithm for superior vena cava syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 603px; height: 559px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NSCLC: non-small-cell lung cancer; SCLC: small-cell lung cancer.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome-a proposed classification system and algorithm for management. J Thorac Oncol 2008; 3:811. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_1_4114=[""].join("\n");
var outline_f4_1_4114=null;
var title_f4_1_4115="Plaque sarcoidosis - annular";
var content_f4_1_4115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plaque sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Annular sarcoidosis. Erythematous, indurated, ring-like plaques with central clearing are present on the back.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc. Original photo provided by NYU (Tisch) Department of Dermatology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_1_4115=[""].join("\n");
var outline_f4_1_4115=null;
var title_f4_1_4116="Development of the adreno-genital primordium";
var content_f4_1_4116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Development of the adreno-genital primordium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 479px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHfAb4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1/wAB+D9D1bwpZ32o2bT3c7StJI08mWPmMOzV0H/CvvDH/QM/8mJf/iqPhd/yImmf9tf/AEa9dVQByv8Awr7wx/0DP/JiX/4qj/hX3hj/AKBn/kxL/wDFV1VFAHK/8K+8Mf8AQM/8mJf/AIqj/hX3hj/oGf8AkxL/APFV1VFAHK/8K+8Mf9Az/wAmJf8A4qj/AIV94Y/6Bn/kxL/8VXVUUAcr/wAK+8Mf9Az/AMmJf/iqP+FfeGP+gZ/5MS//ABVdVRQByv8Awr7wx/0DP/JiX/4qj/hX3hj/AKBn/kxL/wDFV1VFAHK/8K+8Mf8AQM/8mJf/AIqj/hX3hj/oGf8AkxL/APFV1VFAHK/8K+8Mf9Az/wAmJf8A4qj/AIV94Y/6Bn/kxL/8VXVUUAcr/wAK+8Mf9Az/AMmJf/iqP+FfeGP+gZ/5MS//ABVdVRQByv8Awr7wx/0DP/JiX/4qj/hX3hj/AKBn/kxL/wDFV1VFAHK/8K+8Mf8AQM/8mJf/AIqj/hX3hj/oGf8AkxL/APFV1VFAHK/8K+8Mf9Az/wAmJf8A4qj/AIV94Y/6Bn/kxL/8VXVUUAcr/wAK+8Mf9Az/AMmJf/iqP+FfeGP+gZ/5MS//ABVdVRQByv8Awr7wx/0DP/JiX/4qj/hX3hj/AKBn/kxL/wDFV1VFAHK/8K+8Mf8AQM/8mJf/AIqj/hX3hj/oGf8AkxL/APFV1VFAHK/8K+8Mf9Az/wAmJf8A4qj/AIV94Y/6Bn/kxL/8VXVUUAcr/wAK+8Mf9Az/AMmJf/iqP+FfeGP+gZ/5MS//ABVdVRQByv8Awr7wx/0DP/JiX/4qj/hX3hj/AKBn/kxL/wDFV1VFAHK/8K+8Mf8AQM/8mJf/AIqj/hX3hj/oGf8AkxL/APFV1VFAHK/8K+8Mf9Az/wAmJf8A4qj/AIV94Y/6Bn/kxL/8VXVUUAcr/wAK+8Mf9Az/AMmJf/iqP+FfeGP+gZ/5MS//ABVdVRQByv8Awr7wx/0DP/JiX/4qj/hX3hj/AKBn/kxL/wDFV1VFAHK/8K+8Mf8AQM/8mJf/AIqj/hX3hj/oGf8AkxL/APFV1VFAHK/8K+8Mf9Az/wAmJf8A4qj/AIV94Y/6Bn/kxL/8VXVUUAcr/wAK+8Mf9Az/AMmJf/iqP+FfeGP+gZ/5MS//ABVdVRQByv8Awr7wx/0DP/JiX/4qj/hX3hj/AKBn/kxL/wDFV1VFAHK/8K+8Mf8AQM/8mJf/AIqj/hX3hj/oGf8AkxL/APFV1VFAHK/8K+8Mf9Az/wAmJf8A4quC+KGh2HhuXSpNDjls3mWZZCk8h3AeXjqxr2evK/jn/wAwT/tv/wC06AOq+F3/ACImmf8AbX/0a9dVXK/C7/kRNM/7a/8Ao166qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKwfE/i3R/DcedTu1ExGVt4/mkb/AID2+pwK8j1/4qa5rFwbbw9AbONuF2L5kz/pgfgPxr0sHlWJxa5oq0e70Rz1cVTpaN3fZHud5eW1lCZr24ht4h1eVwi/ma5HVfid4X0/Ki9a7kH8NtGW/wDHjhf1ryCLwh4g1qb7Tq9yys3V7mUySflz+RIresfh7p0ODdzz3LdwMIp/Ac/rXTKhlWF/j13N9or9dV+KITxVX4IWXmauo/GqIEjTtHdx2eeYL/46Af51gz/FfxRfOUsbe0i9BDAzt+pP8q6iz8OaPaY8jTrfI6F13n82zRe67pGmfu57y3iK/wDLNPmI/wCArk0qeZYHm5cJhHN+bb/DUp4Sta9WrZf16HGP4g+IV+M+dqKg/wB2FYf5AUwxfECY7vtuqjt/x/7f03iujTx1orXCx+ZMFJx5hjwv+P6V1AIIBByDVYnOsVhLKWFhC+14v/gBSwNKte1Vyt2Z5oP+FgW3S81U9+bzzP8A2Y1Kvir4gaf9+W+ZB18y1WQfntP867rV9SttJsmurxysSkDgZJJ6ACuftvH2izNiQ3MA9ZI8/wDoJNaYfNcXioOosHGcV2j/AMOTUwlGlLldZp+pTs/jDrts+zULGznweflaN/5kfpXU6X8ZNInIXUbG7tGPUoRKo/Hg/pTLe80nWo9sUtrdr/cbDH/vk81QvvBuiXYJ+yeQ5/ihYrj8On6VjLMMtnLkxOHlTfk/0dvyKWFxCV6VRSXn/TPRtH8W6DrG0afqltJI3SNm2Of+Atg1u188aj8OXGW06+VvRJ1x/wCPD/Cqttd+NvChHkTXn2dP4c+fFj6HIH6VccuwWK/3PEK/aWj/AK+RDrV6X8an81qfSNFeM+HvjKwKx6/YAjoZ7U/zQn+R/CvUNB8Q6Vr8Hm6TexXGPvIDh1+qnkVw4vLMThNasNO+6+81pYinV+FmtRRRXAbhRRRQAUUUUAFFFFABRRRQAV5X8c/+YJ/23/8AadeqV5X8c/8AmCf9t/8A2nQB1Xwu/wCRE0z/ALa/+jXrqq5X4Xf8iJpn/bX/ANGvXVUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFef/ABv13XNA8HQT+FriK31W51C2s4nljDr+8fbyCDxyOa9Aqjq+k2GsQRQ6nax3MUUyXCLIOFkQ5Vh7g80AeG6F8b79ovGOoalp8rHTG02zi0zYVaC8lMkcyMyqzFRInoxwBgZOK67w58Ub691zQdJ1nw1caZc6ne3dp5sxliTbDAJVljWWJHZXztwQpBHfpXaTeD/Ds76y02jWMh1jZ/aAeIMLnZnaWB4JGTg+vPWs9vht4NfTU0+Tw3pslms/2kRyRBv3mAu4k8ngAc9higDk/Dvxav8AxFP4ft9J8MJLPqtvc3JDaiFEKQXJgJyY/myBu4x1x71mXfxgvbq81LTrfT4I7e4stSfTdUtZZXUyWqMSf3kKI/TqjOAeMmvUNG8I6BostnJpWl21q9nFJBbmNceXHI+91HsW5qjb/Drwhb30t5b+H7CK5lEyvIke0kSgiQcdiCePc0AYq+N5tB+CWh+KdSifUr6bTbF3TeI/OnmWNclsYUFnyTjA9O1QXPjzxPYeItM8PXXhbTrjWL1Z5F+y6v8AugkYiO4logQT5hGCM/LnkNx3baHpb6CmiS2FtLpCQLbC0kjDx+WoAVdp7AAflWdongnw3oVzBcaRo9raTweYY5I1O4GQKHOe+QiDnsooA4TRvi7fatr88Np4Uv59GSa6txdxJMWR4FY/OTEIgHK7QBKSCRuxXO6p8Z/ENx4ZvJ9P0nTrDV7a6s1ks555hNBHNJtKyJLAmTnau5dy/MTnjB9Zk8BeFJNYm1R9A0438xcyS+SPnLqVZiOhJDEE4ycmo7b4d+EbbSr3TYfD2nrZXuwXEXl58zYcoCTz8p5Hp2oA6CyuHkgt1vVhgv3hWSW3SbzNjY+YA4BYA5G7Az6DpVqsDUPB3hzUrOztb7RbGeKziWG2LxAvAijACP8AeXA9DXAeOr208ExmLQfEmtxaiRlLF7kXsS+m/wA8Oyr6BWB9OK2oYepiJqnSV2yJ1I01zSdkep6pqVnpVm93qNzHb26dXc4/Aep9hXjPi/4r3l/I1l4Xie3jY7ftDLmV/wDdH8P6n6VwVy/jnxrePeXS22oxR8KVY2yp/sop3KT+I9zXW+H7zSfDaAalo+r6dc4w9zdWvnLn/rpFvRR9SPevXtgsqV669pW/l6L17/j6HMlWxT9z3Yd+5S0bwPe6jL9r12aSMOdzKW3Sv/vE9P1Nd/pelWWlw+VY26RDuQPmb6nqaTStX03VojJpd/aXiDqbeZZMfXB4qzd3MNnbSXFzII4YxuZj2FeJjs1xeYy5ZvTpFbfd1+Z6FDCUcOrxWvdkkjrGjPIyoijJZjgAe9cXrXj+ztWaLTYjdyDjzCdqD+p/T61yHi3xRca3O0cRaKwU/JFnG73b1Pt2rnK+pyrhSCiquN1f8vRer/r5nl4vNpN8tDbubWr+J9V1TctxcskR/wCWUXyL/ifxzWMis7hUUsxOAAMkmtDQ9GvNau/Iso84+/I3CoPUmvVvDvhew0KMS4Et0B808nb12jsK9bHZpg8mh7KnFc3SK0+/t+ZyUMLWxsueT07v9DmvCngZiUu9bXCj5ltu5/3v8Pz9K725vrS1OLm6ghOOkkgX+deb+LfGk91O9rpErQ2qnBmThpPoew/WuJZizEsSWPUnvXlPI8Zm7WIx9Tl7RS2X6fi+51LHUcJ+7oRv3fc94uobHWrCSCRorm3fg7HBwfUEdDXl3inwjdaMzz2+64seu8D5k/3h/Xp9K521uZ7SZZbWaSGUdGRsGvTPBni/+03Ww1Tat0RhJMYEvsR2P86FgMbkCdbDS9pT3lHb59fvXzVg9vQx75Ki5ZdGeXIzIwZGKsOQQcEV02keNdWsAqSyC7hH8M3Lf99dfzzXVeKPA8F4HudJCwXPUxdEf6f3T+n0615ncwS2s7wXEbRyocMrDBBr2sNisBndKzim1unuv67o4qtKvgZ6O3mtmeveH/GGnauyQsTa3TcCOQ8Mf9lu/wChrpa+d69C8D+L38yPTtWk3Kflinc8g9lY/wBa+aznhf2MXXweqW8evy7+m56eCzTnahW37nXav4c0vVQxurVRKf8AlrH8r/mOv45rh9T8F6ppE4u9EuJJfLO5TG2yZPpjr+H5V6hRXg4HO8XgvdhK8ez1X/A+R318DRr6tWfdHH+FPize2Ei2fiaBriNTtM6LtlT/AHl6N+h+texaNrFhrVmt1pd1HcQnqUPKn0I6g+xrzbXfD2n61GftcWJsYWZOHH49/oa4C50nXvBl79v0q5k8pf8AlvD6ejr6fXIr26f9n5t/C/dVez+F+n9fJnnzjXwnxe9Hv1R9L0V5n4I+KllqpjtNdEdjengS5xDIfqfun68e/avTAQQCDkGvKxWDrYSfJWjZ/n6HRSqwqrmgwooormNAooooAKKKKACvK/jn/wAwT/tv/wC069Uryv45/wDME/7b/wDtOgDqvhd/yImmf9tf/Rr11Vcr8Lv+RE0z/tr/AOjXrqqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAopCQoJJAA7mvFviZ8SHunfR/DMrGNjslu4jy5/ux47e/ftx17cDgauNqclNer6IxrVo0Y3kanxK+Ji6eZdL8OyK94PlluhgrF6qvq3v0H16cT4X8HTajL/AGjrxk2O2/y3J3yk85Y9Rn8zWj4L8HLaCO/1VA1zw0cJ6R+59/bt9endV2Y3NqWAg8Jlz1+1Pq/T/P7u5NDByrP2uI+S/wAyOCKOCJIoUWONBhVUYAFSUUV8m227s9fYyNV8N6Nqsgl1DTLSacdJjGBKv0cfMPwNeS+Og638mnaLq+pR2cDYaOec3KFx1/1mWwOmN1eueKNS/srQ7q6U4lVdsf8AvHgf4/hXhpJJJJyT3r7LhTLVXlLFVdo6L16v5fqeLm2JcEqUd3v6FazW6WNheyQyODw0SFAR7gk8/jWto2mzatqMNnbj53PLHoo7k/SqNesfDjRvsGlfbZlxc3QBGf4Y+w/Hr+VfV5xmCy3Cua+J6L1/4B5WDw7xNVRe3U6LR9Nt9JsY7W0XCKOW7se5PvXL/EzWTZ2CadA+JbkZkI6iP/65/ka7avEfGN8dQ8R3soOUV/LT6Lx/TP418Rw3hXjse61bXl9536vp/n8j3Myq+wockNL6fIxa81+IOsTS6obCGRkggA3BTjcxGefpx+telV4jrU5udXvZs53zOR9MnFff5hNxgorqeJgYKU230O++HutSXtrJZXTl5oAGRj1KdP0P8xXZI7RuroxVlOQQcEGvH/BNybbxLZnOFkJib3yMD9cV69V4Kp7SlaXTQnFw5Kl11PbPB2s/21o0c0hH2mP93MB/eHf8RzVTxv4cTWbEzW6AX8IyhH8Y/un+lcb8Mr82uvm2ZsR3SFcf7Q5B/LI/GvWa/OM0pTybMufD6L4l6Pp6br0Pfwso43DWqa9GfPBBBIIwR2pK7H4kaL9g1MX0C4t7oktj+GTv+fX8646v0nA4uGMoRr09n+HdfI+br0ZUajpy6HrXw9146pp5tLl913bAck8unY/UdD+FddXhfhnUjpWt2t1nCBtsnuh4P+P4V7mORxX5vxNlyweK56atGevz6r9fmfSZZiXWpWlvH+kLSHkc0tFfOnonF+JvA9tfb7jS9ttcnkx/8s3/APiT9OKzfCnjnWvBl2NO1aKW4sUODBIfnjHqjent0+nWvRqzta0ez1i18m9iDY+644ZD6g19Hgc+ah9Wxy9pT/Fej/r1PNxGATftKD5ZfgzvvD2u6d4gsFu9KuFmj6MvRkPow7GtSvme5sNb8DakuoaZO/kg4EyD5SP7si/48enNev8AgH4h2PiZUtboLaarj/VE/LJ7of6Hn610YzK1Gn9Zwkuek+vVev8AXqc9LEvm9nVXLI7miiivHOsKKKKACvK/jn/zBP8Atv8A+069Uryv45/8wT/tv/7ToA6r4Xf8iJpn/bX/ANGvXVVyvwu/5ETTP+2v/o166qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApCQoJJAA7mlrxf4veOmuJZfD2iSErny7qVOS5/55rj8j69PXPZgcDUxtVUofN9kY160aMeZlb4o/EB9VlfQ/Dzs1qT5c00fJnPTYv+z/AD+nU8FeEk0tEvL9Ve/Iyq9RF/8AX96PBHhVNLiS9vlDX7jhTyIh6fX3/D69hW+aZpTpU/qGA0gvil1k/wDL8/Td4TCSlL29f4ui7BRRRXzJ6gUUUUAcR8VmcaLaqPuG45+u04/rXl1e9azplvq+nyWl2D5bcgr1UjoRXnq+AJZbyeKDUYWSFwjloyGGQGHHQ8Ed6+84bznC4fCOjWlyuLb2ez9PuPBzLB1alXngrpmH4P0Zta1iOJlP2aPDzH/Z9Px6V7WoCgKoAA4AHas3w/o1toliLa1BJJ3PI33nPr/9atOvns9zX+0sReHwR0X6v5noYDCfVqdn8T3I7h/Kgkk6bFLfkK+fGJZizHJJyTX0HOu+CRAMllIx+FfPdfQcF2tW7+7+p5+dbw+f6DZG2Rs2M7QTivBySxJPJPJr3ecEwSAckqQPyrwevpcx+z8/0OTAfa+Rb0h/K1ayk5+SdG/JhXuFeGaf/wAf9t/11X+Yr3Oqy7aROP3iaHh+Y2+uafKDjbOhP03DP6V7xXz7ZEi8gKcsJFI+ua+gq+S4zilUpS7p/hb/ADPQyV+7Nehm+INLj1jSZ7OTALjKMf4WHQ/57V4ddQS2txJBOhSWNirKexFfQdcx4q8I22uSC4jkNtdgYLhchx7j1964uHM7jgJOjXfuS1v2f+TN8xwTxCU6fxL8Tx6ve9FLto9iZf8AWGCPd9dozXH6R8PYYLhJdRuvPVTnykTAP1J7V3g4HFa8T5th8dyU8O78t23/AMOTlmEqUOaVTS4tFFFfJHrBRRRQA2RFkRkkUMjDBVhkEe9ed+KvBLwu19oIb5TvMCn5lPqh/p+XpXo1Fd+X5lXy+pz0Xp1XR+pz4jDU8RHlmjE+FnxDu7+8h0PW0knuG+WK5Ay3A6Sfl978/WvXK880mwtYddju4reNLmWRFeQDlgG/z+npXodduLxdHF1XUoQ5F1Xn1OWnRnRjyzlcKKKK5iwryv45/wDME/7b/wDtOvVK8r+Of/ME/wC2/wD7ToA6r4Xf8iJpn/bX/wBGvXVVyvwu/wCRE0z/ALa/+jXrqqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKx/FmvW3hvQ7jUbs52DbHHnmRz0Uf54GTV06cqklCCu2KUlFXZyXxc8aHQNP/s3TpNuqXS8sp5hj6bvqeQPz9K4P4d+Gtipq1+mXbm3Rh0H98+/p+fpWV4csLrxf4iuNU1YmSIP5kzHo7dkHtjt2AxXqgAAAAwB0FexmuJjllD+z6D99/G/0/rp6s58HSeJn9YqbLZfqLRRRXyJ7AUUUUAFFFFABWDp8pTxdqsDH5ZYopV+qjDfzWt6sOZPK15rnH3Hhjb2WVZBn8WiQV3YGKmqsX1i/waf6HPXfLyvz/wAzcooorhOgK8C1aA22q3kBGPLmdPyJr32vHviLZG18TzOBhLhVlX8sH9Qfzr6/g6uoYmdJ/aX5P/gnj5xTvTjPs/zOYrwidPKnkjP8LFefY17vXi/ia3Nt4gv4yMfvmYD2JyP0NfZ5ivdizzMA9ZIi0KPzdbsE/vToD9Nwr22vJfAdubjxLbHGViDSH8BgfqRXqF3NcxMot7TzwRyfMC4/OjAe5Tcn3FjneaijX0WIzaxYxDq86Lx/vCve68E8EPqs/iO2aHRvOMGZSv2lF4HA5PuRXrP9reIP+ha/8n4/8K+L4urqriKcI9F6bvz9D1Mog405SfVnRUVxvj7WNUsPhrrWpxxnTdSggZ0AdZShBABzjB4rz7R/iJr+n63qdrrySXE+h6DLPcQIAq3UqyxmOcEDgNG4z6c8V8ooNq6PWcknY9zoryOx+J+rRw20mr6dZRQz31lAtyshWPyZywd8Ekjbt69DntVwfEbUr2/Fpo9jp1xJLrVzpULyXDLGyxQrIJCyhuuT0B6UezkHOj1CivLJ/iNqMHjW10v7PYXNg+oppc0kO8NFMyZI3Njdg56LjGOc1Z8Hazq0vwSm1YXZm1WOC9kSe4O45SaUKTnOcBRjPoKHBoOZM9KorynQviHfQWGhR69JprS3mhvqJuRLs3yKqkKRgAMckkDp24rCl+Ietx3lxrkLWa2w8P2uoyWNzOwjyztuWPH8Z4AJ9BwaPZsXOj3OivKz8StUn8WPY2WjRmwt7m3t7gSsVmVZFUmTqFAG4YU53YPIr1SpcXHcpNPYsad/yEbX/rqv8xXc1w2nf8hG1/66r/MV3NdWH2ZhX3QUUUV0GAV5X8c/+YJ/23/9p16pXlfxz/5gn/bf/wBp0AdV8Lv+RE0z/tr/AOjXrqq5X4Xf8iJpn/bX/wBGvXVUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAEgAknAFfO/xF1+bxp4si07TDvsoHMUGDw5/ikPtx+Q9zXofxn8UHR9CGm2km2+vwVJB5SLox/Hp+fpXG/DbQ/slidSuF/f3AxGD/AAx+v4/yxXv4Hly3CyzGoveekF59/wCvPucVVPE1Vh47bs6jRtNh0nTYbO3Hyxjlu7N3Jq9RRXx9SpKrNzm7t6s9qMVFKK2QUUUVJQUUUUAFFFFABVCe2e5uNStohma404yxD1lgkV0H5vV+okm+x61pN4eFS5EL/wC7ICn/AKEUP4V25fU5K6/rXp+NjDEx5qbC2mS4t4p4zlJEDqfYjIqWq8Vt/Z1/f6ZjC20paIf9Mn+ZMew5X/gNWKwxFP2VRwW3T06fgaU5c8VIK5H4j6QdQ0cXUK5ntMtgdSh+9+XB/A111IQCCCMg1pgsXPB1414bxf8Aw6+ZNakq1N05dT54rhPiBoNxc3Md/YwvMSoSVIxluOhx39Pwr3Lxj4NmtZpLzSYmltWO5oUGWj+g7j+VcSeODX6zh8Th8zoc9J6fin5nykoVMHU95f8ABOQ+H+iTafbzXd5G0c82FVGGCqj19Mnt7V11Fdf4R8Hz6lMlzqMbw2I52sMNL7D0Hv8AlV18TQy6hz1ZWS+9+nmTGFTFVPdWrOj+GOkm106TUJlIkucBAeyDv+J/kK7amoixoqIoVFAAAGABTq/JMfjJY3ESrz6/gui+4+sw9FUKaproQXtpb31rLbXtvDc20o2vFMgdHHoQeCKi/syw+2m8+xWv2sw/ZjP5S7zFnPl7sZ25529KuUVyXNjGi8K+H4rW4totC0pLe4IM0S2cYSUg5G4Yw2D61Na6Do9o0bWuk6fC0UpnjMdsi7JCu0uMDhioAz1wMVp0UXYrIy5PD2iy6l/aMmkac+ob1k+1NbIZdy8K2/Gcjsc8Vbs7C0srIWdna29vaDdiGKMIg3ElvlAxySSfXJqzRRcZjf8ACLeH/s8EB0LSvIgZnij+xx7Y2bqVGMAnuRQ/hbw/JLbySaFpTSW6qkLmzjJiVfuhTj5QOwHStmindisjNu9C0i81CK/vNLsJ76LBjuJbdHkTHTDEZGK0qKKQyxp3/IRtf+uq/wAxXc1w2nf8hG1/66r/ADFdzXXh9mc9fdBRRRXQYBXlfxz/AOYJ/wBt/wD2nXqleV/HP/mCf9t//adAHVfC7/kRNM/7a/8Ao166quV+F3/IiaZ/21/9GvXVUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUdxNHbW8s87iOKJS7ueiqBkk/hUleafHLxB/Z/h6PSoHxcX5+fB5ESnJ/M4H0zXTg8NLF140Y9X+HUzrVFSg5voeaTTTePPHktzMH+ys+7af+WcK9F9if5kmvU1VUUKoAUDAA7CuU+HGk/YNF+1SDE93h/og+6P5n8RXW1XEONjXxHsKXwU/dX6v9PkXl1B06fPL4pasKKKK8E9AKKKKACiiigAooooAKrajbG7sJ4A2xnQhW/ut2P4HBqzRVQm4SUo7oTSkrMdrMv2/RtN8Twx4eOPyb5B1VM4b/v24P4Fqo3WoW9vc2tu7ZmuWxGq88YySfatLwTdK2r6np8KG5sJh5rsq7o4peAyE9PmGDj1DZ61Brfh+y0KHTI7MyM0+octK25hGsMxVAeyrxj6+9e3Wo0qvvTurJtLys2k/T8VbpqefTqSh7q11/W34/gLRRRXhHohWfe6Npt6xa6sbeVz1YoN359a0KKunVnSfNBtPy0JlFSVpK5m2mhaXaSCS3sLdJAchtgJH0J6VpUUUVKtSq71JNvzdwjCMFaKsFFFFQUFFFFABRRRQAUUUUAFFFFABRRRQBY07/kI2v/XVf5iu5rhtO/5CNr/11X+Yrua68Psznr7oKKKK6DAK8r+Of/ME/wC2/wD7Tr1SvK/jn/zBP+2//tOgDqvhd/yImmf9tf8A0a9dVXK/C7/kRNM/7a/+jXrqqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5u8Q3beNviNJsYtZ+Z5UZHQQp1I+vJ+rV7H8U9bOh+DbySN9tzc/wCjQ4OCC2ckfRdx/KvLvhXpmy2udSkX5pD5Uef7o6n8TgfhXvZfL6jg6uPfxfDH1f8AX4M460fb1oUOm7O8RVRAqABVGAB2FOoor45u57YUUUUAFFFFABRRRQAUUUUAFNdFdGR1DKwwQRkEelOooTsBUsrabTQBo97c2SDpCrb4v++GyB/wHFZvjHxXcWf9nHWVtZDDI8iG23K8nyFcFDkAfN13fhW7XifjS8e98TXzOSRFIYVHoFOP55P419PkFCeZYhwrO8Unfvrpa+55eYTjhqalBWd9O33HVwfEiMzYn011iz1SUMw/Agfzrs9I1Wz1a28+xmEi9GXoyn0I7V4LRoGra9o2ox3Nu9gBnDqd+GX0Ne7mnC+GdK+Ei4yXq0/W5w4XNKilaq7o+iKK5z/irD0/sHH/AG1pf+Kt/wCoF/5Gr88sfQ3Oiornf+Kt/wCoF/5Go/4q3/qBf+RqLBc6Kiud/wCKt/6gX/katTSf7S8l/wC1/sfnbvl+y7tu3Hfd3pWC5N9stvtX2X7RD9pxnyd4349dvWrFeD6LoOoWvjmNNP027urW51CWe4l1PSfJnss5zJHd9HPoMnPTFP0fVfGmpeG/Fs32q8lvdEt20mAWo3m5uklJeYADJbbsHHqa0dPzJ5/I91orxSS28Y2Os3Zg1DxLc29pqenmASpuSaKVFNxuwg3KpyMDAX2NGiav4j1HxfKLC41q6ktfEd3BOjJiySxQsNhYgLvzt2jJNHs/MOc9rqH7TB9rFr58X2op5oh3jfszjdt64zxmvnwx+M9as9esp4PES215pFwxtrmOVtk6upVBI6gMWGRhAAQcD21ToerXl7Z3NhJ4mtGtvCkypcGFopmuFnysDZTPUcKMEqB26ns7bsOfyPdKhubmC1RXup4oUZgitI4UFicADPc+leH3V34+l1HTprmXWbX/AEKxlg8izkkRpDGpnWZEXAYvuBD4wMYxTrfTNb0u61+G2g117iXxPFcDdbGSGS2Z0zKG24LYByQeABnFHs/MOfyPdKK828MS6u3jS5GvN4jW7+3XAhSOI/2d9l2t5ZLY2+nffuxkYzXpNQ1YpO5Y07/kIWv/AF1X+Yrua4jSv+Qlbf8AXQfzrt66sPsznrboKKKK6DEK8r+Of/ME/wC2/wD7Tr1SvK/jn/zBP+2//tOgDqvhd/yImmf9tf8A0a9dVXK/C7/kRNM/7a/+jXrqqACiiigAooooAKKKKACiiigAooooAKKKKACiioL+6isbK4u7htsMEbSOfQAZP8qaTbsgbseG/HHVX1LxRaaPbHetooBUd5Xwcflt/M11mkWSadpltaR42woFyO57n8Tk15x4PWXxB41uNUuhkq7XT9wGJ+Ufhn9K9Tr1OIpqhCjgI/YV36v+vxMctjzudd9Xp6BRRRXy56oUUUUAFFFFABRRRQAUUUUAFFFFABXkXxB0aaw1ma8WMm0uW3hwOFY9QffPP4167UdwIjBJ9oCNDtJcOMjHvXq5Rmc8tr+0irp6Nf11OXGYVYmnyt2sfPdWtMsZtRv4bW3UtJIwHA6DuT7CvTbHwto2r6fb3zWZt2nXftikIGD046dPSug0jRrDSEK2FusZb7z9Wb6k19ji+LaFOEo04PnWmtrJ+t3/AME8ajlM5NOTXKX0UKiqvQDAp1Fcz4p8a6L4bJjvbgyXWM/Z4Buf8ew/EivziUktWfUUaFSvLkpRbfkdNRXkUnxnhEuI9EkaL+81yA35bT/Ous8L/EPQ9flS3WR7O8bhYrjA3H0Vuh+nB9qhVYN2TO2tk+NoQ56lN2+T/K52NFFFaHmhXG6z4r8P+DrmXT47KVTHA+oXKafagrDGTzJJjAGTn1Jrsq80+JfgXVfEepy3GiXMNn9rsfsF3I9yyb03E4MYjYNjPGGQ9iSKqFm9SZXtobWofEPRtP1ewsLtLyM3xiWGcxDy2MgBXvu7gEgYB71U0zx74Yg1Q2NpaXNml1ezxvdfYvKt3uVyZNz9Cx2k55z3NRz/AAs0ifUkvXvtSSTzLaZ443jCPJAFCE5QsBhRkBsVfX4e6R5FtC8t5JFBqM2phWdfmkkDBlPy/c+c8DB96r3Be8ZWofFLT30S/udKtrv7Smnzahafa4CkdxHGcbgc52kkehq5b+PrW3OqPqjoEs4bFhDbwuZDJcKSqDnDEnoBjHeua8O/CvUPPmi8QahjTBpculwQW9yZnjjkYE7WaJdoAGACGPPJ4rrZ/h3o841LzJb3ffJaKXEihoWtgRE8ZC8Nzk5yD6dqb5EJczGt8RtGWCFvI1JrqS6ksvsa2rNOsyLuKFB7EHIyOevWt7wvr1l4l0WDVNN80W8pZdsqbHRlYqysOxBBrF0/wBpdneWN59pv5ry2vZNQaeaRS9xM6bCXwoGAuAAoUDFbPhfQbXw3pZsLGSaSHzpJt0zAtudy56AcZJxUPltoUubqa9FFFSUWtK/5CVt/10H867euI0r/AJCVt/10H867euvD7M5q26CiiiugxCvK/jn/AMwT/tv/AO069Uryv45/8wT/ALb/APtOgDqvhd/yImmf9tf/AEa9dVXK/C7/AJETTP8Atr/6NeuqoAKKKKACiiigAooooAKKKKACiiigAooooAK88+N+sf2d4R+xRtia/kEfB52L8zH/ANBH/Aq9Dr53+JmpP4q8frYWb7oLdhaRkcjOfnb88/gor2Mkw6q4pVJ/DD3n8v8AgnLjKjjT5Vu9DZ+Gen/ZNANy64kun3/8BHA/qfxrrqitYI7a2ighGI4lCKPQAYFS18/j8U8XiJ139p/h0/A9ShSVGnGC6BRRRXIahRRRQAUUUUAFFFFABRRRQAUUUUAFY/iuUx6HcIhIaZTHkdlwS5/BAx/CtisTWV+0yzJwVhiSLH+3PII/0jEv513ZbBTxMXLZav5f8GyOfEycaTtu9DR0yD7NplpAeDFCifkoFWqKQkAEk4A6k1xzk5ycn1N4qysjgPir40bw7ZrY6cw/tO5XO7r5KdN31Pb6GvnTVNT8qRmkZprlyWYsckk9ya2/GuttqutalqkhJEkhMYPZRwg/LFcBI7SOzucsTkk1ywj7aV3sj7pWyfDRpU1+8krt/wBfci42qXRbIdQPQKMVo6dqQuGEcoCS9iOhrAoBIIIOCOhredCElZKxyYfNMRRnzSk5Lqn/AFofT3wh8bSakBomrStJdopNvM5yZFHVT6kDnPcZ9OfU6+PfD2pzQSWt/bvsubeQMCP7ynNfW+lXseo6ZaXsP+ruIllX2DDOKypSesZbo4s/wVOlOOJofBP8H/wf8y3RRRWx88FFFFABRRRQAUUUUAFFFFAFrSv+Qlbf9dB/Ou3riNK/5CVt/wBdB/Ou3rrw+zOatugoooroMQryv45/8wT/ALb/APtOvVK8r+Of/ME/7b/+06AOq+F3/IiaZ/21/wDRr11Vcr8Lv+RE0z/tr/6NeuqoAKKKKACiiigAooooAKKKKACiiigAoopGIUEsQAOST2oA5j4j+Ix4a8MXFzGw+2S/ubcZ/jI+9+AyfwA715B8LtJLST6rOOmYos9z/E39PzqLx3rM3jnxnHaaexayhYw2/pjPzSH64z9AK9C06zisLGG0txiKJQq+/ufc17mPl/ZeXrDf8vKusvKPb+vM5cNH6zX9r9mO3r/X6FmuVvPHWkWnjq18KSi4OozxhxKEHkoxDMqM2chiEJAxzkV1VeWar8K7i/u77Vf7fnj1uXU01GCQIDBGUIEalOp2plc7h9K+Sil1PXlfodPqnjzR7PxFYaJBPHd6hc3YtJI4XBMBKlst+WMdeatr418MvZTXceu6dJbQ7BI6Tq20vnaDg9TtbA6nFcva/Du9ttbtZk1a2OmW+sSawsBtT5xeQEMpk34IGeDtzTB8MMeA9C0OPUUjvtJuBcpdLEwWVgX4ZVYNjDkZDAjsaq0O4ryOoufHXha1sre7uNe05LedDJE5mH7xQdpwOpweCKlvvGPh2wltY7zWLKJrqNJoS0g2ujkhW3dMEg4PfFcrpHw2eyvEuJLuzH+g3Vq0UFu4TdOwJYb5Hbsc5JzntWRrXwk1HUdEtdLHiCP7NFp0NlslgkZUaM5LookCgt33Bj6UWh3C8ux6L4e1+LWr3WraKB4m0y7No7MQQ52q2R7fNUaeMfDj3N3brrVgZbRGececMRqpAYk9OCQD6ZpPC/h99F1DX7lrhZhql8bsKFx5Y2Ku3rz93rXHN8PbiLwu/hK51+0TRpQ6WI+yAXPmGTzl3MXw+3acgAFhnNK0Wx3Z2UXjHw5Jpq6gut2C2TTfZ/OeYIokwW2knGDgE4PbmqWnfEHw1qGrX+nwapbiSzhS4aV5FEbxsu7crZ5AGMnjGRWI3w6ubu/TUdT1O3m1CTWLbVLkRWxSFlhiaNY1UsSCQ2SxJ+lT698PZNW1LxKRqUcGna9aQwTRLATJE8IIjKNuA285II56ZFO0O4ryOisfF/h6+t1ntNYs5IjOttu8wD9633U56E9vXtWpp+oWmpQvLYXMVxEkjRM8TblDKcMM+x4rzuL4bXjaLq2n3WoWGdUa3S6nitpTI0UROTmSV/nOQAeAuOAeMdj4J0SXw54btdIluIriO0zHDIkXlkx5+XcBxux1I6nnvSko9GNN9TdoooqCgrLjUSW2muclr67mv/8AtlEvlR/gdyt+NWNVaT7E0VucXE5WCI+juQqn8Cc/hVi7SNdengtxi2063hsIh6YXc36Mg/4DXp4ReyoVKvdW/T82n8jlre9UjD5/19zJKyfFtybPwvq1wpw0dpKyn32nH61rVzfxI/5EbWf+uB/mK8qWiZ6WEip14RfVr8z5R11ttmF/vOBWBW3r/wDqYv8AeNYlLDL3D6vOpN4prskFFFFbnlGvocyxxXHmMqIuGJY4Ar6P+GXjbw7F4J02HUPEGkW9zEHjMc17GjAB2xwWz0xXzboH+vl/3f619P8AwSLHwOmRgC4kx7jiuZWVZndmSlPKabvopf5/1sbn/Cc+Ev8AoaNC/wDBhD/8VVnTfFPh/VLtbXTNd0q8unBKw295HI5AGThQSelbNQ3kJubSeASyQmVGTzIiA6ZGNykgjI6jg1tofJanBeF/iVBrHijVdOubQWdjbxS3FpetJlbmKKQxyNjHGCCcegq7b/EvQZbG7upFvreO3sxqAE9uVM1sW2iWMd1yR6HkcVXsvhP4YsW0p7OG4hksI2iZ1kGbpHQo6y8YIYE527eScYp0fwv0cadeWc17qlws9iNNjklmQvbWwYMI4/kwBkDlgx4HNW+Qn3h1t8RILrxdp2i2+j6r5V5A0y3Mts8RGGC52MoOznO7IxxxzV7w9470nXPEE2iwR3dvqEcTTeXcRhdyhgD0JweRwcHnpVrUPCdnea3pmqi6vbe6sYWth5LqFmiJBKPlTx8o+7g+9ZfhL4caV4Y1a3v7G81GV7eB7aGKd4yiRuwYj5UBJyOpJPrml7tg96521FFFQWFFFFAFrSv+Qlbf9dB/Ou3riNK/5CVt/wBdB/Ou3rrw+zOatugoooroMQryv45/8wT/ALb/APtOvVK8r+Of/ME/7b/+06AOq+F3/IiaZ/21/wDRr11Vcr8Lv+RE0z/tr/6NeuqoAKKKKACiiigAooooAKKKKACiiigAry740eMP7NsToenyYvLlP9IZTzHGe31b+X1Fdf468T2/hXRJLuXD3L5S3hz99/8AAdT/AIkV4b4Q0m48S61Pq+rM0sQk3uz/APLWTrj6D0+gr28rw1OlB4/E/BDbzfT+u/zOPETlOSoUvif4I6H4daB/Z9j9vuUxdXC/KD1RO34nr+VdLrWpQaPo97qV42Le0heeQ+ygnA9+KudKxvF/h+DxRokmlXk00VpK6NMIiAZFVg2wn0OBnFfOYzGTxteVeru/wXY9WjRVCmoQ6HM+GfiZY6j4VvtY1qzl0mWynFvNZljNJuYKYwoCgktuGBj1pul/E2wc6i+sQXFjHFqX9n2yfZpGlc+UHwyAEhuvGO1E3wp0QTag1jcX1lHeCBtkUu7y5oW3RyqX3HcORg5GCas2Hw7tba9ivJ9Uv7u6TU/7VaSURgvL5fl4IVQAuOcACsPcL94tP8Q/D6atBp7TXIllkihLm2cRxyyAFI3bHysQRwemecUmnfETQNQ1S3sLZ7zzLh5Y4ZHtJFikkjzvRXIwWGDwP51Vu/AGkTeL5tUgvnt7ueSO7uLYRwSbypADAujOgJXBKkZ9qRvh/pNrY6Zbz6hcpDZ3VzPGzSKhd7gOCucf7ZxjnpRaAe8U9c+Ken2+ga5c6ZBcHU9MgS4NpewvCWRpAm7ntk/XNej15ZZfCPRW02+tYtYu54p7FdMZkWBfLRJQ/wDAgBbIwS2ScnNep1MuXoON+oVheMtOn1DQpDYAHUrR1u7PJxmaM7lU+zcofZjW7RUp2G9Slo2owatpNnqFqSYLmJZUyMEAjOD6EdCKu1y3hr/iU+INW0I4WB2OpWQ6fu5GPmoP92XJ9hIorqabVgQUUUUhhRRSdKAE00JN4jheY4ttNhe9mPYHBVM/h5h/4DVTSTJJZi4nGJ7pmuZB6FyWx+GQPwp2CPCE8pH73XrpYU7H7OP6GNHb/gdQa7q9totg1zdE4ztRF6u3oK9ivSn7OnhaavJ9PT/gtr5HFTmuaVaT0X9fkl95pVkeLrJtR8L6raIMyS2zhB6tgkfriuJk+I14ZSY7G3WPPCszE4+vH8q6zwt4otteVowhgu0G5oic5HqD3pYzIcbhaTq1Ye71s07etjTC5lRlVXs5ap3XyPk/W4y9nuA+4wJ+nSufr134oeGG0HxDcKI/+JfdlpYCBwAeqfgT+WK8sv7N7WTB5jP3WrwsPLlvTe5+g5pBYiMcbS1jJfd/WxVoop0aNI4RFLMegFdR4qTbsjW8PocTSduFH+fyr6n+EdobTwHp+8YaYvKR9WOP0Ar518M6PNfXlnplou64ncLn0J6k+wGT9BX1pp9pFYWFtaQDEMEaxIPZRgVyU3z1HM788f1bBUcI/i3f4/q/wLFFFFbnyQUUUUAFFFFABRRRQAUUUUAWtKGdStsf3xXb1xWj/wDITt/96u1rrw/ws5q24UUUV0GIV5X8c/8AmCf9t/8A2nXqleV/HP8A5gn/AG3/APadAHVfC7/kRNM/7a/+jXrqq5X4Xf8AIiaZ/wBtf/Rr11VABRRRQAUUUUAFFFFABRRRQAVV1S/ttL0+e9vpRFbwqXdj/T1PbFWiQASTgCvn/wCJ/iybxXrMejaMTJYRSbV2H/XydN3+6Ocfifp6GW4CWNq8u0VrJ9kYYisqMb9XsZOqX1/8RPFpc7orZeEXqIIgf1Y/qfbp6bYWkNhZxWtqgSGJdqj+v1rO8L6HFoWmrAmGnf5ppP7zf4DtWzWGdZnHFzVGhpShol38/wCv1Z0YLCujFzn8T3/yCuV+KF3qlj4D1e50AzjVI0UweTHvfO9QcLg54z2rqqK8NOzudr1R4yZPF+n+JCi6rrV5aW3iC1tVEsCFZraZQZWYrGMhT0IwF/lWttW8eDxJqG+S8F6j3ix2ElrI0EihH8gowi8tRkJ8xkyc4PWvYNX1jT9Ht/O1K6it07bjy30HU/hXGXHxV0WOUrFbX0qD+MIoB+gLZ/lRLEQhpKx24XKcZjFzUKbku/T7zzmGXxKZdU1bSH1+51keGoQ093ZMjrci4DSxxqyAEAFsAA98E1teIdU1fxNf6iY7PVf7Ki1PR5bKK4sniKjcxlYAqDjIBJPTjsa9Z8O6/p/iCzNxpspcKcOjDDofQj/IrVq1VT1RyVcPOjN06iaa3TPB3l13S/Dv2Wyh1mza61rUWa4tY3+Qbsx7lWN2YNn5cADjJOK9F8J+JLiDwd4auPFC3Ed7fIsM08kWxY5TwvmDjYWOAOMZIHGRXZ1X1CzttRsp7O+hSe2nQpJG4yGU9RQ5p9CFFosUVymg3lxompJ4e1iZ5kcE6beynm4QdYnP/PVB3/jUbuobHV1DVhpnL+OVaxhsfEEIO/SJTJMFGS1sw2zD8FxJ9YxXTKwZQykMpGQQeCKSWNJYnjlRXjcFWVhkEHqDXN+BZHtrK60K4Zmn0eX7MpY5LwEboW9/kIUn+8jU90HU6eiiikMKq3kUl5Jb6bAWWW9fyiy9Ujxl2/BQce5FWqm8OyRWqap4jvc/ZbaNreDHJKqcyEe7OAo/3PeuzA0uepzWvb8X0X3/AIXMMRPlhbv/AExmuvHN4hjtLdQtrpVuIlUdBI4Bx+CBP++zXlvxYlc6pZQkny1hLjnuWIP8hXounJMtuZbrm6ndp5j/ALbHJH0HQewFcf8AFHS3uLKDUIVLG3ykgH909D+B/nXtZNiaazWDk9NYp+dt/m7/AHnFi6UvqjS33/r0PMau6PfyaZqdveRE7onBIHcdx+IyKpVntcanvITT4GGeD9p6/wDjlfpNfkcHCorp6bN/kfNwuneO6PoLxBoth4k0h7O+TfDINyOv3kOOGU9jXz54w8B6roMkguLZruw6i4iQsuP9ofwn6/nXt+n3niiGwtom0CxJSJVJOpkE4AH/ADyqx/aPib/oX7D/AMGh/wDjVfh9agnJ2e3U/TMszmtgVypc0Xun+h8pHS7UnOxh7BjW94e8L6hqsqx6Np0soJwZAuEH1c8D86+hH/tmRy8nhPSGc9Wa/BP/AKJqyt/4lVQF8PWAA4AGpn/41WXsJPSUj1XxJSpq9CglLv8A8MkZfw68CReF4murt1n1SVdrOo+WIf3V/qa7iud/tHxN/wBC/Yf+DQ//ABqpbS+8QSXMS3WiWcMDMA8i6gXKjuQvljP0yK2jDlVkfOYnFVMVUdWq7tm7RXh3xiMkPi17oTQakI7RUTRrtLlCSTndbNF8pkPA55GPpWxa+I/E6+P9P8LbXgjn8jURJIiu0NmIj5sLHu3mKF3defpV+z0uc3PrY9ZorwyDxJ41u5bArrbQJfjU12jT4z5H2Y5Qgkclhxzxjtnmmat4/wBf8ixU6s1hdTeGodRiiislla4vTIyiPBUkBsAYHTtin7Jhzo92orxHXfHPia28XWFvHJNa7Z7GK6sZYV2MJQvmGP8AdliASRuMi4Ixg1jodWudIisbvWLu41K38Y26AT2+Wth50m2TkcqcZ25wNvGAaPZvqHOfQ1FeGah4v8Y2Vm9pJfkx2+s3dhPqxtUQqkccbRbh5bou4uwzt/hxx1oi1fXZvEelXWrauRHd+HpgUht2NtczLIRsCso5YDdnA44HBo9mw50e50V4lY+JdVttM8PW9zqT+HNNbRIriOa301ZlnuCcGLbsIAAA+RcMc8GvbamUeUady5o//ITt/wDerta4rR/+Qnb/AO9Xa104f4WYVtwoooroMQryv45/8wT/ALb/APtOvVK8r+Of/ME/7b/+06AOq+F3/IiaZ/21/wDRr11Vcr8Lv+RE0z/tr/6NeuqoAKKKKACiiigAooooAKKK5H4keLY/Cuil4irajcZS2Q84Pdz7D9TgVrQoTxFRUqau2TOapxcpbI5T4zeNfscD6Bpkv+kyr/pUin/Vqf4PqR19vrxi+APDf9m2wvrxMXky/KpHMan+p/8AretYngTQpdVvn1nVN0qeYXUycmWTOSx9QD+v0r02vTzjFwwVH+zcM/8AG+77f5/d3MsFRdaf1mr8l+oUUUV8oesFcj488ZQeG7byYNk2pyDKRE8IP7ze3t3qfx34ph8M6ZuXbJfzZEER/wDQj7D9f5ch8J/AVz401R9e8QmR9MWTcd+c3bjsP9kdz+A74wnOUpeyp7v8D6PKssoxovMcw0ox2XWT7L+v1KngzwBr3xCujq2rXT29g7c3Moy0mDyI16Y7Z4A9+lewWXwf8H21ibeSwluZGXBnlnff9RtIA/AV38MUcEKRQxrHEihURAAqgdAAOgqrrWp2ujaVdajfyeXbW0ZkdvYdh7noB6mu2lgqVKN5K76tnFjeJMfjaqhh5OnHaMY6ei01f5dkfMPg+Obwt8UbjR2kLRedJaOT/GBko2PwH5mvaq8W8Em48V/Eq41udNqLK93IB0XOQi5/Efgpr2muDDfC7bX0PT4s/wB6pqXx8keb11/r0sFFFFdJ8sZ+u6Tba1pslnd71ViGSWNtskLjlXRuzA8g1m+GtXuXuZtG1zYutWq7y6rtS7izgTIO3oy/wt7FSeirnfG1jbzaT9vkuhYXenkz2t7jJhfGMEfxKw+Ur3B9cEO6tqOMJTklFXbOirltf/4lHijStZHy291jTLw9gGbMDn6SEp/22ry6/wDitrGrRmKzSPTHjAWZE+d92OSGI+6eoIGcVzGq6tqmp2ssF5ql9Ikgxhp2OD1BAz2OD+FcssXGErWPrMLwdi8RR9q5KN9lu/R9uz7H1DRXzjoHjrxNYwQtNqEskmP3iXB80E9+Tk4+hr1Pwz43mutKXUNbtTBZyz/Z0uIULIsgUEq3UjOQR17+ldGFvinKNNXcVf5XS077nm5rkOIyynCtUacZNJd7tN2ae2x2N5580kFjZHF5dt5cbYz5Y/ikPso59zgd60PEnkRvp3h6xG21skSecew/1ak9ySCx/wB0etWNFiXQ9Ku/EOsIyXcyAJCfvRpn5IgP77EjPuQO1ZFlHNtluLwhry5czTkcjcf4R7KAFHsK9iVsJRst/wBevyitvN3R8sv31S/T9P8Ag/kWaa6q6srqGVhggjIIp1Zerz7454F3GGGPzbpkOCEPCxg/33Pyj6k9hXn4ahKvUUI/8MdVWoqcXJnGN4NsdZlnudGu2gt1laPa6blJHUoc/d571raD4Es9PuEuLuZruVDuVdu1Afpzmuk0i0+xadDCQocAs+wYG4nLYHYZJx7Vdr1cVnuMkpUIVXybLa7Xra+py0sBRVpyj734fcFFFFeGdwUUUUAFFFFABXPa3N4f8OXr+IdUKW95cKliJ9rySSDOViRFyTzk4Ue/auhrj/iVot9qun6bPo8cj6np96l1AUZBtIVgch8Bhz0yD3z2LjuJ7FiXx34dj01L/wC2zPas8ke+KzmkKtH9/cqoSuM8kgCs3UfGHgjTNYj1i71CJb+awjCzpHLJm1ZiyH5QQF3EnJ6d65rTvhZf6h4ctItc1FYLwXN3czW/lJcwnz2zkqcKXXGQwGAScCtq3+GMMOmXlmNUkIudFj0Yt5I+UJu/eYz1O7p7dau0F1IvJ9DoLrxz4cttU/s+XU1NzuiQ7IpHRWk+4pdVKgtkYBOaztC8dpql7ZQPawW32m+vbICS5JY/ZwSWUBMHOMkErgdz0rj9R+H+ur4iSz0oFdCk1CzvriaZ48M0SpuZQPnBO3G3pnnOOK6my+HFvb3unzyX7ypa3l/dGPyseYLpCrLnPG0Hr39qLQSHeTNO2+IHhe5gvJodVQxWkP2iVmikUGLdt8xcr86543LkZq94d8VaL4jmu4tGvRcS2hXzk8t0K7hlThgMggcEZFccfhRFJpc9lc63cTounHS7NmgUfZ4S4Y5x99vlAzxx2rrNI8NJp3ibUNYW5aRru1gtjEUwF8oNznPOd1JqPQacup0NFFFQUXNH/wCQnb/71drXFaP/AMhO3/3q7WuvD/CzmrbhRRRXQYhXlfxz/wCYJ/23/wDadeqV5X8c/wDmCf8Abf8A9p0AdV8Lv+RE0z/tr/6Neuqrlfhd/wAiJpn/AG1/9GvXVUAFFFFABRRRQAUUUUAV9RvINOsZ7y7kEdvAhkdj2Ar5wuJrv4geM5Lifclvnp2hhB4Ue5/mSa7L47eJSWh8PWj+k11tPX+4n/s3/fNSeC9FGjaOiyLi6mxJMe4PZfw/nmvfpTWU4F4p/wAWppHyXf8AryONw+t1/ZfZjv8A5f15m3bwx20EcMCBIo1Cqo6ACpaKK+Nbbd2e0lbRBWdr2rW2iaVNfXjYjjHCjq7dlHua0GIVSzEBQMkntXiXinUb3x94uttH0UGS3EnlwLnCsf4pG9sZ/Ae5rKrU5Fpu9j2clyv+0K3vu1OOsn2X/B/4JL4N0DUPid4ylub9nWwjIa5kXoifwxp7nn9T9fqOxtLews4bSzhWG2hQJHGgwFUdBWV4L8N2fhTw/b6ZYjIQbpZSMGWQ/eY/54AA7VuV24TDexjd/E9znz/OP7RrKFFctGGkV5d/V/ggr5x+N/jOTxJrUfhrRGaW0glCSGM/8fE+cYHqqnj65PYGvSfjZ4xbwv4Z+z2Um3VL/MURB5jT+J/1wPc57V5n8IPDAjh/t29TMsmVtlP8K9C/49B7Z9a58bVc5ewh8z1OH8LTwGHlnGJV7aU13l3+X+b6I6/wR4dj8N6JHbfK11J89xIP4m9B7DoPz710NFFTGKirI8HEYipiasq1V3lJ3YUUUVRiFeVfG7VHUWGlxsQjg3EoHfnC/wDs36V6rXinxtB/4Sm0bHBs1Gf+BvXNim1Tdj6ThOlGpmcObom/nY8xvrdy63NrgXUYwAeBIv8AcP8AQ9jU1pcpdQiSPI5wyngqR1B96mpYLeS1lfUrNDI4O2eBRzImPvL/ALQ/UcelLKsC8yrxw17edr2S306n32e5ksjw8seo8y0Tje129E72duz/AM1qlfTPwC0+3n+HQW7gSVGvmmCyKCAyhMEfQrXhDokq/OoYEdxV6PxBr+m6SthpGp3NtZoSfKhfYeevI5NfZ/6qV8qU69OfOrdF726eivrt3PzTMeLqPE1OlgnFUZc17yl7uzW9rrftbzPYPjVq+v6Rqel3cNlFNokDbyN2S8hGMsOxAPB56/gJ/DmvWXiDT1urF/8Afjbhoz6Ef1r5wur26u5WkuriaVz1Z3JJr2rwn8P9W/sbwrq2gzJbXUyv9tMpynlFiVyvfI7Dvjp1rwoThmDbpXXKktbJXv8Ahom3q7vsdeZ5NDJ8LThiZR55N6xT2Svr315UmkrJ63OzlkmluI7LT4xNfzDKIfuovd3PZR+vQVHNbwrcJplq5mtrKXzru4brc3f+CenQHA/hrRvvL8PwNpOkStNrV2A91evgtGvTefQ9QidB17HNS1t47W3SGEYjQYGTkn3J7nvmuqpKODpckPil1/XyXZfN9D5CKdefNLZf1/w/3dyaiiivJO0KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigC5o/wDyE7f/AHq7WuK0f/kJ2/8AvV2tdeH+FnNW3CiiiugxCvK/jn/zBP8Atv8A+069Uryv45/8wT/tv/7ToA6r4Xf8iJpn/bX/ANGvXVVyvwu/5ETTP+2v/o166qgAooooAKKKKACqOuanBo+kXeoXR/c28ZcjufQD3JwPxq9XkPx913y7ay0SF/mlP2icD+6DhR+Jyf8AgIrty7CPGYiNHo9/TqY16vsqbmcR4Ptp/Eniy41W/wDnCSG4kJ6FyflH0H9K9UrA8E6X/ZegQI64nmHmyeuT0H4DA/Ot+sM+xyxeLfJ8EfdXov8AP8rHRgKHsaKvu9WFFFZ3iDVYdF0e5v7j7sK5C5xubso+prxW0ldnoU6cqs1Tgrt6I4j4u+J/sVn/AGNZPi4uFzOwP3I/7v1b+X1rtvgX4HHh/Rhq+oRY1S/QFQw5hiPIX2J4J/AdjXmvwj8NTeOPGc+s6wPNsrWQTzbukkh+4n0GMkegA719O0YKl7WXt5fI+jz7ERyvCxyjDv3nrUfd9v66W8wooor1D4o+WvH1zJ42+LstkjE28U32JMfwxxk7yPx3mvYIIo4II4YVCRRqERR0UAYArxf4Uf6R48uZbgYlEUr4PJDFgDz+Jr2yvDw75uao92z7nil+wnRwMPhpwX3vd/ggooorpPlQooooAK8s+OFgWg03UEHCM0Dn68r/ACavU6yfFOkJruhXenuQrSrlGP8AC45U/n+lZVoc8HE9PJsasDjadeWyevo9GfNFWtPuPIm+b7jcH/Gorq3ltLmW3uEMc0TFHU9QR1FRVwYPF1cFXjiKTtKLv/wPnsz9ix+CoZlhZ4atrCa/4Zr03R0vUZFFZOn3vl4jlPydj6VrA5GR0r9yyfOKGa0FVpPXquqf+XZ9T+bM/wAgxOR4l0K6vF/DLpJf59109LMo3toryLKMAZG/Pp619GWPxV8Gabp1pZw30rxwRLEuyBuAoA74rwEjIIPSudlXZK6jsSK+O4so08smq9GCtUbv01XX53fzv3PsuE6D4mpfVMZVkvYL3bW+F9Ne1l8rLoekz+K7DTfiBNqml6lc3um3rD7SLhTvUE/rt7e3FewKQwBBBB5BHevlOvoj4c37aj4O06SRsyRoYWJ/2TgfoBXxv114qrKbilfse9xHkEMtwtKdOTlb3W3a9t1sltqu+x0tFFFanxoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFzRgTqlvj+9/Su1rjND/wCQtb/U/wAjXZ114f4Wc1bcKKKK6DEK8r+Of/ME/wC2/wD7Tr1SvK/jn/zBP+2//tOgDqvhd/yImmf9tf8A0a9dVXK/C7/kRNM/7a/+jXrqqACiiigAooooAQkKCSQAO5r5suJz4y+JM1w3zWrTFh6eSnC/mAPzr2n4oav/AGN4K1CVW2zTr9mi/wB5+Dj6Dcfwryv4U6fstbu/cfNI3lIfYcn8yR+Ve7gJfUsDWxv2n7sfV7/5/I46sfbV4Uem7O+ooor489sK8e+L+sSahrFtoVllxCyl1X+OVvuj8Af/AB6vVdXv49L0u6vZ/wDVwRlyPXA4H49K81+BmjSeJfHtxrd+PMjsibliRw0zE7Py+Zv+AiuesnNxpR6/kfT8O04YeNXNKy92ktPOT2/rzR7p8PvDUXhTwrZ6YmDMo8y4cfxyt94/TsPYCujoor2YxUIqK2R8dXrzxFSVao7yk7v5hRRRVGR8q6Gn9gfGO6s3+SP7XPbjIxlWJ2fn8v517TXmP7QejzaR4zs9ftFKpeKrbx/DNHgfyCn8DXfaBqcWs6Pa38BG2ZAxH91u4/A5FeJSXs5zpPoz7jiD/a8PhsxjtKKi/wDEv6f3GhRRRXQfLBRRRQAUUUUAeb/FPwc2oo2r6ZHm7jX9/GOsigfeHuB+Y+nPjVfVtea/ED4fC/aTUdCRUujzLbjhZPdfRv0P168OJw9/fgfecNcSxoxWDxb937Mu3k/Ls+noeOVZtrySAY+8n901DPFJBK8U0bRyodrI4wVPoRTKwwmMr4KoquHk4yXb+tfmfdY3AYbMaLo4mCnB9/zXb1RpPqeV+SPDepPSs0kkkk5JorW8MaDd+JdXTTNNMP2uRGaNZW2h9oyQD64B6+ldeYZtjM1lH6zPmtsrJb+hwZbkuXZDTnPDQ5E9ZNtvRebb0Rk17r8HY2TwcrN0e4kZfpwP5g15Xqng3X9IvI7fVdOlsw7hBNLgQ5Jx/rB8v61734e0+DStEs7K1cPFDGAHHRz1LfiST+NYYSnKM25K1jwuMcfRng4U6UlLmd7rVWXn8zRooor0T81CiiigAooooAKKKrzXtrBJsmuYI3/uvIAfypDjFydoq5YopFIZQVIIPQilpiCiiigAooooAKKKKACiiigC9of/ACFrf6n+Rrs64zQ/+Qtb/U/yNdnXXh/hZzVviCiiiugxCvK/jn/zBP8Atv8A+069Uryv45/8wT/tv/7ToA6r4Xf8iJpn/bX/ANGvXVVyvwu/5ETTP+2v/o166qgAooooAKKKKAPGP2g9RJl0nTVPAD3Dj1z8q/yf860vDNmLDQLG3xhliBb/AHjyf1Jrj/ivJ/anxPFnksI/Ithz64Y/q5r0PpXrZ0/Y4DDYddU5P57fmzDALnr1KnbQWiiivlj1jzj41ap9n0a106NsNdSb3H+wnb/voj8q9J+CGg/2J4Bs3kXFxfn7XJ64YDYP++Qp/E14l4qjfxZ8VLfSo2Pl+dHZgj+FQcufwJb8q+qYY0hhSKJQkaKFVR0AHAFTgo89aVTtoj6XOpfUcpw+BW8/fl+n9eQ+iiivVPiwooooA5z4geGIfFvhi60yUqkx/eW8h/glH3T9OoPsTXzX8OvFc/hjxFqWi6whjsIrg28hJyYp1OHP+7nAOPTPbn6W8c6zcaPogGmqj6vfSrZWEbDIM79GI/uqAzt/soa43xf8INM1Pw5Z22lMLfVLKERpcv8A8vJ6ky46sxLHd1yx61w4vDuX7yn8SPpckzSlCDwGNf7mbv6O2/p19V2vfQjdJY1eNldGGVZTkEeoNOrw+z1jxL8PL86bqtpJ5AJIt5/ukesb88fTI9s122nfE/QblR9qNzZvjkPGWGfYrn+VcccRF6S0fmdeM4bxdF89Be1pvZx1uvRf8FeZ3VFYVr4t8P3WPK1ezBPZ5An/AKFite3uYLld1tPFKvrG4YfpWqknszxKuGrUf4kHH1TRNRRRVGIUUUUAYviDwxpWvp/xMbVWlAwsyfLIPx7/AEORXAal8JXDFtM1NSvZLhMEf8CX/CvWaKynRhPWSPVwWd47Arlo1Hbs9V+O3yPC5fhh4gRsL9jkHqsxx+oFbfhHwbqvhbXNO12+ntkjtLiMvGjFm2MwV+wAwrE/hXrNVdTtBf6bdWjHaJ4miz6ZBGazWGhF80d0epLizG14+yrW5Xo9Oj3/AAOi1XVo9fsNa0rw3qaR6xbAptKjkjqBuBBBOULAHBz6Vxnhax0+1snl0+GSJ5WPnrKxLrIDhlYdAwOQQMVOmjQR2VpDE8sU1qMw3UbYlR+7BvUnJOcg55Brg/iJ4k1HRbi4hSWKPUr2NTNLCMCQD5RMF/5ZyEDaw5BwCMEVtWq/bmtjiy/B/XL4PCStd3162723XVL7L0s73Nfxn8QbPQ3e0sFW81BeGGf3cZ/2iOp9h+Yrj7Gb4h+Kw11pcd+1vnhoAIY/oGOAfzNdj8H/AIVxXNvDr3imHzVkAktrOToR1DyDvnqF/P0r3dEWNFRFCooACgYAA7ClSwtSuueo7LsjvxOZ5fkr+r4OkqtRfFOWqv1SX+VvmfMXhfxtq2j65/ZHiwS7Q4iZp12yQMehPqv17HIr16uD/aZ0ZUudI1mJADIGtZmA6kfMn14L/kK6TwhqH9qeGNNuydzyQgOfVl+Vv1BqIKVOpKlJ3tsY5zSoYnCUczw8FDnupJbKS/zs/wADYooorc+aOH+KviSfQ9Jgt7B/Lu7wsBIOqIMZI9DyAD9a5vwx8Hdb8RaLDq0t9bWoul82JJtzOynkM2Omevfg1V+N827XrCHP3Lbf/wB9MR/7LX07pVt9j0yztsY8mFI8emFA/pWNGjHE1ZKeyPsKmYVMjyrDywtlOq227X0X/Dr+mfLWpaV4w+Gd4jy7hZs2BJGxktpfY+h69QD6V6d4O8T2vibTvOg/d3MeBNCTkofUeoPY16tqun2mq6fPY6hAlxazrskjccEf4+/avl7xPpF/8LfHKSWxaSxky8DN0miJ+ZG/2hx+h70VqLwj5o6w/IVDEUeJqcqVSKhiYq6a0U/J+f8Aw60uj2uiqul30Gp6fb3to2+CZA6n+h9x0q1Wqd9T5KcJQk4yVmgooopkhRRRQAUUUUAXtD/5C1v9T/I12dcZof8AyFrf6n+Rrs668P8ACzmrfEFFFFdBiFeV/HP/AJgn/bf/ANp16pXlfxz/AOYJ/wBt/wD2nQB1Xwu/5ETTP+2v/o166quV+F3/ACImmf8AbX/0a9dVQAUUUUAFFFR3Eq29vLM/3Y1Ln6AZoSvogPnSJ/7U+LV1N95PtkzA+ybtv8hXp1eWfDJWufEl1cyckQsxP+0zD/69ep16XFLti4UltCKX5meVL9y592wpksixRPI5wiAsT6AU+sPxtc/Y/CWrTA4P2dkB92G0fzr5iTsmz2MPSdarGkvtNL72cJ8BLU6v8S7jUplyYIZbnP8Atudv8nb8q+mK8N/ZhssW2vXzD7zxQKcdMBmP/oS/lXuVb5dG1BPvqepxhW9pmcoLaCUV91/zYUUUV3Hy4UUVzfj7V7nTNDWDSiv9talKtjp4IyBM+fnI7qih5D7IaAKGkofEXjm71l8NpujeZp9iOz3BwLiUf7uBEPQrL612dZ/h7SLbQdDsdKsQwt7SJYlLHLNjqzHuxOST3JJrQoAp6rpdjq9o1rqlnBd2558uZAwz6jPQ+9cBqnwW8JXrlreK8sSe1vPkfk4avS6KynRp1PjVztwuZYvB/wC71HH0en3bHh998AbVsmw16aP0E1uH/UMP5Vz9/wDAzxHaN5mm6hYXBXp87RP+HBH619IUVzyy+g+lj2qPGGa09JVFJeaX6JM+Uru48deA54/7WjuhbltoFyfOhf2DgnB9gQa9L8IeKrLxLZ74D5V0g/e27H5l9x6j3r1jVNPtNVsJrLUbeO4tZl2vG4yCP8fftXzb8Qvh7qngPUBrPh+WaTTEbcsq8yW/s/qvbPTsffkq0J4b3o+9H8UerQxWC4hXsa0VSxHRrSMvJ+f49n0PW6K4jwP48tddVLS/KW2pYxgnCS+6+/t/Ou3qoTU1eJ85jMFWwVV0a8bNf1dd0FFFFWcoUUUUAMmlSGF5ZWCRopZmPQAck1414K09/iF8UfNu1LWSubmZT0EKYCp+PyqfqTXRfFjxVDaafLotnJuvJwBMVP8Aq07g+56Y9D9K7X4AeFn0Twu+p3key81MiRQRysI+5+eS30IrBR9vWVPotWfWYK+UZXVx09KlT3Yd7Pd/r8l3PUQAAABgUtFFe0fCHn/x200ah8N9QcDMlo8dyn4NtP8A46zV578Frzz/AA1cWrH5re4OB6KwBH67q9x8RWA1TQNSsCAftVtJDz6spA/nXzZ8ELry9Y1G0Jx5sAkwfVWx/wCzmvKxa5cRGXdWPs8rf1nIsRR605KS+en6M9joooqj5s8W+IK/bvihZ2p7vbw+n3iD/wCzV9VV8tXS/afjtZA8Aaja++doT+eK+paeX71H5n0PFHu4bBU+1O/32/yCuT+JnhOPxf4XnsgFF7H+9tZD/DIB0+h6H657V1lFehOCnFxlsz5bDYiphasa9J2lF3R8t/CnxBJpOqy6Bqe6JJZCsYk4MUwOCp9M4x9R717HXEfH7wNIsx8U6REccfbkjHKkdJR/I/QH1NL8OPGEevWS2d7IF1SFcMCceco/iHv6j8a8aF6M3Rn8j7POMPDMqCzfCLR/Gv5Zd/68n1O2oooroPlAooooAKKKKAL2h/8AIWt/qf5GuzrjND/5C1v9T/I12ddeH+FnNW+IKKKK6DEK8r+Of/ME/wC2/wD7Tr1SvK/jn/zBP+2//tOgDqvhd/yImmf9tf8A0a9dVXK/C7/kRNM/7a/+jXrqqACiiigArD8cXH2XwdrUwOCLSUA+5Ugfqa3KyvFGkLr2g3emPM0C3ChTIoBIwwPT8K2w8oxqxc9rq/pciom4tLc8P+EsPGpTkf8APNAf++if6V6JT/DHw/OgWk0EV8s/mSb9zR7ccAY6n0/WtZvD10PuyQn8T/hSzqt9bxs61PWLtb5JI1wSVGjGEtzGrifi/ceT4LlTOPPmjj+vO7/2WvS20G9HQRn6NXEfFHwV4g13S7O10u0SUpP5j5mRcfKQOp9zXi1qc+RpI97JalGOPoyqySimnduy01NX9nez+zfDwTY5uruWXP0wn/sldn4s8VaL4Ss7S68RXy2VvdXKWcUjRuwaVgSqnaDjhW5OAMcmqnw20a48P+CNK0y9QJcwI3mKCCAzOzHkdfvVkfGDwTJ4703QNO2wvZ2+rxXV6srFd0AjlRwvB+b5xjp9a78PDkpRi+xw5xiFicfWqxd05O3pfT8DoNN8XaHqXiTVNAsdQSbVtMVXu4QjgRBsYyxG09egJx3rRGqaebI3gvrU2gOPP85fLz0+9nFeGSfA7U7ePxdZabqqeVq+mQ26X1w5M09wJvNkM2B91+VJ54PTjFVLj4O63JpEqx6XYw3LXqXYhTVl2CRYmTeF+x+Vg5XKmMk4+8D12PNPoFr+zU24a7twbjiEGRf3n+7zz+FYs1lA/jaHU7++tT5Fv9lsLYsAySOcyvz1YqIwMcgBv7xrx/Vfg74lurBLaZvDt5c3OlW+nvdlDANLkjlLtJbRrHg5B6Dy/mGeBxWp4j+Ed7qWp+JtSSDTZNUu9WsLywvZT++iihEYkG7blSdrcDg8UAe0C9tTdSWwuYTcRrveLzBvUepHUCszxB4n0rQdE1HVb25V7bT4hNcCAiR1U9DtHrnivF4PhPrWkeINR1SdLe+CSX91Ffx3e2Z1mjkHltEINzt8wHMu3jgdqx/DXwq8Qaz4FEyabpeiTT+GF0uOFXZZbuVnRzLcfu12EbcY+Y5J5oA+j7TUrO7h82C5hdMhThwdrEZCn0PPSooNWgn1O7slSYG2jSVpmTETBs/dfoSMHPpXi+tfBq5k1TUF0ez0m10e7l0mR7aM+WrfZ2YzEqq4yQ3B75Oa0fE/wmvb6fxbb6EdP07TdQsrC3s4AWWP9xIXeN1UZVGBxxnqeOxAPYbS6t72ATWc8VxCTgPE4dSfqKmrmfAWmXGmaZdrdaFo+hPNcmUWmlSb4yNiLuY7EG87T0XoF75rpqACmyIskbJIqsjAqysMgjuCKdRQB4f8RPgus8kmoeD9sUpO5rB2wpP/AEzY/d+h49COlcFpvjbxF4WuTp+u2sswj4MV0Ckqj2YjkfXNfVtUNY0bTtatvs+rWNveRdlmQNj3B7H3FefVwCb56T5X+B9ZhOJ3KksNmVNVoLZv4l8+v4PzPF9L+JXh+8UC4lmspD/DNGSM/Vc/ritg+MPDwj3/ANr2mPZ+fy61e1f4I+F7xmeya909j0WKXen5OCf1rEHwBsfNyddufL/u/Z1z+ef6Vh7LFR0smdFuHa3vqrOHk1f8k/zZS1H4m+H7ZCbWSa9bt5MZA/NsfpmuO1H4g6/r84sdBtHt2l+VUt1MszfQ4/kPxruvh18I/DKT63aakt3eT6ZqUkG2SXYhRlSZDhcH7soHXHB+lewaPoumaLB5Ok2FtZxnGRDGFLfU9T+NV9UrzfvSsvImGaZNgoqVCi6k/wC89E/1/wDATxf4a/B6c3kereMlGAfMSxY7i7dcyn9dvfv3B93AAAAGBS0V30KEKEeWB8/mmbYnNKvtcQ9tktl6f1cKKKK2PNCvlfwzH/ZHxjvLIDCC6ubcf7o3bf5Cvqivl/xen2D49SgDG6/hPHP+sVD/AOzV52YqyhLsz6/hN+0ji8P/ADU2/u/4c9foooqT588f0gBvjzbbgD/xMB1/3a+oa+XtH/5L1b/9f/8A7LX1DVZd8M/U+g4t3wv/AF7iFFFFeifIDJY0ljeOVFeNwVZWGQwPUEdxXz38SfhVf6LfNrXg5ZpLVW8w28JPm259U7sv05HuOa+h6Kwr4eFeNpHq5TnGIyurz0dU909mv66nzL4a+KTRhbfxDAzkcfaIRz/wJf8AD8q9A0/xPomoIGtdTtWJ/haQI3/fLYNdZ4s+HnhzxQ7S6hYiK7brc2x8uQ+57MfqDXmupfAE7y2ma6NvZLi35H/AlP8ASvPdDE09F7yPoXWyHMPfblQm91a8flb/AIHodpHIki7o3Vx6qc04kAEk4A6k15bL8DPE8Lbra+0t/QiaRW/9A/rSL8D/ABZP/rr3S1x08yeQ/lhDU81f/n2xf2Rlb1WOjb/D/wAE9Cvdc0qxBN3qNpFjs0y5/LOTXI658UNJs0ZdMSS+m6A4KRg+5PJ/AfjS2HwCvGIOoa7bxDuIIGk/Ula7bw98GvC2lOsl1FPqcw5/0p/kz/uLgEexzVKliZ7JRDkyDB+9UqyrNdErL8bfgzkfgxq3ijX/ABPLe3UBl0ck75SNkcLAcLH/AHvQj8SfX3io4IYreFIbeNIokG1URQqqPQAdKkr0MPRdGHK3c+bzTHU8diHVpU1TjZJJeXfzCiiitzzgryv45/8AME/7b/8AtOvVK8r+Of8AzBP+2/8A7ToA6r4Xf8iJpn/bX/0a9dVXK/C7/kRNM/7a/wDo166qgAooooAKKKKACiiigAooooAKKKKACuV+Jfimbwd4WbVrayS9lFxBbrC0vlhjJIqfewcY3eldVVTVNMstWtfs2p2sN1b71k8uZAy7lIZTg9wQCKAPJfEPxI1LwvqfiO41nTT9r0/Rra6NlDfeZb+ZLctEoBMakdVLP6Z44rMg+IfifRvE/imz1OOyvNTl1bS9KsbZLhhZ20k9uWLbyu7b8pJ4zuOBXst5oGkXtxdz3mm2k8t5bi1uGliDGWEEkI2eq5J4PrXN6x8M/Dl14du9H0qwstHgunjeU2tlAwcp93ckiMp6nkjPfNAHE3Pxk1VYrext9Ctn1ufV77SlCSSzQ5tQpZhsjLsWLYAA6ZJ6V6n4M1i51/wvp+p32ny6bd3EeZrOU5aFwSGUnA7g9hWF4e+GHhjSPCg8P3GnQapYm4e7f7dDG+Zm6sFChU9AFAAHFdbpmn2elWENjplrBaWcK7Y4IECIg9ABwKALVFFFABRRRQAUUUUAFFFFABRXHxfEjw3Nrb6ZbXN3cSR3S2MlxBYzyW0dwzBRE0yoUDZIHJwM9a6lLy2knlgS5haaEZkjDgsg9x1H40AczYH7D8UNWt+ianpsF2g9ZIneOQ/98vAPw9662udv4La88TaXqtvqForaZFOlyu8E+TMqn14G6OM5P92tePUrGWze7jvbZ7RM7pllUouPVs4oAt0Vz2i+MtD1e0vrq3voo7ezvpdPkknYRqZYzhtpJwR6HvVm28Rafc+KLnQIndtQgtI71xt+Ty3YqpDdzlTQBsUUUUAFfMfxVAj+N4dOGM9oxI9dqD+gr6cr5j+KJ8/45+UvBFzZpk+pWM/1rz8y/hx9V+p9dwb/AL3V/wCvcvzR63RRRUHgHjV+32H45WUjfcOoWrE47Nsyf1NfU1fKfxeR7DxnaXsQwWhjlU4/iViP6CvqayuEvLOC5hOY5o1kU+oIyP50Ze7SqR8z6LiZe0weCrrrDl+6xNRRRXpnxwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5X8c/+YJ/23/9p16pXlfxz/5gn/bf/wBp0AdV8Lv+RE0z/tr/AOjXrqq5X4Xf8iJpn/bX/wBGvXVUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeH6P8OvG+g6ho+m6PqltDoNjrRv2uY76WJ7i0eXfJBLAEKu/YNuxjjHPEehfCfXbHV4XlOkotkmqBtRikY3Oqm73bFnGwbQm4Hlm5UY717H4j1E6P4e1TU1jErWVrLcCMnAbYhbGe2cV5ha/EHVbq+8A3+r6abC21qG6u44bO+81XhWy84GRTGMnOcKCMcHJ6UAYFt8HNa0vTLEaBDoVnqP/CMyaXeSNGGS4umdG3OpTEgIVhuYHtwQMVWsfg/4jhsNUBttJEUur6fqa6XJdl4LlIUZZYpXWFVG4kNxHjKjgjmnx/FjXU1az8RanbwR6NL4butWh0yzuDIXCyoE8wlQA/JBIyBk8cVtX3xi1bRrTWE1nRbB7+zgsJI/sd07xM10xC7jsyAoAJwDnt1oAx5vhR4ofQ/sQsvD4t59av7+ewWUBEjnVfKEcrQMVCEHIVFJGBkV1Xwh8Aa34T1a2utYktXSPQbbTD5Upc+ZHI7HqB8uGGP5V1nw48Sap4j029fXdIfS721uTBtIdVmTarLIodVYA7sYI7V1tABRRXGfED4haR4Ng2XLfadSZcx2cTDd7Fj/AAr79fQGonUjTXNJ2R0YXC1sXUVGhFyk+iOvnmit4ZJriRIoY1LO7nCqB1JJ6CvllLxfFvxmfULbL27XfnIxz/q4gAp9shV/Om6v4g8X/Eu7aBA4sA2fIi+SCP03H+I/XJ9BXoPgXwhB4YtnZnE9/MAJZQMAD+6vt/OvJrVnipJRXup39T7ahhafDmHqutNSr1I8qivsp93/AFtpfc6qiiitj5A89+M2kteaFBqES7nsnO/A/gbAJ/AhfzNd18CfE8Wt+DoNPkkH2/TFEDoTyYx9xh7Y+X8PcVJPDHcQSQzoskUilHVhkMDwQa8T1Sy1f4beKItT0eRhbFiIpDyrqeTFIPw/HGRyOMOd4er7VbPRn1WXRp5vgHlc5WqRfNBvr3X5/n0PrGiuV+H/AI203xnpgns2EV5GB9otWPzRn1Hqvof5Hiuqr2ITjOPNF3R8ZiMPVwtR0a0eWS3TCiiiqMQooooAKKKKACiiigAooooAKKKKACvK/jn/AMwT/tv/AO069Uryv45/8wT/ALb/APtOgDqvhd/yImmf9tf/AEa9dVXK/C7/AJETTP8Atr/6NeuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAiureG7tZra6jSW3mQxyRuMq6kYII9CKpR6FpUbaU0en2ytpSGOxIjH+jKU2EJ/dG35eO1aVFAHKr8PvC9vDqA0rRNN025vbeW3e5tbSIOFkGG4KlT2OGBHHIIrI8D/AAo8PeFbfV4jGupDVVjjukuraBYmRM7VEUaKgGWJPBJNeg0UAZfh/wAP6P4cs3tNA0yz062d/MaO1hWMM2MbjgcnAAz7VqUVyHxP8YxeDfDj3Q2vfz5itIm/ifHLH/ZXqfwHepnNQi5S2RvhcNUxVaNCiryk7IwPi98Sk8KQ/wBm6QY5dalXJJ+ZbZT/ABEd2PYfieMA+TeDfBN34kuDrHiOWc28zeZ87EyXBPcnqB79T29ab8PfDM3ifVJdc11nnt/NLkycm4kzk59VHf8AL1r2cAAAAYA6AV4zcsTL2lTboj7fFYmlkFJ4HAu9V/HPrfsv609dobK0gsbaO3tIUhgQYVEGAKnopjSKvU81dWtSoR5qklFeeh8n71SV92x9FRGcdgaBMvcEV56zvAN8vtUX9Xq78pLVbUbG21KyltL6FZreUYZG7/4H3qdWDdDmnV6UJwqR5oNNMzTlTkmtGjxDxBoOreANYi1fQ7mUWyt+7nXqmf4XHQg9PQ1718MvHtn4003nbBqsCj7RbZ/Denqp/ToexOfdW8V1byQXMaywyKVdGGQQa8U8QabqHw78U22q6LI622/dA55HvE/qMfmPcVlGUsJLmj8L3R9dSqUuJKP1bE2WIivdl/N5P+vNdU/rGisLwV4ktPFfh621SyON42yxZ5ikH3lP9PUEGt2vZjJSSktj4StRnQqSpVFaSdmgoooqjMKKKKACiiigAooooAKKKKACvK/jn/zBP+2//tOvVK8r+Of/ADBP+2//ALToA6r4Xf8AIiaZ/wBtf/Rr11Vcr8Lv+RE0z/tr/wCjXrqqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooARiFUsxAUDJJ7V8reLdSuPiV8RzFau32FGMMB7JCp5f6nk/iBXtfxw11tD8AXYhfbcXzC0QjqAwJb/wAdDD8RXmvwX0YW+kz6rKv726Yxxn0jU8/m3/oIry8dL2lSNFbbs+0yCKy3A1c1l8b9yHr1f9dn3PQLC0gsLKG0tUEcEKhEUdgKn6ClqC4f+EfjXFmGNhgMPKtLpsu76I+fhGVepq9XuxskpbheBWLrviHStCjD6pexwEjKp1dvoo5NYnxH8YL4Y05Y7ba+pXAPlKeQg7uf6Dufoa+fb27uL66kubyZ5p5Dud3OSTXxWFwGIziX1rFyaj0/4HZHoSqRoLkgj2q6+LujRsRbWV9MB/EQqA/qTVrTfir4fupAlwLuzJON0sYZfzUk/pXglFes+HcG42Sfrcx+tVD6ysL22v7ZLmxuI54W6SRsGH6Vejm7P+dfKnh/XtR0C9Fzplw0bfxoeUkHow719AeB/Fdr4p04yxr5N3FgTwE52k9CPUGvJqYfF5HP21CV4df+Cv1NlKGIXLJanZVneINJt9b0m4sLofJKvytjlG7MPcGrcD5G09ulTV9tgsXTx2HjWhs+nZ9UcPv4aqnF2ad0zyX4O69ceD/Hkmh6kxS2vJfs0q54WXOEcexJxn0bPavpuvl/406X9n1Gy1eAFDMPKkZePnXlTn1x/wCg19BeBNZ/4SHwhpWpsQZJ4R5hH/PRflf/AMeBruwE3FyovpqvQ9vienHF0KGbU1bnXLL/ABL/AIZ/JI3qKKK9I+OCiiigAooooAKKKKACiiigAryv45/8wT/tv/7Tr1SvK/jn/wAwT/tv/wC06AOq+F3/ACImmf8AbX/0a9dVXK/C7/kRNM/7a/8Ao166qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPBv2nrs+ZoFmD8oE0rDPU/IB/7N+ddD4StRZ+GNLgAxttoyf94qCf1Jrkv2nFI1vRGwdpt3AP8AwIf4iu40chtIsWU5BgQg/wDARXjy1xM36H2uO9zI8HFbNyfzu/8AMuVTc5Yn1q233TWVqLvHp908WfMWJiuPXBxXyPF1Rv2NJbO7/JL82eTgV8Uj5s8cau+t+KL67ZiY95jiHoi8D/H6msGiivfpU40oKnHZKxztuTuwooorQQV1Pwz1Z9J8Y2DBsRXLi2kGeCHOB+RwfwrlmyFO0ZOOB0zUmhtfya1p6QWkbStcRhB52MtuGBnbWOIpKtRnCWzTHGXLJM+uIzhx9at1yQ1DxLuH/Egsf/Bmf/jVW/7R8Tf9C/Yf+DQ//Gq8rhOM40akJNWununuvJ+RpjWnJNFD4s2oufBV0+MtbvHKv/fQU/oxrd/ZxvDceBJ4GJP2a9dFHopVW/mWrkvHd94gfwjqa3Wh2McJi+ZxqJYjkY48oZ5x3pv7O9/4jh0LVhp2iWl1EblSTLqJi2tt7DymzxivqaSaxKfkeqqinw/UhK/uzTWjt067dz6EorC0i+8Q3F6E1XRLKyttpJli1EzMD2G3yl/nXi/xfunsfH+s3Xiiwl1HTYdMjfQrSWaeK1mlGTMu6JT+/OMLn25HBr1T48+haK+eNW+JWueHdDvrZY7zT5D4ZsLvRbeW0kuGWYp+9VpChLFeAS/oSe9dT8O73Vf+FyeMrXVtZu3ilhtLi1spYcRuhgXc8ZxhQjHacdScnmgD16iiigAooooAKKKKACvK/jn/AMwT/tv/AO069Uryv45/8wT/ALb/APtOgDqvhd/yImmf9tf/AEa9dVXK/C7/AJETTP8Atr/6NeuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDw/9p6zLWOg3oHEcksLH/eCkf+gGtLwNdC88IaTKDnFusZPuvyn9Vro/jbpB1f4d6iI0LTWm27QAf3Pvf+Olq8x+CmpifR7vTnb57aTzEH+w3/1wfzryKy5MU/7yPtIf7Xw9Fx3ozd/R/wDBaPR6puuCVI9qu1BcJ/EPxr53ifBSxGGVaC1h+T3/AEPGwdRRnyvqfLfjPRX0DxHeWJBEStvhPrGeV/w+oNYdfRnxC8HxeKbBGiZYdRgB8qU9GH9xvb37fnXgOr6Ve6PeNa6lbSW8y9mHDD1B6Ee4oynMoYykk3763X6jrUnCXkUaKKK9YxCu4+EOjtqfi2K4ZM29iPOc9t3RB9c8/wDATXLaLpN9rV8lpptu80zdcDhR6segHua+ivBHhqHwvoq2iMJLhzvnlAxvb0HsO3/168PO8wjhqDpRfvy09F1f+R0Yek5yv0R0kQzIPbmrVRQJhcnqalru4dwTwuDTmtZa/wCX4a/MxxdTnqadDj/ivci38E3i5w0zxxr/AN9An9FNbf7N9o0HgS5nYf8AHxeuy/7oVV/mDXnfxv1NWk0/S0bJXNxIPT+Ff/Zvzr3b4c6OdC8EaPp8i7ZY4A8g9Hc72H4FiK9vDLnxLfZHuYz/AGTh+nTe9Wd/kv8Ahl950lFFFesfFhRRRQAUUUUAFFFFABRRRQAV5X8c/wDmCf8Abf8A9p16pXlfxz/5gn/bf/2nQB1Xwu/5ETTP+2v/AKNeuqrlfhd/yImmf9tf/Rr11VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMljSaJ45VDxupVlIyCD1Br5SeKb4b/ABLmtp9/2NXKk/8APS3flW98cH6qRX1hXnPxn8CnxZoy3enoDrFkpMQ/57J1Mf17j3yO+a4sbQdSClD4on0vDWY0sNWlhsT/AAqq5X5dn/W2/QejrIiujBkYZVgcgil615D8OfGp0tl0TXi0UMbFIpZAQYTn7j56DP5fTp68pDKGUgqRkEd65KdSNSN0Z5pldbLazpVNuj6Nf1uiCSIjlenpVDUdPtNRgMGoWsNxF/clQMB+fStemlQ3UA18zjuGIVJ+1wsuR9uny6oypYxpcs1c4C5+Gfhmd9y2csPqI5mx+pNPtfht4Yt2BNg0zDoZZnP6AgV3RiT0NHlIO1cX9i5u/ddbT/FL/I1+s0N+X8DN0+wtNPgEFhbQ28X9yJAo/Sr8cXdvyqUKB0AFOruwHDNOjP2uJlzvt0+fcyq4xyXLBWCq2pXsGnWE95duEghUuze3+PapZ5o7eF5p5FjiQbmdzgKPUmvF/GviO68Z6xb6LoMckts0oSNF4M7/AN4+ij3+p9vpatVU15nVk+UzzGtbaEdZS6Jf5/8ADln4eaZP8QPiWb69jJs4HF1OOoVVPyR/iQB9Axr6krk/hr4Qg8HeHI7Ndr3sv7y6mH8b+g/2R0H4nua6yu3B0HRh7271ZhxFmkMfiVGhpSprlj6Lr8/ysFFFFdZ4AUUUUAFFFFABRRRQAUUUUAFeV/HP/mCf9t//AGnXqleV/HP/AJgn/bf/ANp0AdV8Lv8AkRNM/wC2v/o166quV+F3/IiaZ/21/wDRr11VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHmXxR+Flp4q8zUdKKWes4yxIxHcezeh/wBofjnt45p3iDxJ4Bvf7L1m0lMKf8u05xgesb8jH0yK+sKz9b0XTddtDa6vZQXcHULKudp9QeoPuK4a+CU3z03aR9PlvEbpUfqeOh7Wl57r0f8AXk0eSaH470LVlUC7W0nPWK5+Tn2bofzrqEdXUMjBlPQg5Brm/EXwI064ZpNB1KazJ5ENwvmp9A3BA+ua4yb4ReONKdv7MmhlHUG0uzHn/vrbXI1iKekoX9Dv+oZNjPewuK9n5TW3z0/U9ZoryE+FPilCSnl6ocd/tqP+u805fAHxMviBcC8VG5zNqK4GfYOSPype1qdKb+4P9X8OtZY2nb1X+Z6pd3lrZpvu7iGBP70rhB+tchrfxJ0PT1ZbR3v5x0WEYXPux/pmsiw+BfiG6k36nqNhbhvvEM8r/lgD9a7rw78EPD2nukmqTXOqSD+Fz5Uef91efzYiqUMTU+GNvUPq+RYP3q9d1X2irfj/AMFHkZuPFXxL1EWdhbsbUNkxx5WGL3du/wCP4Cvd/hr8OrDwZb+cxW61aRcS3JHCj+6g7D36n9B2On2Nrp1qltYW8NtboMLHEgVR+AqzXXh8HGm+ebvI83NOIp4ql9UwsPZUey3fq/687hRRRXafNhRRRQAUUUUAFFFFABRRRQAUUUUAFeV/HP8A5gn/AG3/APadeqV5X8c/+YJ/23/9p0AdV8Lv+RE0z/tr/wCjXrqq8n8H+PdN0Dw/b6XqFpf/AGq2aVH2KjLnzGPB3+4rZ/4Wrof/AD66l/37T/4ugDv6K4D/AIWrof8Az66l/wB+0/8Ai6P+Fq6H/wA+upf9+0/+LoA7+iuA/wCFq6H/AM+upf8AftP/AIuj/hauh/8APrqX/ftP/i6AO/orgP8Ahauh/wDPrqX/AH7T/wCLo/4Wrof/AD66l/37T/4ugDv6K4D/AIWrof8Az66l/wB+0/8Ai6P+Fq6H/wA+upf9+0/+LoA7+iuA/wCFq6H/AM+upf8AftP/AIuj/hauh/8APrqX/ftP/i6AO/orgP8Ahauh/wDPrqX/AH7T/wCLo/4Wrof/AD66l/37T/4ugDv6K4D/AIWrof8Az66l/wB+0/8Ai6P+Fq6H/wA+upf9+0/+LoA7+iuA/wCFq6H/AM+upf8AftP/AIuj/hauh/8APrqX/ftP/i6AO/orgP8Ahauh/wDPrqX/AH7T/wCLo/4Wrof/AD66l/37T/4ugDv6K4D/AIWrof8Az66l/wB+0/8Ai6P+Fq6H/wA+upf9+0/+LoA7+iuA/wCFq6H/AM+upf8AftP/AIuj/hauh/8APrqX/ftP/i6AO/orgP8Ahauh/wDPrqX/AH7T/wCLo/4Wrof/AD66l/37T/4ugDv6K4D/AIWrof8Az66l/wB+0/8Ai6P+Fq6H/wA+upf9+0/+LoA7+iuA/wCFq6H/AM+upf8AftP/AIuj/hauh/8APrqX/ftP/i6AO/orgP8Ahauh/wDPrqX/AH7T/wCLo/4Wrof/AD66l/37T/4ugDv6K4D/AIWrof8Az66l/wB+0/8Ai6P+Fq6H/wA+upf9+0/+LoA7+iuA/wCFq6H/AM+upf8AftP/AIuj/hauh/8APrqX/ftP/i6AO/orgP8Ahauh/wDPrqX/AH7T/wCLo/4Wrof/AD66l/37T/4ugDv6K4D/AIWrof8Az66l/wB+0/8Ai6P+Fq6H/wA+upf9+0/+LoA7+iuA/wCFq6H/AM+upf8AftP/AIuj/hauh/8APrqX/ftP/i6AO/orgP8Ahauh/wDPrqX/AH7T/wCLo/4Wrof/AD66l/37T/4ugDv6K4D/AIWrof8Az66l/wB+0/8Ai6P+Fq6H/wA+upf9+0/+LoA7+iuA/wCFq6H/AM+upf8AftP/AIuj/hauh/8APrqX/ftP/i6AO/orgP8Ahauh/wDPrqX/AH7T/wCLo/4Wrof/AD66l/37T/4ugDv6K4D/AIWrof8Az66l/wB+0/8Ai6P+Fq6H/wA+upf9+0/+LoA7+iuA/wCFq6H/AM+upf8AftP/AIuj/hauh/8APrqX/ftP/i6AO/ryv45/8wT/ALb/APtOtX/hauh/8+upf9+0/wDi65Hx34gh8aXGnQ6Na3W62WV5DMEUYJQDHzH0oA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_1_4116=[""].join("\n");
var outline_f4_1_4116=null;
var title_f4_1_4117="Scapular strength W PI";
var content_f4_1_4117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F71135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F71135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scapular strengthening exercise - \"W\"",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Position the arms to form a \"W.\" Hold the arms bent with elbows pointed towards the feet and hands pointed towards the head.",
"    <br/>",
"    (B) Squeeze the shoulder blades (arrows) and raise the arms until they are parallel with the floor, hold for a second or two, then return arms to the starting position; repeat 10 to 15 times.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_1_4117=[""].join("\n");
var outline_f4_1_4117=null;
var title_f4_1_4118="Atherosclerotic plaque on CT";
var content_f4_1_4118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F75835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F75835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Atherosclerotic plaque on CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atherosclerotic plaque of the descending thoracic and abdominal aorta on CT. Severe atherosclerotic plaque (arrows) visualized by CT in axial (panel A) and sagittal (panel B) projections.",
"    <div class=\"footnotes\">",
"     CT: computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Pierre Maldjian.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_1_4118=[""].join("\n");
var outline_f4_1_4118=null;
var title_f4_1_4119="Clinical manifestations, pathologic features, and diagnosis of hepatosplenic T cell lymphoma";
var content_f4_1_4119=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of hepatosplenic T cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/1/4119/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4119/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4119/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/1/4119/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4119/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/1/4119/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4119/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/1/4119/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral T cell lymphomas (PTCL) are a heterogeneous group of generally aggressive neoplasms that constitute less than 15 percent of all non-Hodgkin lymphomas (NHLs) in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among these, in decreasing frequency of occurrence, are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral T cell lymphoma, not otherwise specified (NOS)",
"     </li>",
"     <li>",
"      Anaplastic large cell lymphoma, primary systemic type",
"     </li>",
"     <li>",
"      Angioimmunoblastic T cell lymphoma",
"     </li>",
"     <li>",
"      Extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type",
"     </li>",
"     <li>",
"      Subcutaneous panniculitis-like T cell lymphoma",
"     </li>",
"     <li>",
"      Enteropathy associated T cell lymphoma",
"     </li>",
"     <li>",
"      Hepatosplenic T cell lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hepatosplenic T cell lymphoma (HSTL) was initially described as a neoplasm of mature",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T cells that infiltrate the sinusoids of the spleen, liver, and bone marrow. Initially called hepatosplenic",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T cell lymphoma, the preferred nomenclature was changed to hepatosplenic T cell lymphoma when cases were identified with the clinicopathologic features of HSTL that expressed the",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    T cell receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation, pathologic features, and diagnosis of HSTL will be discussed here. The other",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphomas and the treatment of the PTCLs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link\">",
"     \"Initial treatment of peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSTL is a very rare neoplasm accounting for less than 1 percent of non-Hodgkin lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/1\">",
"     1",
"    </a>",
"    ]. The exact incidence is unknown and fewer than 100 patients have been reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/3\">",
"     3",
"    </a>",
"    ]. The median age at diagnosis is approximately 35 years and there appears to be a male predominance.",
"   </p>",
"   <p>",
"    Ten to 20 percent of patients have a history of chronic immune suppression, such as that associated with treatment for a prior solid organ transplantation, lymphoproliferative disorder, or inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Regarding the latter, there has been an association between the development of HSTL with the use of tumor necrosis factor (TNF) blockers, thiopurine, and the anti-TNF monoclonal antibodies",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    in young patients with Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of HSTL is largely unknown. One proposed mechanism is chronic immune suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/1\">",
"     1",
"    </a>",
"    ]. Up to 20 percent of HSTLs occur in patients who are immunosuppressed, such as solid organ transplant recipients. As such, some cases of HSTL may represent a post-transplantation lymphoproliferative disorder of host origin. Also important is isochromosome 7q, which is found in association with the majority of cases. At present the genes that are dysregulated by this genetic aberration are unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28280?source=see_link\">",
"     \"Malignancy after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gene expression profiling (GEP) studies may shed some light on the pathogenesis of this disorder. As an example, an unsupervised analysis in one GEP study found that HSTLs clustered together, while other T cell lymphomas with gamma-delta expression were scattered throughout the alpha beta T cell lymphoma cluster, suggesting that HSTL is a unique entity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Genetic features'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with HSTL present with marked hepatosplenomegaly and thrombocytopenia without lymphadenopathy. Common signs and symptoms at presentation include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/3,8,9\">",
"     3,8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Splenomegaly (100 percent)",
"     </li>",
"     <li>",
"      Hepatomegaly (40 to 71 percent)",
"     </li>",
"     <li>",
"      Systemic B symptoms of fever, night sweats, or weight loss (67 to 80 percent)",
"     </li>",
"     <li>",
"      Thrombocytopenia (64 to 100 percent)",
"     </li>",
"     <li>",
"      Anemia (57 to 73 percent)",
"     </li>",
"     <li>",
"      Neutropenia (36 to 57 percent)",
"     </li>",
"     <li>",
"      Abnormal liver function tests (38 to 57 percent)",
"     </li>",
"     <li>",
"      Abnormal lymphocytes in the peripheral blood (10 to 27 percent)",
"     </li>",
"     <li>",
"      Adenopathy (0 to 13 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although circulating neoplastic cells are not usually prominent, subtle bone marrow involvement can be detected in almost all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/3,8-12\">",
"     3,8-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Patterns of involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSTL characteristically involves the sinusoids of the spleen, liver, and bone marrow (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85920 \" href=\"UTD.htm?17/23/17791\">",
"     image 1",
"    </a>",
"    ). As described above, peripheral blood involvement may be identified in up to 30 percent of cases, but is often subtle. The circulating cells are usually bland, resemble monocytes or atypical lymphocytes, and require flow immunophenotyping for positive recognition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Spleen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gross examination of the spleen reveals a large diffusely red spleen without nodules, which is a reflection of the red pulp expansion and white pulp effacement by the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/8\">",
"     8",
"    </a>",
"    ]. Atypical lymphoid cells infiltrate the cords and sinuses of the red pulp (",
"    <a class=\"graphic graphic_picture graphicRef73607 \" href=\"UTD.htm?0/54/874\">",
"     picture 1",
"    </a>",
"    ). These neoplastic cells may form clusters within the sinuses and there may be admixed macrophages exhibiting erythrophagocytosis. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Morphology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gross examination of the liver reveals diffuse enlargement with no masses. Atypical lymphoid cells infiltrate dilated sinusoids, but the portal tracts and hepatocytes are generally uninvolved (",
"    <a class=\"graphic graphic_picture graphicRef62858 \" href=\"UTD.htm?40/22/41321\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50070 \" href=\"UTD.htm?6/35/6711\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef85921 \" href=\"UTD.htm?2/43/2740\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Morphology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow biopsy typically demonstrates a hypercellular marrow with trilineage hyperplasia and large hyperlobulated megakaryocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/13\">",
"     13",
"    </a>",
"    ]. Infiltration of variably dilated sinuses by atypical lymphoid cells is frequently subtle and can be more easily identified by staining for T cell antigens, such as CD3 (",
"    <a class=\"graphic graphic_picture graphicRef72180 \" href=\"UTD.htm?41/7/42104\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/8\">",
"     8",
"    </a>",
"    ]. Erythrophagocytosis may be prominent. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Morphology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morphology of the infiltrating atypical lymphoid cells in HSTL is similar whether they involve the spleen, liver, or bone marrow. These are monotonous, medium-sized lymphoid cells with round or slightly irregular nuclei, loosely condensed chromatin, and a moderate amount of pale cytoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/1\">",
"     1",
"    </a>",
"    ]. Nucleoli are small and distinct. Mitotic activity is generally low [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/14\">",
"     14",
"    </a>",
"    ]. Histologic transformation to large cell or blastic morphology may occur with disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor cells express CD2, surface CD3, CD7, and CD16 (",
"    <a class=\"graphic graphic_picture graphicRef59379 \" href=\"UTD.htm?41/10/42151\">",
"     picture 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef85922 \" href=\"UTD.htm?10/20/10569\">",
"     picture 7",
"    </a>",
"    ). In most cases, CD4, CD5, and CD8 are not expressed, nor are B cell surface markers (eg, CD20). CD56 expression is variable. Most cases of HSTL express the",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T cell receptor (TCR gamma positive), but rare cases express the",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    T cell receptor (TCR beta positive). The cytotoxic granule protein TIA-1 is expressed, but perforin and granzyme B are absent, features consistent with a non-activated cytotoxic T cell phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/8,9,15-17\">",
"     8,9,15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell receptor (TCR) gene studies demonstrate clonal rearrangements. The gamma and delta genes are most frequently rearranged. The TCR beta gene is rearranged in",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    variants and may be involved in nonproductive rearrangement in some cases of",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    HSTL.",
"   </p>",
"   <p>",
"    Conventional cytogenetics or fluorescence in situ hybridization (FISH) will demonstrate isochromosome 7q or other chromosome 7 abnormalities in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/1,4,8,18,19\">",
"     1,4,8,18,19",
"    </a>",
"    ]. Other cytogenetic changes that have been reported include trisomy 8 and the loss of a sex chromosome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/1\">",
"     1",
"    </a>",
"    ]. The tumor cells are Epstein-Barr virus (EBV) negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HSTL is usually made based upon biopsy specimens of the liver or bone marrow, which show accumulation of malignant cells within the sinusoids (",
"    <a class=\"graphic graphic_table graphicRef55385 \" href=\"UTD.htm?5/61/6109\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef85921 \" href=\"UTD.htm?2/43/2740\">",
"     picture 4",
"    </a>",
"    ). Patients presenting primarily with splenic enlargement may be diagnosed by splenectomy.",
"   </p>",
"   <p>",
"    The diagnosis is principally made based upon the demonstration of infiltrating atypical lymphocytes that express CD2, surface CD3, CD7, and CD16, and do not express CD4, CD5, CD8 or B cell surface markers (eg, CD20) (",
"    <a class=\"graphic graphic_picture graphicRef85922 \" href=\"UTD.htm?10/20/10569\">",
"     picture 7",
"    </a>",
"    ). The atypical lymphocytes should express",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T cell receptors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    T cell receptors. Cytogenetics demonstrating isochrome 7q is not necessary, but is quite useful for, supporting the diagnosis of HSTL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of HSTL includes other types of T cell lymphomas and B cell disorders that present with splenomegaly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Splenic marginal zone lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic marginal zone lymphoma (SMZL) typically presents with splenomegaly, lymphocytosis, and cytopenias. Unlike in HSTL, which only involves the red pulp, pathologic examination of the spleen in SMZL demonstrates involvement of both the white and red pulp in practically all cases. In addition, the immunophenotype is markedly different than that of HSTL. The tumor cells express surface immunoglobulin (eg, IgM+, IgD+), B cell antigens (CD19, CD20, CD22) and bcl-2. They typically are CD5-, CD10-, CD43-, CD23-, and CD25-. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     T cell large granular lymphocyte leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell large granular lymphocyte (LGL) leukemia typically presents in older adults with neutropenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anemia along with a subtle chronic peripheral blood lymphocytosis. Up to 50 percent of cases are associated with splenomegaly. The great majority of T cell LGL leukemias express CD3, CD8, CD16, and CD57, and do not express CD4. Molecular studies demonstrate T cell receptor rearrangements. It is notable that although most cases of LGL leukemia have an",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    TCR phenotype, a subset exhibits a",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    TCR phenotype. The clinical setting, immunophenotype, and the presence of large intracytoplasmic granules in T cell LGL leukemia help to distinguish it from HSTL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21018?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Aggressive NK leukemia/lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive natural killer (NK)",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    can present with marked hepatosplenomegaly and demonstrates a similar immunophenotype to HSTL with expression of CD2, CD16, and CD56. However, unlike HSTL, aggressive NK",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    lacks expression of both T cell receptors and CD3; typically demonstrates azurophilic granules in the cytoplasm; and expresses all the cytotoxic protein markers (granzyme B, TIA-1, and perforin). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20040?source=see_link\">",
"     \"Natural killer (NK) cell large granular lymphocyte leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Acute lymphoblastic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like HSTL, precursor T-lymphoblastic",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    typically presents in older children and young adults. Blasts are present in the peripheral blood, bone marrow, or tissue biopsy and can be identified by their positivity for TdT, which is negative in HSTL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other gamma/delta lymphomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoplasms of",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T cells may occur in other sites, particularly mucosal or cutaneous tissues; these appear to behave similarly to primary extranodal",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    T cell or NK cell neoplasms of the same sites, and do not show the same proclivity to involve the sinuses of the liver, spleen, and bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Thus, as with certain other",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphomas, the site of presentation and pattern of tissue involvement are important defining criteria for the diagnosis of HSTL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of HSTL is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial treatment of peripheral T cell lymphoma\", section on 'Hepatosplenic T cell lymphoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=see_link\">",
"     \"Treatment of relapsed or refractory peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the relatively bland appearance of the cells, this is an aggressive tumor with a median survival of less than two years. While patients typically respond to initial chemotherapy, relapses are common. There are case reports of long term survival after allogeneic hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial treatment of peripheral T cell lymphoma\", section on 'Hepatosplenic T cell lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prognostic models used for other types of non-Hodgkin lymphoma have limited applicability to patients with HSTL. Most patients fall into the low risk category when assessed with either the International Prognostic Index (IPI) or the similar Prognostic Index for T cell lymphomas (PIT) (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4119/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatosplenic T cell lymphoma (HSTL) is a neoplasm of mature T cells that infiltrate the sinusoids of the spleen, liver, and bone marrow. Initially called hepatosplenic",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T cell lymphoma, the preferred nomenclature was changed to hepatosplenic T cell lymphoma when cases were identified with the clinicopathologic features of HSTL that expressed the",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    T cell receptor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HSTL is a rare neoplasm accounting for less than 1 percent of non-Hodgkin lymphomas. It most commonly presents in young men with a median age at diagnosis of 35 years. Ten to 20 percent of patients have a history of chronic immune suppression related to treatment for solid organ transplantation, lymphoma, or inflammatory bowel disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with HSTL present with marked hepatosplenomegaly and thrombocytopenia without lymphadenopathy. Other common findings include systemic B symptoms (fever, night sweats, or weight loss), anemia, neutropenia, and abnormal liver function tests. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of HSTL can made based upon the evaluation of a biopsy specimen of the liver, bone marrow, or spleen (",
"      <a class=\"graphic graphic_table graphicRef55385 \" href=\"UTD.htm?5/61/6109\">",
"       table 1",
"      </a>",
"      ). These biopsies demonstrate the accumulation of malignant cells within the sinusoids of the liver and bone marrow and within the red pulp of the spleen (",
"      <a class=\"graphic graphic_picture graphicRef85921 \" href=\"UTD.htm?2/43/2740\">",
"       picture 4",
"      </a>",
"      ). The infiltrating atypical lymphocytes express CD2, surface CD3, CD7, and CD16, but do not express CD4, CD5, CD8 or B cell surface markers (eg, CD20) (",
"      <a class=\"graphic graphic_picture graphicRef85922 \" href=\"UTD.htm?10/20/10569\">",
"       picture 7",
"      </a>",
"      ). In addition, the atypical lymphocytes should express",
"      <span class=\"nowrap\">",
"       gamma/delta",
"      </span>",
"      T cell receptors",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      T cell receptors. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/2\">",
"      Gaulard P, Bourquelot P, Kanavaros P, et al. Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas. Am J Pathol 1990; 137:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/3\">",
"      Falchook GS, Vega F, Dang NH, et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 2009; 20:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/4\">",
"      Fran&ccedil;ois A, Lesesve JF, Stamatoullas A, et al. Hepatosplenic gamma/delta T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q. Am J Surg Pathol 1997; 21:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/5\">",
"      Ross CW, Schnitzer B, Sheldon S, et al. Gamma/delta T-cell posttransplantation lymphoproliferative disorder primarily in the spleen. Am J Clin Pathol 1994; 102:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/6\">",
"      Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/7\">",
"      Miyazaki K, Yamaguchi M, Imai H, et al. Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. Blood 2009; 113:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/8\">",
"      Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003; 102:4261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/9\">",
"      Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996; 88:4265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/10\">",
"      Dogan A, Morice WG. Bone marrow histopathology in peripheral T-cell lymphomas. Br J Haematol 2004; 127:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/11\">",
"      Wong KF, Chan JK, Matutes E, et al. Hepatosplenic gamma delta T-cell lymphoma. A distinctive aggressive lymphoma type. Am J Surg Pathol 1995; 19:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/12\">",
"      Cooke C, Greiner T, Raffeld M, et al. Gamma/delta T-cell lymphoma: A distinct clinicopathologic entity. Mod Pathol 1994; 7:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/13\">",
"      Vega F, Medeiros LJ, Bueso-Ramos C, et al. Hepatosplenic gamma/delta T-cell lymphoma in bone marrow. A sinusoidal neoplasm with blastic cytologic features. Am J Clin Pathol 2001; 116:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/14\">",
"      Farcet JP, Gaulard P, Marolleau JP, et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood 1990; 75:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/15\">",
"      Krenacs L, Smyth MJ, Bagdi E, et al. The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity. Blood 2003; 101:3590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/16\">",
"      Boulland ML, Kanavaros P, Wechsler J, et al. Cytotoxic protein expression in natural killer cell lymphomas and in alpha beta and gamma delta peripheral T-cell lymphomas. J Pathol 1997; 183:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/17\">",
"      Salhany KE, Feldman M, Kahn MJ, et al. Hepatosplenic gammadelta T-cell lymphoma: ultrastructural, immunophenotypic, and functional evidence for cytotoxic T lymphocyte differentiation. Hum Pathol 1997; 28:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/18\">",
"      Wang CC, Tien HF, Lin MT, et al. Consistent presence of isochromosome 7q in hepatosplenic T gamma/delta lymphoma: a new cytogenetic-clinicopathologic entity. Genes Chromosomes Cancer 1995; 12:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/19\">",
"      Jonveaux P, Daniel MT, Martel V, et al. Isochromosome 7q and trisomy 8 are consistent primary, non-random chromosomal abnormalities associated with hepatosplenic T gamma/delta lymphoma. Leukemia 1996; 10:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/20\">",
"      Arnulf B, Copie-Bergman C, Delfau-Larue MH, et al. Nonhepatosplenic gammadelta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood 1998; 91:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/21\">",
"      Takimoto Y, Imanaka F, Sasaki N, et al. Gamma/delta T cell lymphoma presenting in the subcutaneous tissue and small intestine in a patient with capillary leak syndrome. Int J Hematol 1998; 68:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/22\">",
"      Saito T, Matsuno Y, Tanosaki R, et al. Gamma delta T-cell neoplasms: a clinicopathological study of 11 cases. Ann Oncol 2002; 13:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/23\">",
"      Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003; 101:3407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/24\">",
"      A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4119/abstract/25\">",
"      Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103:2474.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4714 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_1_4119=[""].join("\n");
var outline_f4_1_4119=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Patterns of involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Spleen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Liver",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bone marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      T cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Aggressive NK leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other gamma/delta lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4714\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4714|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/23/17791\" title=\"diagnostic image 1\">",
"      PET-CT HSTL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4714|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/54/874\" title=\"picture 1\">",
"      HSTCL spleen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/22/41321\" title=\"picture 2\">",
"      HSTCL liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/35/6711\" title=\"picture 3\">",
"      HSTCL liver 40x magnification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/43/2740\" title=\"picture 4\">",
"      Liver biopsy HSTL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/7/42104\" title=\"picture 5\">",
"      HSTCL bone marrow biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/10/42151\" title=\"picture 6\">",
"      HSTCL CD3 staining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/20/10569\" title=\"picture 7\">",
"      HSTL tumor cells immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4714|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/61/6109\" title=\"table 1\">",
"      PTCL path",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17757\" title=\"table 2\">",
"      Int prognostic index NHL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21018?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=related_link\">",
"      Initial treatment of peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28280?source=related_link\">",
"      Malignancy after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20040?source=related_link\">",
"      Natural killer (NK) cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=related_link\">",
"      Treatment of relapsed or refractory peripheral T cell lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_1_4120="Evaluation of health-related quality of life";
var content_f4_1_4120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of health-related quality of life",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/1/4120/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4120/contributors\">",
"     Amy H Peterman, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4120/contributors\">",
"     Nan Rothrock, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4120/contributors\">",
"     David Cella, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/1/4120/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4120/contributors\">",
"     Paul J Hesketh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/1/4120/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4120/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/1/4120/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although difficult to define precisely, quality of life has an inherent meaning to most people. It is comprised of broad concepts that affect global life satisfaction, including good health, adequate housing, employment, personal and family safety, interrelationships, education, and leisure pursuits. For matters related to health care, quality of life has been applied specifically to those life concerns that are most affected by health or illness, hence the term \"health-related quality of life\" (HRQL) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific measures to evaluate the outcome of an illness or its treatment include quantity and quality of life, and economic cost. Although length of survival was previously considered the most important among these, the impact of illness on quality of life has received increasing recognition. As an example, improvements in HRQL are one of two potential benefits that were considered by the United States Food and Drug Administration for the approval of new anticancer drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In particular, HRQL has been a fundamental concern of oncologic practice since 1949, when Karnofsky and Burchenal developed a clinical scale to quantify the functional performance of cancer patients (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Increasing interest in the systematic assessment of HRQL in cancer patients using standardized, self-administered measures has emerged over the past two decades [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/5\">",
"     5",
"    </a>",
"    ] and has become an important focus of benefit for newer therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Here we will discuss assessment of HRQL in patients with medical illness, emphasizing malignant disease. Issues specific to HRQL in patients with head and neck cancer and those undergoing hematopoietic cell transplantation are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3466?source=see_link\">",
"     \"Quality of life in head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25529?source=see_link\">",
"     \"Quality of life following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINING HRQL",
"    </span>",
"    &nbsp;&mdash;&nbsp;HRQL can be formally defined as: \"The extent to which one's usual or expected physical, emotional and social well-being are affected by a medical condition or its treatment\" [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/9\">",
"     9",
"    </a>",
"    ]. This definition incorporates the two widely accepted aspects of quality of life: subjectivity and multidimensionality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HRQL represents a subjective appraisal of the impact of illness or its treatment; individual patients with the same objective health status can report dissimilar HRQL due to unique differences in expectations and coping abilities [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/11\">",
"     11",
"    </a>",
"    ]. As a result, HRQL must be measured from the individual's viewpoint rather than that of outside observers (ie, caregivers or healthcare professionals).",
"   </p>",
"   <p>",
"    Multidimensionality is the other important component of HRQL. The multidimensionality of HRQL is reflected in the work of the Patient-Reported Outcomes Measurement Information System (PROMIS) Cooperative Group, an NIH-funded national effort that has produced a comprehensive, conceptual framework of self-reported health (",
"    <a class=\"graphic graphic_figure graphicRef72832 \" href=\"UTD.htm?40/3/41018\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Developed with the input of hundreds of people with a wide variety of medical conditions, the healthcare providers who treat them, members of the general population, and extensive literature reviews, the framework is divided into Physical, Mental and Social health. Each of these major components encompasses multiple subcomponents (eg, the mental health component is comprised of affect, behavior, and cognition). These subdomains are further divided (eg, negative affect is comprised of anxiety, depression, anger, experience of stress, and the negative psychosocial impact of illness).",
"   </p>",
"   <p>",
"    The utility of the PROMIS system for patient-reported outcomes is discussed further below (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Disease-specific'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MEASURING HRQL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A vast array of validated and reliable questionnaires are available for assessment of HRQL [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/14\">",
"     14",
"    </a>",
"    ]. They include generic health status instruments, generic illness instruments, and disease-specific instruments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Generic health status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generic health status questionnaires are applicable to all populations and can be completed by individuals both with and without medical illness. These instruments provide benchmarks for comparison across diverse groups, such as healthy and ill populations, or different age groups. Examples include the Nottingham Health Profile (NHP) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/15\">",
"     15",
"    </a>",
"    ] and the Short Form-36 (SF-36) from the Medical Outcomes Study [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Generic illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generic illness instruments are applicable to populations with any medical illness or condition, and can be used to compare different illnesses, levels of disease severity, or types of interventions. Such cross-disease comparisons are increasingly important in the allocation of limited healthcare resources [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition to measuring general health status, these instruments typically assess the individual's perception of the functional impact of the illness or disability. Examples include the Sickness Impact Profile (SIP) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/19\">",
"     19",
"    </a>",
"    ] and the Functional Assessment of Chronic Illness Therapy (FACIT) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Disease-specific",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease-specific measures are designed to assess the HRQL of individuals with specific illnesses (eg, cancer, diabetes), specific types of treatment (eg, chemotherapy, lung transplant), or specific symptoms (eg, nausea, urinary incontinence). Compared to other types of instruments, these measures provide a more detailed assessment for specific diseases and are also likely to be more sensitive to specific treatment-related changes in HRQL. Examples include the Diabetes Quality of Life instrument (DQOL) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/21\">",
"     21",
"    </a>",
"    ] and the Functional Living Index - Cancer (FLIC) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One trend in HRQL research is to combine generic and disease-specific instruments, in order to fully cover important areas that may impact on HRQL. As an example, in one report of patients undergoing knee replacement surgery, the generic illness instrument was more sensitive to general health status and the presence of comorbidity, while the disease-specific measure was more sensitive to the degree of knee disability [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Combined instruments for patient-reported outcomes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     PROMIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Patient-Reported Outcomes Measurement Information System (PROMIS,",
"    <a class=\"external\" href=\"file://www.nihpromis.org/\">",
"     www.nihpromis.org",
"    </a>",
"    , [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/12\">",
"     12",
"    </a>",
"    ]) presents a new set of multidimensional HRQL instruments that combine features of the three categories above. PROMIS instruments are applicable across chronic illness populations in addition to having cancer-specific instruments [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/24\">",
"     24",
"    </a>",
"    ]. Item banks for computerized adaptive testing and short forms exist for physical functioning, pain interference, pain behavior, pain intensity, fatigue, sleep disturbance, sleep-related impairment, sexual functioning, depression, anxiety, anger, alcohol use, psychosocial impact of illness, applied cognition, ability to participate in social roles and activities, satisfaction with participation in social roles and activities, companionship, emotional support, informational support, instrumental support, isolation, and global health in adults.",
"   </p>",
"   <p>",
"    In addition, there are pediatric instruments for physical functioning (upper extremity, mobility), pain interference, fatigue, depression, anxiety, anger, peer relationships, and asthma impact. Instruments were developed using rigorous qualitative [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/25,26\">",
"     25,26",
"    </a>",
"    ] and quantitative [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/13,27,28\">",
"     13,27,28",
"    </a>",
"    ] methods, including use of item response theory, an analytic strategy that allows for the creation of customized short forms and use of a common metric [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Neuro-QOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Quality of Life in Neurological Disorders (Neuro-QOL project,",
"    <a class=\"external\" href=\"file://www.neuroqol.org/\">",
"     www.neuroqol.org",
"    </a>",
"    ) is a similar effort to PROMIS, funded by the National Institute of Neurological Disorders and Stroke, to develop and test HRQL instruments that are applicable across the many neurological conditions. Utilizing a methodology similar to PROMIS, these instruments have been validated in five adult and two pediatric diseases (stroke, amyotrophic lateral sclerosis [ALS or Lou Gehrig's disease], multiple sclerosis, Parkinson's disease, adult and pediatric epilepsy, and the muscular dystrophies). It is hoped that the resulting HRQL tools will be used to facilitate the comparison of results from clinical trials and other clinical research across conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Proxy or caregiver evaluations of HRQL",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are situations (eg, children, elderly, cognitively impaired patient) where patient self-reported HRQL must be substituted by proxy assessment. Where it has been studied, there appears to be general agreement between the patient's assessment and that of the proxy in most studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. However, the possibility of bias related to the subjective burden of caring for the individual must be considered when the proxy is a caregiver [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     UTILIZATION OF HRQL DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information regarding the impact of an illness or medical condition on HRQL can be put to use in several ways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials that compare two (or more) treatments often include a HRQL analysis as one means of determining overall clinical benefit, particularly when treatment-related side effects are considerable. Compared to the control therapy, the alternative treatment option may be associated with a variety of combinations of relative survival benefit and HRQL. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Longer survival with better HRQL",
"     </li>",
"     <li>",
"      Similar survival but better HRQL",
"     </li>",
"     <li>",
"      Shorter survival but better HRQL",
"     </li>",
"     <li>",
"      Longer survival but with inferior HRQL",
"     </li>",
"     <li>",
"      Shorter survival with an inferior HRQL",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although no individual would purposely select a treatment that results in both shorter survival and a worse HRQL, improved HRQL during therapy may be perceived as sufficiently compelling (particularly during cancer treatment) to outweigh a somewhat shorter survival duration.",
"   </p>",
"   <p>",
"    Improvement in HRQL as an end point in clinical research requires recruitment of sufficient numbers of subjects for a trial to have adequate power. Instruments measuring HRQL with a limited coefficient of variation can decrease the size of a trial needed and offer an important advantage in this regard [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Planning tools for future clinical care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because HRQL information can provide a detailed assessment of disease and treatment effects, and their global impact on the individual's daily life, it can be used as a planning tool for assessing the need for further treatment, rehabilitation or palliative care. In particular, HRQL assessment may reveal anxiety or depressive symptoms, or a complaint of pain or dyspnea that may initiate patient-physician communication about medical, psychological or social interventions to improve the patient's well-being [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43719?source=see_link\">",
"     \"Functional problems in the patient with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38840?source=see_link\">",
"     \"Pulmonary rehabilitation in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Capturing changes in clinical status during treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The opportunity to utilize patient-reported quality of life to guide individual clinical care is increasingly important to clinicians. For instance, a brief multi-dimensional HRQL instrument might be administered at every chemotherapy visit. The treating nurse or physician can then review the current HRQL for indications of problems and compare it to the HRQL from the previous visit. Significant changes can be flagged for follow-up by the physician or nurse. This may be of significant benefit in busy practices where there is not always sufficient time to ask the questions one would like. A quick glance at a standardized computer-generated printout of HRQL scores and changes from the last visit's scores could catch a problem that might otherwise be missed. In a study of patients with advanced lung cancer, acceptance of and compliance with weekly assessment of HRQL was high [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/39\">",
"     39",
"    </a>",
"    ]. Most patients reported that weekly assessment aided in focusing discussions with their health care team. Providers found temporal changes in patient responses over time to be useful.",
"   </p>",
"   <p>",
"    Routinely providing HRQL information to oncologists can improve patient-physician communication [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/38,40\">",
"     38,40",
"    </a>",
"    ]. There is a suggestion that this may have a positive effect on some aspects of HRQL. Although it has yet to be empirically demonstrated, it is also possible that early identification of problems through routine HRQL assessment could prevent costly emergency room visits or hospital admissions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Predicting treatment response",
"    </span>",
"    &nbsp;&mdash;&nbsp;HRQL data can also be used to predict the outcome of treatment. As an example, in patients with metastatic lung cancer, pretreatment HRQL predicted the likelihood of an objective response to chemotherapy treatment, and the change in HRQL between baseline and six weeks after treatment initiation also predicted survival [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    .) The importance of this type of information for stratification of patients during random treatment assignment is obvious [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment decision-making",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolongation of life, without regard for the quality of that life, is not a universally desired goal. When considering aggressive, life-prolonging treatments and end-of-life decisions, it is necessary to consider each individual's assessment of what makes life worth living. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link\">",
"     \"Ethical issues near the end of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients are willing to consider aggressive and potentially toxic treatments despite slim chances of survival; medical issues do not always constitute the main factors considered. In one series, aggressive therapy was more likely to be accepted among patients with a positive sense of social well-being or children living at home [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/44\">",
"     44",
"    </a>",
"    ]. In a second report, 388 older adults were presented with 17 decision situations depicting terminal and nonterminal conditions with a very low quality of life and asked to rank the acceptability of several end of life options [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/45\">",
"     45",
"    </a>",
"    ]. The majority chose striving to live and seeking active treatment over death, even if they had a poor HRQL characterized by pain, immobility, and extreme dependence on others. Psychosocial variables, including religiosity, values, and fear of death contributed significantly to the decision-making process (see",
"    <a class=\"local\" href=\"#H19\">",
"     'The influence of nonmedical issues'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CHALLENGES FOR HRQL STUDY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the progress in HRQL research over the last two decades, several challenges remain. As an example, the establishment of psychometrically valid instruments has been largely met in oncology; in contrast, evaluation of HRQL in other diseases is in varying stages of development [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/46\">",
"     46",
"    </a>",
"    ], although efforts such as PROMIS and Neuro-QOL are encouraging. Challenges that extend across disciplines include the identification of what constitutes clinically significant differences and meaningful changes in HRQL, the development and testing of conceptual models linking medical and psychological variables to HRQL [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/47\">",
"     47",
"    </a>",
"    ], and the development of item banks and computerized adaptive testing (CAT) to measure HRQL in a way that permits comparison across diseases and treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Defining a clinically meaningful change",
"    </span>",
"    &nbsp;&mdash;&nbsp;What degree of change in HRQL is of sufficient magnitude to warrant a treatment modification by the physician? Identifying changes in HRQL that are clinically significant involves determining whether the change that is observed in response to an intervention is meaningful and important, or statistically significant yet clinically irrelevant [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One approach to answering this question is to compare changes in HRQL scores with global ratings of change in different life dimensions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/50\">",
"     50",
"    </a>",
"    ] or in life stress units [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/11\">",
"     11",
"    </a>",
"    ]. As an example, in one report, a minimally important difference (MID) was defined based upon patients' global ratings of change, and applied to three studies measuring dyspnea, fatigue, and emotional function in patients with chronic heart and lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/50\">",
"     50",
"    </a>",
"    ]. The MID was represented by a mean change in score of approximately 0.5 per item on the HRQL instrument, when responses were presented on a seven point Likert scale.",
"   </p>",
"   <p>",
"    Complementary approaches to this question have received considerable attention. For example, clinically-meaningful differences or changes can be calculated by comparison of HRQL score differences or changes to parallel differences or changes in meaningful anchors, such as the patient's global rating of change mentioned above or clinical measures relevant to a given condition (such as tumor response in oncology or hemoglobin change in anemic patients). Other important HRQL anchors used in oncology, for example, include disease",
"    <span class=\"nowrap\">",
"     stage/severity,",
"    </span>",
"    treatment status, progression-free survival, and performance status.",
"   </p>",
"   <p>",
"    Distribution-based methods calculate an MID by applying a criterion of one-third to one half of the pooled standard deviation of the measure at the baseline assessment. Results from several studies indicate that similar estimates are obtained regardless of the method used [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. In part because of this, the widespread use of a standard deviation to define meaningful group differences across HRQL measures has been advocated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/54\">",
"     54",
"    </a>",
"    ]. Although this may be useful as a general guideline for clinicians who are not familiar with particular HRQL measures, more precise estimates can be obtained for specific instruments when they are used to calculate sample size for a research study or other similar purpose. In these cases, multiple methods for deriving a range of recommended MIDs may be most appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     The influence of nonmedical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second challenge is to develop and test models of non-illness-related factors (eg, psychological, social, cultural, and economic issues) that might influence the impact of a particular level of impairment on HRQL. In one model, the amount of distress and dissatisfaction experienced by the patient as a result of the symptoms and functional limitations induced by illness and its treatment is filtered by individual factors, sociocultural influences, and available resources [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/43\">",
"     43",
"    </a>",
"    ]. Other proposed models relate physiological variables, symptoms report, and physical functioning to overall HRQL [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/57\">",
"     57",
"    </a>",
"    ]. Evaluation of these interrelationships is critical to an understanding of what influences HRQL and the potential for modifying these factors through targeted interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     HRQL and psychology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the importance of HRQL research to health and the delivery of medical care, its value is not widely appreciated or recognized within the field of psychology. Few relevant publications appear within the psychology literature, despite the rapid growth of the field over the last twenty years. One possibility is that the focus on HRQL as an outcome indicator for medical illness and its treatment has forced the publication of pertinent studies in the medical rather than psychology literature.",
"   </p>",
"   <p>",
"    However, the field of psychology has made valuable contributions to the field of HRQL research. The development of valid and reliable instruments to measure the patients' perspective of their illness and treatment was made possible by the demonstration of their psychometric properties; this is largely the work of psychologists. With the increasing emphasis on the evaluation of HRQL among populations with mental illness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4120/abstract/57-60\">",
"     57-60",
"    </a>",
"    ], it appears likely that the next decade will witness a growing recognition of HRQL research by psychology, as the past decade has shown its growth within medicine and health care in general.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality of life is comprised of broad concepts that affect global life satisfaction. For matters related to health care, quality of life has been applied specifically to those life concerns that are most affected by health or illness, hence the term \"health-related quality of life\" (HRQL). (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A formal definition of HRQL is: \"The extent to which one's usual or expected physical, emotional and social well-being are affected by a medical condition or its treatment\". This definition incorporates the two widely accepted aspects of quality of life: subjectivity and multidimensionality. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Defining HRQL'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A vast array of validated and reliable questionnaires are available for assessment of HRQL, including generic health status instruments, generic illness instruments, disease-specific instruments, and combined instruments such as Patient-Reported Outcomes Measurement Information System (PROMIS) (",
"    <a class=\"graphic graphic_figure graphicRef72832 \" href=\"UTD.htm?40/3/41018\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'PROMIS'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are several areas where HRQL information is of value in medical care; examples are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical trials: Improvement in HRQL as an end point in clinical research (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical trials'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Clinical care:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      As a tool for assessing the efficacy and tolerability of treatment, capturing changes in clinical status during treatment that might otherwise be missed, and evaluating the need for further assessment, treatment, rehabilitation or palliative care (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Planning tools for future clinical care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Capturing changes in clinical status during treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Predicting treatment response'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      As an aid to decision making in patients who are faced with aggressive, life-prolonging treatments, and end-of-life decisions (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment decision-making'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/1\">",
"      Bergner M. Quality of life, health status, and clinical research. Med Care 1989; 27:S148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/2\">",
"      Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 1985; 69:1155.",
"     </a>",
"    </li>",
"    <li>",
"     Karnofsky DA, Burchenal JH. Evaluation of Chemotherapeutic Agents, Macleod CM (Ed), Columbia University Press, New York 1949.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/4\">",
"      Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984; 2:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/5\">",
"      Cella D, Wagner L, Cashy J, et al. Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy. J Natl Cancer Inst Monogr 2007; :53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/6\">",
"      Ganz PA. Quality of life and the patient with cancer. Individual and policy implications. Cancer 1994; 74:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/7\">",
"      Sloan JA, Cella D, Frost M, et al. Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc 2002; 77:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/8\">",
"      Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/9\">",
"      Cella DF. Measuring quality of life in palliative care. Semin Oncol 1995; 22:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/10\">",
"      Aaronson NK. Quality of life: what is it? How should it be measured? Oncology (Williston Park) 1988; 2:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/11\">",
"      Testa MA, Simonson DC. Assesment of quality-of-life outcomes. N Engl J Med 1996; 334:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/12\">",
"      Cella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007; 45:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/13\">",
"      Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol 2010; 63:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/14\">",
"      Kirkova J, Davis MP, Walsh D, et al. Cancer symptom assessment instruments: a systematic review. J Clin Oncol 2006; 24:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/15\">",
"      Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985; 35:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/16\">",
"      Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/17\">",
"      Reeve BB, Potosky AL, Smith AW, et al. Impact of cancer on health-related quality of life of older Americans. J Natl Cancer Inst 2009; 101:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/18\">",
"      Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27:S217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/19\">",
"      Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19:787.",
"     </a>",
"    </li>",
"    <li>",
"     Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Scales, Evanston Northwestern Healthcare, Evanston 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/21\">",
"      Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). The DCCT Research Group. Diabetes Care 1988; 11:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/22\">",
"      Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 1984; 2:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/23\">",
"      Hawker G, Melfi C, Paul J, et al. Comparison of a generic (SF-36) and a disease specific (WOMAC) (Western Ontario and McMaster Universities Osteoarthritis Index) instrument in the measurement of outcomes after knee replacement surgery. J Rheumatol 1995; 22:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/24\">",
"      Garcia SF, Cella D, Clauser SB, et al. Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol 2007; 25:5106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/25\">",
"      DeWalt DA, Rothrock N, Yount S, et al. Evaluation of item candidates: the PROMIS qualitative item review. Med Care 2007; 45:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/26\">",
"      Irwin DE, Varni JW, Yeatts K, DeWalt DA. Cognitive interviewing methodology in the development of a pediatric item bank: a patient reported outcomes measurement information system (PROMIS) study. Health Qual Life Outcomes 2009; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/27\">",
"      Reeve BB, Hays RD, Bjorner JB, et al. Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care 2007; 45:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/28\">",
"      Revicki DA, Chen WH, Harnam N, et al. Development and psychometric analysis of the PROMIS pain behavior item bank. Pain 2009; 146:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/29\">",
"      Cella D, Gershon R, Lai JS, Choi S. The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. Qual Life Res 2007; 16 Suppl 1:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/30\">",
"      Arlt S, Hornung J, Eichenlaub M, et al. The patient with dementia, the caregiver and the doctor: cognition, depression and quality of life from three perspectives. Int J Geriatr Psychiatry 2008; 23:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/31\">",
"      Gundy CM, Aaronson NK. The influence of proxy perspective on patient-proxy agreement in the evaluation of health-related quality of life: an empirical study. Med Care 2008; 46:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/32\">",
"      Klaassen RJ, Barr RD, Hughes J, et al. Nurses provide valuable proxy assessment of the health-related quality of life of children with Hodgkin disease. Cancer 2010; 116:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/33\">",
"      McGrath C, McMillan AS, Zhu HW, Li LS. Agreement between patient and proxy assessments of oral health-related quality of life after stroke: an observational longitudinal study. J Oral Rehabil 2009; 36:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/34\">",
"      McPhail S, Beller E, Haines T. Two perspectives of proxy reporting of health-related quality of life using the Euroqol-5D, an investigation of agreement. Med Care 2008; 46:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/35\">",
"      Karlawish JH, Zbrozek A, Kinosian B, et al. Caregivers' assessments of preference-based quality of life in Alzheimer's disease. Alzheimers Dement 2008; 4:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/36\">",
"      Cheung YB, Goh C, Thumboo J, et al. Variability and sample size requirements of quality-of-life measures: a randomized study of three major questionnaires. J Clin Oncol 2005; 23:4936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/37\">",
"      McLachlan SA, Allenby A, Matthews J, et al. Randomized trial of coordinated psychosocial interventions based on patient self-assessments versus standard care to improve the psychosocial functioning of patients with cancer. J Clin Oncol 2001; 19:4117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/38\">",
"      Detmar SB, Muller MJ, Schornagel JH, et al. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA 2002; 288:3027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/39\">",
"      Davis K, Yount S, Del Ciello K, et al. An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration. J Support Oncol 2007; 5:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/40\">",
"      Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 2004; 22:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/41\">",
"      Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/42\">",
"      Eton DT, Fairclough DL, Cella D, et al. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 2003; 21:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/43\">",
"      Gotay CC. Trial-related quality of life: using quality-of-life assessment to distinguish among cancer therapies. J Natl Cancer Inst Monogr 1996; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/44\">",
"      Yellen SB, Cella DF. Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol 1995; 13:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/45\">",
"      Cicirelli VG. Relationship of psychosocial and background variables to older adults' end-of-life decisions. Psychol Aging 1997; 12:72.",
"     </a>",
"    </li>",
"    <li>",
"     Spilker B. Quality of life and pharmacoeconomics in clinical trials, Raven Press, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/47\">",
"      Buchanan DR, O'Mara AM, Kelaghan JW, et al. Challenges and recommendations for advancing the state-of-the-science of quality of life assessment in symptom management trials. Cancer 2007; 110:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/48\">",
"      Sprangers MA, Moinpour CM, Moynihan TJ, et al. Assessing meaningful change in quality of life over time: a users' guide for clinicians. Mayo Clin Proc 2002; 77:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/49\">",
"      Cella D, Bullinger M, Scott C, et al. Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life. Mayo Clin Proc 2002; 77:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/50\">",
"      Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/51\">",
"      Yost KJ, Sorensen MV, Hahn EA, et al. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health 2005; 8:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/52\">",
"      Funk GF, Karnell LH, Smith RB, Christensen AJ. Clinical significance of health status assessment measures in head and neck cancer: what do quality-of-life scores mean? Arch Otolaryngol Head Neck Surg 2004; 130:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/53\">",
"      Gulbrandsen N, Hjermstad MJ, Wisl&oslash;ff F, Nordic Myeloma Study Group. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 2004; 72:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/54\">",
"      Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/55\">",
"      Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof 2005; 28:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/56\">",
"      Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol 2011; 64:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/57\">",
"      Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995; 273:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/58\">",
"      Atkinson M, Zibin S, Chuang H. Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Am J Psychiatry 1997; 154:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/59\">",
"      Graf J, Lauber C, Nordt C, et al. Perceived stigmatization of mentally ill people and its consequences for the quality of life in a Swiss population. J Nerv Ment Dis 2004; 192:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4120/abstract/60\">",
"      Fujii DE, Wylie AM, Nathan JH. Neurocognition and long-term prediction of quality of life in outpatients with severe and persistent mental illness. Schizophr Res 2004; 69:67.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2833 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_1_4120=[""].join("\n");
var outline_f4_1_4120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINING HRQL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MEASURING HRQL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Generic health status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Generic illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Disease-specific",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Combined instruments for patient-reported outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - PROMIS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Neuro-QOL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Proxy or caregiver evaluations of HRQL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      UTILIZATION OF HRQL DATA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Planning tools for future clinical care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Capturing changes in clinical status during treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Predicting treatment response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment decision-making",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CHALLENGES FOR HRQL STUDY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Defining a clinically meaningful change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      The influence of nonmedical issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      HRQL and psychology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2833\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2833|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/3/41018\" title=\"figure 1\">",
"      PROMIS domain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2833|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43719?source=related_link\">",
"      Functional problems in the patient with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38840?source=related_link\">",
"      Pulmonary rehabilitation in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25529?source=related_link\">",
"      Quality of life following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3466?source=related_link\">",
"      Quality of life in head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_1_4121="Treatment and prophylaxis of spontaneous bacterial peritonitis";
var content_f4_1_4121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prophylaxis of spontaneous bacterial peritonitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/1/4121/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4121/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/1/4121/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4121/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/1/4121/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4121/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/1/4121/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous bacterial peritonitis (SBP) is defined as an ascitic fluid infection without an evident intra-abdominal surgically treatable source; it occurs primarily in patients with advanced cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnosis is established by a positive ascitic fluid bacterial culture and an elevated ascitic fluid absolute polymorphonuclear leukocyte (PMN) count &ge;250",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"    An important issue in differential diagnosis and therapy is distinguishing SBP from a surgically treatable cause of secondary bacterial peritonitis (eg, due to a perforated viscus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12296?source=see_link\">",
"     \"Diagnosis of spontaneous bacterial peritonitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of SBP are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/0/7172?source=see_link\">",
"     \"Clinical manifestations of spontaneous bacterial peritonitis\"",
"    </a>",
"    .) The American Association for the Study of Liver Diseases (AASLD) guideline for SBP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/2\">",
"     2",
"    </a>",
"    ], as well as other AASLD guidelines, can be accessed through the AASLD web site at",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     www.aasld.org/practiceguidelines/Pages/default.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric therapy of suspected SBP must be initiated as soon as possible to maximize the patient's chance of survival. The recommendations that follow are consistent with a 2009 guideline issued by the American Association for the Study of Liver Diseases (",
"    <a class=\"graphic graphic_table graphicRef70375 \" href=\"UTD.htm?5/18/5422\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main indication for empiric therapy is the otherwise unexplained presence of one or more of the following findings that are characteristically seen in SBP (",
"    <a class=\"graphic graphic_table graphicRef71038 \" href=\"UTD.htm?17/61/18395\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Temperature greater than 37.8&ordm;C (100&ordm;F)",
"     </li>",
"     <li>",
"      Abdominal pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tenderness",
"     </li>",
"     <li>",
"      A change in mental status",
"     </li>",
"     <li>",
"      Ascitic fluid PMN count &ge;250",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Concerns about the safety of paracentesis should not prevent this crucial diagnostic procedure from being performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12296?source=see_link\">",
"     \"Diagnosis of spontaneous bacterial peritonitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Decision to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with fever, abdominal pain or tenderness, or altered mental status, treatment can be started as soon as ascitic fluid, blood, and urine have been obtained for culture and analysis. In patients without these findings, it is reasonable to wait until the results of the PMN count are available (",
"    <a class=\"graphic graphic_algorithm graphicRef59554 \" href=\"UTD.htm?11/26/11695\">",
"     algorithm 1",
"    </a>",
"    ). Collection and processing of the specimen should take no more than one to four hours from the time of the paracentesis. Patients with ascitic fluid PMN counts &ge;250",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    in a clinical setting compatible with ascitic fluid infection should receive empiric antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ascitic fluid PMN count is more rapidly available than the culture and appears to be a relatively reliable guide as to who really needs empiric antibiotic coverage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Delaying treatment until the ascitic fluid culture grows bacteria may result in death from overwhelming infection.",
"   </p>",
"   <p>",
"    In some patients, infection is detected at the",
"    <strong>",
"     bacterascites",
"    </strong>",
"    stage before there is a neutrophil response [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40292?source=see_link\">",
"     \"Spontaneous bacterial peritonitis variants\"",
"    </a>",
"    .) Patients with bacterascites who do not resolve the colonization and who progress to SBP commonly have signs or symptoms of infection (usually fever) at the time of the paracentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. When bacterascites is detected, options include treatment (as detailed below) for symptomatic patients or repeat paracentesis for asymptomatic patients. Treatment should be given if the PMN count in the follow-up specimen has risen to &ge;250",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Patients with alcoholic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with alcoholic hepatitis regularly develop fever, leukocytosis, and abdominal pain, which can mimic SBP. However, they also can develop SBP. Potentially contributing to the diagnostic uncertainty is that patients with alcoholic hepatitis frequently have a peripheral leukocytosis. Patients with a peripheral leukocytosis do",
"    <strong>",
"     not",
"    </strong>",
"    have a proportional increase in PMNs in ascites unless they also have SBP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/6\">",
"     6",
"    </a>",
"    ]; thus an elevated ascitic fluid PMN count must be presumed to represent SBP. Empiric antibiotic treatment (for presumed ascitic fluid infection) of patients with alcoholic hepatitis who have fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peripheral leukocytosis can be discontinued after 48 hours if ascitic fluid, blood, and urine cultures demonstrate no bacterial growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Microbiology and choice of antibiotic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of SBP are due to gut bacteria such as Escherichia coli and Klebsiella; however, streptococcal and, infrequently, staphylococcal infections can also occur (",
"    <a class=\"graphic graphic_table graphicRef80188 \" href=\"UTD.htm?22/8/22667\">",
"     table 3",
"    </a>",
"    ). As a result, relatively broad-spectrum therapy is warranted in patients with suspected ascitic fluid infection until the results of susceptibility testing are available.",
"   </p>",
"   <p>",
"    There are accumulating data to guide the optimal selection and dose of antibiotics for treatment of SBP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/7\">",
"     7",
"    </a>",
"    ]. At least nine controlled trials evaluating antibiotic treatment of SBP have been published, but their varying study designs limit direct comparisons [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/7\">",
"     7",
"    </a>",
"    ]. Nevertheless,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or a similar third-generation cephalosporin is a reasonable choice for suspected SBP (",
"    <a class=\"graphic graphic_algorithm graphicRef59554 \" href=\"UTD.htm?11/26/11695\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/1,3,8\">",
"     1,3,8",
"    </a>",
"    ]. One controlled trial, for example, included 73 patients with cirrhosis and severe infection (either SBP or bacteremia) who were randomly assigned to cefotaxime or the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/8\">",
"     8",
"    </a>",
"    ]. The following benefits were noted with cefotaxime:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher rate of resolution of the infection (85 versus 56 percent), even though almost all of the organisms in both groups were sensitive to the antibiotics",
"     </li>",
"     <li>",
"      No nephrotoxicity versus 5 percent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"     </li>",
"     <li>",
"      No superinfection versus 14 percent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    2 g intravenously every eight hours produces excellent ascitic fluid levels [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/9\">",
"     9",
"    </a>",
"    ]. Lower doses or less frequent dosing can be used, especially in patients with impaired renal function. One study, for example, compared two different doses of cefotaxime in 143 patients with SBP: 2 g Q6h and 2 g Q12h [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/10\">",
"     10",
"    </a>",
"    ]. The rate of infection resolution was the same in both groups (77 versus 79 percent).",
"   </p>",
"   <p>",
"    We prefer a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    dose of 2 g Q8h. The dose can be adjusted for azotemia; however this may not be necessary. We have used this dose even in patients with creatinines &gt;4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    without toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/9\">",
"     9",
"    </a>",
"    ]. Blood and ascitic levels can be high when this dose is used in the setting of azotemia; however this may be good in that the killing power is greater [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/9\">",
"     9",
"    </a>",
"    ]. The main adverse drug reaction of cefotaxime is rash, which occurs in about 1 percent of patients. The spectrum of coverage can usually be narrowed after the culture results have returned.",
"   </p>",
"   <p>",
"    Other antibiotics can be used for the treatment of SBP. However, a drug with no published utility for this specific indication should be avoided.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     Levofloxacin",
"    </a>",
"    can be used for patients with a penicillin allergy, although it does not penetrate into ascitic fluid to the same extent as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    . However, quinolones should not be used in suspected SBP in a patient who had been receiving a quinolone for prophylaxis. Organisms infecting patients who have been on quinolone prophylaxis are usually (94 percent) susceptible to cefotaxime [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/11\">",
"     11",
"    </a>",
"    ]. Nephrotoxic antibiotics should specifically be avoided because the underperfused kidneys in cirrhosis tend to be exquisitely sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=see_link\">",
"     \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A concern related to the choice of antibiotics is the emergence of resistant infections, especially in centers in which a quinolone is used for SBP prophylaxis. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Efficacy of prophylaxis'",
"    </a>",
"    below.) This was illustrated in a report from a center in Spain in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    prophylaxis is used routinely [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/13\">",
"     13",
"    </a>",
"    ]. Multiresistant bacteria comprised 18 percent of total bacterial infections. These changes in flora and susceptibility were attributed to use of norfloxacin prophylaxis and invasive procedures (eg, intravascular lines and urinary catheters). Many liver units have avoided the use of urinary catheters for decades. This study provides some data to support the wisdom of this policy.",
"   </p>",
"   <p>",
"    Patients with cirrhosis who develop SBP in the absence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    prophylaxis can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    as outlined above. Future data may show that added gram-positive coverage may be needed in patients who develop SBP while on norfloxacin prophylaxis.",
"   </p>",
"   <p>",
"    Resistance to third-generation cephalosporins also appears to be an increasing concern, at least in some regions. A report of 246 episodes in Spain found that 22 percent were due to strains that were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (mainly extended spectrum beta-lactamase-producing Gram-negative bacilli and Enterococci) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/14\">",
"     14",
"    </a>",
"    ]. The risk of resistance was related to patient characteristics and the clinical context. It was highest in nosocomially-acquired cases (41 percent) and in patients with frequent contact with the healthcare system (22 percent) compared with only 7 percent among community-acquired cases. A dose of 1 g of ceftriaxone does not appear to be high enough to treat SBP; 2 g daily appears to be the minimum dose in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/15\">",
"     15",
"    </a>",
"    ]. In settings where such resistance has been documented,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    can be used empirically as an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    , although there is much less clinical experience. As a general rule, the selection of antibiotics for SBP should include consideration of local resistance patterns, and coverage should be rapidly adjusted when culture and sensitivity data are available.",
"   </p>",
"   <p>",
"    Patients with suspected secondary bacterial peritonitis should receive broader coverage with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . A similar regimen should be used with polymicrobial bacterascites [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40292?source=see_link\">",
"     \"Spontaneous bacterial peritonitis variants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Possible oral treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain oral agents may be as effective as parenteral therapy in the treatment of uncomplicated SBP. One trial, for example, included 123 patients with SBP (who were not vomiting or in shock) who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    , 400 mg twice daily, or parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/17\">",
"     17",
"    </a>",
"    ]. The infection resolution rate was 84 and 85 percent in the two groups. Another trial demonstrated comparable outcomes with a short course of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (200 mg IV Q12H for two days) followed by oral therapy (500 mg PO Q12H for five days) compared with intravenous therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Confirmatory trials are awaited before oral treatment of this life-threatening infection and can be enthusiastically recommended. We have successfully used oral therapy in patients with asymptomatic SBP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal failure develops in 30 to 40 percent of patients with SBP and is a major cause of death [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/19\">",
"     19",
"    </a>",
"    ]. The risk may be decreased with an infusion of intravenous albumin. Once it has developed, treatment with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Intravenous albumin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of renal failure is associated with activation of the renin-angiotensin system and a decrease in effective arterial volume. Thus, it has been hypothesized that plasma volume expansion could attenuate the hemodynamic changes in patients with SBP, thereby preserving renal function. A meta-analysis of four controlled trials (with a total of 288 patients) evaluated the impact of albumin infusion (in addition to antibiotics) on renal impairment and mortality in patients with SBP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/20\">",
"     20",
"    </a>",
"    ]. Albumin infusion was associated with a significant decrease in the incidence of renal impairment (8 versus 31 percent) and a significant reduction in mortality (16 versus 35 percent). These data support the use of albumin infusion in patients with SBP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Pharmacological management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients develop renal failure coincident with SBP, with or without albumin infusion. This may be rapidly progressive and fatal. Pharmacological management of such patients is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link\">",
"     \"Hepatorenal syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Repeat ascitic fluid analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A follow-up ascitic fluid analysis to document resolution of the infection (ie, the culture is now sterile) and a marked decrease in PMN count is not needed in many patients with SBP. The majority of patients have a typical history including advanced cirrhosis, characteristic symptoms and ascitic fluid analysis (total protein concentration &lt;1",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    glucose concentration &gt;50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and lactate dehydrogenase less than the upper limit of normal for serum), infection with a single organism, and a dramatic clinical response. Repeat paracentesis is not necessary in such patients.",
"   </p>",
"   <p>",
"    However, repeat paracentesis should be performed if the setting, symptoms, analysis, organism(s), or response are atypical. Lack of resolution of the infection raises the possibility of secondary peritonitis and prompts further evaluation and, when appropriate, surgical intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12296?source=see_link\">",
"     \"Diagnosis of spontaneous bacterial peritonitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended duration of therapy in SBP is decreasing as studies document the efficacy of short-course treatment. As an example, a randomized controlled trial involving 90 patients compared 5- and 10-day courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/21\">",
"     21",
"    </a>",
"    ]. There were similar rates of bacteriologic cure (93 versus 91 percent), recurrent infection (11.6 versus 12.8 percent), and infection-related mortality (0 versus 4.3 percent) with both regimens. Another randomized trial has demonstrated that treating until 48 hours after signs and symptoms of infection have disappeared is also effective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We treat for five days and then reassess the patient; even bacteremic patients receive only five days of treatment as they did in the 5- versus 10-day trial. Only patients who grow an unusual organism (eg, one that is regularly associated with endocarditis) would be considered for longer treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/21\">",
"     21",
"    </a>",
"    ]. Treatment is discontinued if there has been the usual dramatic response. If, however, fever or pain persists, paracentesis is repeated, and the decision to continue or discontinue treatment is determined by the PMN response.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If the PMN count is &lt;250",
"      <span class=\"nowrap\">",
"       cells/mm3,",
"      </span>",
"      treatment is stopped.",
"     </li>",
"     <li>",
"      If the PMN count is greater than the pretreatment value, a search for a surgical source of infection is undertaken.",
"     </li>",
"     <li>",
"      If the PMN count is elevated but less than the pretreatment value, antibiotics are continued for another 48 hours, and paracentesis is repeated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infection-related mortality from SBP has plummeted in recent years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/1\">",
"     1",
"    </a>",
"    ]. Several reports have found no infection-related deaths if treatment was started prior to shock or frank renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/17,21\">",
"     17,21",
"    </a>",
"    ]. In one systematic review, in-hospital mortality was best predicted by the presence of renal dysfunction (mortality rate 67 versus 11 percent in those with and without renal dysfunction respectively) and higher MELD scores [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of the short-term outcome related to the SBP, patients who have severe enough liver disease to develop SBP have a poor long-term prognosis. In-hospital, non-infection-related mortality may be as high as 20 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/17,21\">",
"     17,21",
"    </a>",
"    ], and one- and two-year mortality rates are approximately 70 and 80 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Thus, liver transplantation should be seriously considered for survivors of SBP who are otherwise good transplant candidates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EFFICACY OF PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of risk factors for the development of SBP (including ascitic fluid protein concentration &lt;1.0",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    variceal hemorrhage, and a prior episode of SBP) and the recognition that most of the flora originate in the gut have led to randomized controlled trials of selective intestinal decontamination [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/25-32\">",
"     25-32",
"    </a>",
"    ]. A meta-analysis included 13 randomized controlled trials in which antibiotic prophylaxis was given to hospitalized patients with cirrhosis with a variety of different risk factors for infection (such as low protein ascitic fluid, gastrointestinal bleeding, and a history of SBP) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/28\">",
"     28",
"    </a>",
"    ]. The combined analysis showed an overall mortality benefit (RR 0.70, 95% CI 0.56-0.89) and a decrease in bacterial infections (RR 0.39, 95% CI 0.32-0.48). Similar conclusions were reached in at least two subsequent meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A concern with prolonged antibiotic prophylaxis is the selection of resistant gut flora, which can subsequently cause spontaneous infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/27,30,35-38\">",
"     27,30,35-38",
"    </a>",
"    ]. Fortunately these organisms remain sensitive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/13\">",
"     13",
"    </a>",
"    ]. A quinolone should not be used in suspected SBP in a patient who had been receiving a quinolone for prophylaxis.",
"   </p>",
"   <p>",
"    Whether prophylaxis should be given intermittently or continuously remains unsettled. There are randomized trials that support either continuous prevention or inpatient-only prevention of infection in patients with low protein ascitic fluid.",
"   </p>",
"   <p>",
"    The following regimens have been used in studies of intermittent prophylaxis (our recommendations appear below) (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Prophylaxis'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single weekly dose of 750 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/39\">",
"       39",
"      </a>",
"      ]. In this trial, 60 patients with cirrhosis and a low ascitic fluid protein concentration (&le;1.5",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      were randomly assigned to weekly ciprofloxacin or placebo for six months. There was a significant decrease in the incidence of SBP with ciprofloxacin (3.6 versus 22 percent) without the development of acquired resistance to ciprofloxacin.",
"     </li>",
"     <li>",
"      One double-strength tablet of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX) five days per week [",
"      <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/40\">",
"       40",
"      </a>",
"      ]. In this trial, 60 patients with cirrhosis were randomly assigned to TMP-SMX or placebo. Active therapy markedly decreased the incidence of SBP (3 versus 27 percent). No side effects were noted.",
"     </li>",
"     <li>",
"      Restricting the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       norfloxacin",
"      </a>",
"      for the indication of ascitic fluid protein &lt;1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      to hospitalized patients only, with discontinuation of the drug at the time of discharge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effects of continuous prophylaxis was evaluated in a placebo-controlled trial involving 100 patients with &lt;1.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    of total protein in ascitic fluid who were randomly assigned to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 mg daily) or placebo for 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/31\">",
"     31",
"    </a>",
"    ]. SBP occurred less frequently than in the placebo group, but the difference was not statistically significant. However, the probability of survival was significantly higher in patients randomized to ciprofloxacin (86 versus 66 percent). SBP and sepsis were the most frequent causes of death in the placebo arm, while gastrointestinal bleeding was responsible for most deaths in the ciprofloxacin arm.",
"   </p>",
"   <p>",
"    The most compelling randomized controlled trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    with placebo in patients with cirrhosis and ascitic fluid total protein &lt;1.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    who fulfilled either of the following two criteria: a Child-Pugh score &ge;9 points and serum bilirubin &ge;3",
"    <span class=\"nowrap\">",
"     mg/dL;",
"    </span>",
"    or a serum creatinine &ge;1.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or blood urea nitrogen &ge;25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or serum sodium &le;130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/32\">",
"     32",
"    </a>",
"    ]. The patients treated with norfloxacin had the following significant benefits: fewer episodes of SBP (7 versus 61 percent), a lower rate of hepatorenal syndrome (28 versus 41 percent), and improved survival at 3 months (94 versus 62 percent) and 12 months (60 versus 48 percent). It is unusual to demonstrate a survival advantage in treatment of a complication of advanced cirrhosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cost effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cost analysis of the use of prophylactic antibiotics was performed by evaluating studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    400 mg once daily, and TMP-SMX one double-strength tablet five days per week [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/41\">",
"     41",
"    </a>",
"    ]. Norfloxacin prophylaxis resulted in savings between $2216 and $8545 per patient per year, while TMP-SMX prophylaxis resulted in similar savings between $2934 and $9251. The benefit of either regimen was minor in patients without a history of SBP. By comparison, an increased benefit was noted in patients with an ascitic fluid total protein concentration &le;1",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    and the greatest benefit was observed in patients with a previous episode of SBP. The analysis assumed that antibiotic prophylaxis remains effective in decreasing the frequency of SBP over an entire year; validation of this assumption requires extension of the follow-up period in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     In the setting of bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic prophylaxis is recommended for patients with cirrhosis who are hospitalized with gastrointestinal bleeding based upon a mortality benefit that has been demonstrated in randomized controlled trials. We generally use intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    1 g intravenously daily in this setting and switch patients to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    (400 mg orally twice daily) after bleeding has been controlled and patients are stable and eating [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/42\">",
"     42",
"    </a>",
"    ]. Seven days of total antibiotic treatment are given.",
"   </p>",
"   <p>",
"    The trial that validated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    in this setting gave seven days of intravenous therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/42\">",
"     42",
"    </a>",
"    ]. However, patients hospitalized for variceal bleeding are regularly discharged prior to seven days. Switching to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    orally to complete the seven-day total antibiotic treatment makes more sense than sending them home on intravenous therapy or retaining them in the hospital to complete their treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link\">",
"     \"General principles of the management of variceal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the available data, we limit the use of prolonged outpatient quinolone therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    therapy (one double-strength tablet once daily) to patients who have had",
"    <strong>",
"     one or more episodes",
"    </strong>",
"    of SBP. In settings where norfloxacin is unavailable,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 mg PO once daily) or trimethoprim-sulfamethoxazole (one double-strength tablet daily) is an acceptable alternative. Our approach to patients with cirrhosis hospitalized with gastrointestinal bleeding is summarized above. In patients with cirrhosis who are hospitalized for other reasons and have an ascitic protein concentration of less than 1",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    we use oral norfloxacin (400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or trimethoprim-sulfamethoxazole (one tablet once daily) with discontinuation of the drug at the time of discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/43\">",
"     43",
"    </a>",
"    ]. We do not use weekly or five times per week dosing schedules. The above recommendations are consistent with a 2009 guideline issued by the American Association for the Study of Liver Diseases (",
"    <a class=\"graphic graphic_table graphicRef70375 \" href=\"UTD.htm?5/18/5422\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Effect on hyperdynamic circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other benefits of selective intestinal decontamination include an increase in blood pressure and an increase in systemic vascular resistance, effects that have been documented after four weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/44\">",
"     44",
"    </a>",
"    ]. These hemodynamic improvements, if sustained, may delay development of hepatorenal syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Awaiting liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no published randomized trials of antibiotic treatment versus placebo in preventing infections in patients awaiting liver transplantation. We treat such patients as described above, giving outpatient antibiotics only to patients who have had one or more episodes of SBP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prevention of sclerotherapy-related infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early days of sclerotherapy, the use of long needles and contaminated endoscopic water sources led to bacteremia. Since the recognition of these problems and the use of shorter needles and sterile water, sclerotherapy-related infections have largely disappeared. Thus, parenteral antibiotics to prevent such infections do",
"    <strong>",
"     not",
"    </strong>",
"    appear to be warranted. One study of 97 patients, for example, found a trend toward a lower incidence of bacteremia with imipenem-cilastin than with placebo (1.1 versus 5.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/45\">",
"     45",
"    </a>",
"    ]. This difference was not statistically significant; furthermore, six of the seven episodes occurred after emergency sclerotherapy. Active bleeding appears to be the risk factor for infection in the current era&mdash;not sclerotherapy.",
"   </p>",
"   <p>",
"    Variceal banding is replacing sclerotherapy; banding is even less likely than sclerotherapy to lead to bacteremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuresis concentrates ascitic fluid, thereby raising ascitic fluid opsonic activity, which may help prevent SBP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4121/abstract/46\">",
"     46",
"    </a>",
"    ]. Early recognition and aggressive treatment of localized infections (eg, cystitis and cellulitis) can also help to prevent bacteremia and SBP in these immunocompromised patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Diagnosis and treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An approach to patients with suspected SBP is summarized in the algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef59554 \" href=\"UTD.htm?11/26/11695\">",
"       algorithm 1",
"      </a>",
"      ). In patients with fever, abdominal pain or tenderness, or altered mental status, treatment can be started as soon as ascitic fluid, blood, and urine have been obtained for culture and analysis. In patients without these findings, it is reasonable to wait until the results of the PMN count are available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Empiric therapy of suspected SBP must be initiated as soon as possible to maximize the patient's chance of survival. The main indication for empiric therapy is the otherwise unexplained presence of one or more of the following findings that are characteristically seen in SBP (",
"    <a class=\"graphic graphic_table graphicRef71038 \" href=\"UTD.htm?17/61/18395\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Temperature greater than 37.8&ordm;C (100&ordm;F)",
"     </li>",
"     <li>",
"      Abdominal pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tenderness",
"     </li>",
"     <li>",
"      A change in mental status",
"     </li>",
"     <li>",
"      Ascitic fluid PMN count &ge;250",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most cases of SBP are due to gut bacteria, such as Escherichia coli and Klebsiella; however, streptococcal and, infrequently, staphylococcal infections can also occur (",
"    <a class=\"graphic graphic_table graphicRef80188 \" href=\"UTD.htm?22/8/22667\">",
"     table 3",
"    </a>",
"    ). As a result, we recommend relatively broad-spectrum therapy in patients with suspected ascitic fluid infection until the results of susceptibility testing are available (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     Cefotaxime",
"    </a>",
"    or a similar third-generation cephalosporin appears to be the",
"    <strong>",
"     treatment of choice",
"    </strong>",
"    for suspected SBP.",
"   </p>",
"   <p>",
"    We treat for five days and then reassess the patient. Treatment is discontinued if there has been the usual dramatic response. If, however, fever or pain persists, paracentesis is repeated, and the decision to continue or discontinue treatment is determined by the PMN response.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If the PMN count is &lt;250",
"      <span class=\"nowrap\">",
"       cells/mm3,",
"      </span>",
"      treatment is stopped.",
"     </li>",
"     <li>",
"      If the PMN count is greater than the pretreatment value, a search for a surgical source of infection is undertaken.",
"     </li>",
"     <li>",
"      If the PMN count is elevated but less than the pretreatment value, antibiotics are continued for another 48 hours and paracentesis is repeated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We also generally repeat a paracentesis after 48 hours of treatment if there is clinical suspicion of secondary peritonitis.",
"   </p>",
"   <p>",
"    We recommend giving intravenous albumin as part of the treatment of SBP because of the possible survival advantage (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    )&nbsp;(",
"    <a class=\"graphic graphic_algorithm graphicRef59554 \" href=\"UTD.htm?11/26/11695\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Intravenous albumin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whether intermittent or continuous prophylaxis is preferable remains unsettled, with randomized controlled trials supporting both strategies in high-risk patients (ie, those with a history of SBP or those with an ascitic protein concentration &lt;1.5",
"      <span class=\"nowrap\">",
"       g/dL).",
"      </span>",
"      We suggest the following approaches:",
"     </li>",
"     <li>",
"      We suggest prolonged (ie, indefinite duration), outpatient quinolone therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       norfloxacin",
"      </a>",
"      400",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      therapy (one double-strength tablet once daily) only in patients who have had",
"      <strong>",
"       one or more episodes",
"      </strong>",
"      of SBP (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We do not use weekly or five times per week dosing schedules. In settings where norfloxacin is unavailable,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (500 mg PO once daily) or trimethoprim-sulfamethoxazole (one double-strength tablet daily) is an acceptable alternative.",
"     </li>",
"     <li>",
"      We recommend prolonged prophylaxis (ie, indefinite duration) of patients with cirrhosis and ascitic fluid total protein &lt;1.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      with at least one of the following: (a) Child-Pugh &ge;9 points and serum bilirubin &ge;3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or (b) serum creatinine &ge;1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or blood urea nitrogen &ge;25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or serum sodium &le;130",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with cirrhosis who are hospitalized for gastrointestinal bleeding, we recommend initial intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      1 g daily (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'In the setting of bleeding'",
"      </a>",
"      above.) We transition patients to 400 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       norfloxacin",
"      </a>",
"      orally twice daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (one double-strength tablet twice daily) for seven days of total antibiotic use once bleeding has been controlled and patients have been stabilized and are able to tolerate oral intake.",
"     </li>",
"     <li>",
"      In patients with cirrhosis hospitalized for other reasons who have an ascitic fluid protein concentration &lt;1",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       norfloxacin",
"      </a>",
"      (400",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      with discontinuation of the drug at the time of discharge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H353255290\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's many contributions to our program, in particular, his work on this topic as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/1\">",
"      Such J, Runyon BA. Spontaneous bacterial peritonitis. Clin Infect Dis 1998; 27:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/2\">",
"      Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49:2087.",
"     </a>",
"    </li>",
"    <li>",
"     McHutchison JG, Runyon BA. Spontaneous bacterial peritonitis. In: Gastrointestinal and Hepatic Infections, Surawicz CM, Owen RL (Eds), WB Saunders, Philadelphia 1994. p.455.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/4\">",
"      Runyon BA. Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis. Hepatology 1990; 12:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/5\">",
"      Pelletier G, Lesur G, Ink O, et al. Asymptomatic bacterascites: is it spontaneous bacterial peritonitis? Hepatology 1991; 14:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/6\">",
"      Antillon MR, Runyon BA. Effect of marked peripheral leukocytosis on the leukocyte count in ascites. Arch Intern Med 1991; 151:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/7\">",
"      Soares-Weiser K, Paul M, Brezis M, Leibovici L. Evidence based case report. Antibiotic treatment for spontaneous bacterial peritonitis. BMJ 2002; 324:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/8\">",
"      Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985; 5:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/9\">",
"      Runyon BA, Akriviadis EA, Sattler FR, Cohen J. Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitis. Dig Dis Sci 1991; 36:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/10\">",
"      Rimola A, Salmer&oacute;n JM, Clemente G, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology 1995; 21:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/11\">",
"      Llovet JM, Rodr&iacute;guez-Iglesias P, Moitinho E, et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. J Hepatol 1997; 26:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/12\">",
"      Cabrera J, Arroyo V, Ballesta AM, et al. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982; 82:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/13\">",
"      Fern&aacute;ndez J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/14\">",
"      Ariza X, Castellote J, Lora-Tamayo J, et al. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. J Hepatol 2012; 56:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/15\">",
"      Mazer L, Tabber EB, Piatkowski G, et al. Dosing of ceftriaxone for spontaneous bacterial peritonitis. Hepatology 2012; 56:947A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/16\">",
"      Runyon BA, Hoefs JC, Canawati HN. Polymicrobial bacterascites. A unique entity in the spectrum of infected ascitic fluid. Arch Intern Med 1986; 146:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/17\">",
"      Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996; 111:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/18\">",
"      Terg R, Cobas S, Fassio E, et al. Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study. J Hepatol 2000; 33:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/19\">",
"      Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/20\">",
"      Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 2013; 11:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/21\">",
"      Runyon BA, McHutchison JG, Antillon MR, et al. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 1991; 100:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/22\">",
"      Tandon P, Garcia-Tsao G. Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 2011; 9:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/23\">",
"      Tit&oacute; L, Rimola A, Gin&egrave;s P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/24\">",
"      Andreu M, Sola R, Sitges-Serra A, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993; 104:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/25\">",
"      Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986; 91:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/26\">",
"      Soriano G, Guarner C, Teixid&oacute; M, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991; 100:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/27\">",
"      Gin&eacute;s P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/28\">",
"      Soares-Weiser K, Brezis M, Tur-Kaspa R, et al. Antibiotic prophylaxis of bacterial infections in cirrhotic inpatients: a meta-analysis of randomized controlled trials. Scand J Gastroenterol 2003; 38:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/29\">",
"      Grang&eacute; JD, Roulot D, Pelletier G, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol 1998; 29:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/30\">",
"      Soriano G, Guarner C, Tom&aacute;s A, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992; 103:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/31\">",
"      Terg R, Fassio E, Guevara M, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 2008; 48:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/32\">",
"      Fern&aacute;ndez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/33\">",
"      Saab S, Hernandez JC, Chi AC, Tong MJ. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol 2009; 104:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/34\">",
"      Loomba R, Wesley R, Bain A, et al. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol 2009; 7:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/35\">",
"      Runyon BA, Borzio M, Young S, et al. Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation, and survival in an animal model of cirrhosis. Hepatology 1995; 21:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/36\">",
"      Ortiz J, Vila MC, Soriano G, et al. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology 1999; 29:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/37\">",
"      Wade JJ, Rolando N, Hayllar K, et al. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology 1995; 21:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/38\">",
"      Tandon P, Delisle A, Topal JE, Garcia-Tsao G. High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center. Clin Gastroenterol Hepatol 2012; 10:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/39\">",
"      Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995; 22:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/40\">",
"      Singh N, Gayowski T, Yu VL, Wagener MM. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995; 122:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/41\">",
"      Inadomi J, Sonnenberg A. Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology 1997; 113:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/42\">",
"      Fern&aacute;ndez J, Ruiz del Arbol L, G&oacute;mez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/43\">",
"      Novella M, Sol&agrave; R, Soriano G, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997; 25:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/44\">",
"      Rasaratnam B, Kaye D, Jennings G, et al. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003; 139:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/45\">",
"      Rolando N, Gimson A, Philpott-Howard J, et al. Infectious sequelae after endoscopic sclerotherapy of oesophageal varices: role of antibiotic prophylaxis. J Hepatol 1993; 18:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4121/abstract/46\">",
"      Runyon BA, Antillon MR, Montano AA. Effect of diuresis versus therapeutic paracentesis on ascitic fluid opsonic activity and serum complement. Gastroenterology 1989; 97:158.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1248 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_1_4121=[""].join("\n");
var outline_f4_1_4121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Decision to treat",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Patients with alcoholic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Microbiology and choice of antibiotic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Possible oral treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Renal failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Intravenous albumin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Pharmacological management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Repeat ascitic fluid analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EFFICACY OF PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cost effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      In the setting of bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Effect on hyperdynamic circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Awaiting liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prevention of sclerotherapy-related infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H353255290\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1248\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1248|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/26/11695\" title=\"algorithm 1\">",
"      Dx and Rx of suspected SBP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1248|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/18/5422\" title=\"table 1\">",
"      AASLD ascites guideline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/61/18395\" title=\"table 2\">",
"      Signs and symptoms of SBP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/8/22667\" title=\"table 3\">",
"      Bacteriology of SBP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/0/7172?source=related_link\">",
"      Clinical manifestations of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12296?source=related_link\">",
"      Diagnosis of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=related_link\">",
"      General principles of the management of variceal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40292?source=related_link\">",
"      Spontaneous bacterial peritonitis variants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_1_4122="Autism spectrum disorders in children and adolescents: Behavioral and educational interventions";
var content_f4_1_4122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Autism spectrum disorders in children and adolescents: Behavioral and educational interventions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/1/4122/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4122/contributors\">",
"     Laura Weissman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4122/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/1/4122/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4122/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4122/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/1/4122/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/1/4122/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/1/4122/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autism spectrum disorders (ASD) are a group of biologically based neurodevelopmental disorders characterized by impairments in three major domains: socialization, communication, and behavior. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) categorizes autism spectrum disorders under \"pervasive developmental disorders\" (PDD) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/1\">",
"     1",
"    </a>",
"    ]. These disorders include autistic disorder (classic autism, sometimes called early infantile autism, childhood autism, or Kanner's autism); Asperger disorder (also known as Asperger syndrome); pervasive developmental disorder-not otherwise specified (PDD-NOS), including atypical autism; childhood disintegrative disorder; and Rett disorder.",
"   </p>",
"   <p>",
"    The discussion that follows will focus on behavioral and educational interventions for children with autism and PDD-NOS. Related topics are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=see_link\">",
"       \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=see_link\">",
"       \"Clinical features of autism spectrum disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=see_link\">",
"       \"Diagnosis of autism spectrum disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/54/872?source=see_link\">",
"       \"Autism spectrum disorders in children and adolescents: Overview of management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35562?source=see_link\">",
"       \"Autism spectrum disorders in children and adolescents: Pharmacologic interventions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16234?source=see_link\">",
"       \"Autism spectrum disorders in children and adolescents: Complementary and alternative therapies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41801?source=see_link\">",
"       \"Asperger disorder: Management and prognosis in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with autism spectrum disorders (ASD) have varying degrees of impairment in social and behavioral function (",
"    <a class=\"graphic graphic_table graphicRef72403 \" href=\"UTD.htm?29/6/29804\">",
"     table 1",
"    </a>",
"    ). Management of ASD is individualized according to age and specific needs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/2\">",
"     2",
"    </a>",
"    ]. It requires a multidisciplinary approach that makes use of the child's strengths to address his or her weaknesses.",
"   </p>",
"   <p>",
"    Behavioral and educational interventions target the core symptoms ASD with an objective of improving overall function. Intensive behavioral and educational interventions are the primary component of treatment programs for ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/3\">",
"     3",
"    </a>",
"    ]. The interventions typically are carried out by special education personnel or trained therapists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Goals of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although treatment programs for children with ASD vary, they generally focus on similar objectives. The overarching goals of treatment are to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maximize functioning",
"     </li>",
"     <li>",
"      Move the child toward independence",
"     </li>",
"     <li>",
"      Improve the quality of life for the child and family",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific goals are to [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Improve social functioning and play skills",
"     </li>",
"     <li>",
"      Improve communication skills (both functional and spontaneous)",
"     </li>",
"     <li>",
"      Improve adaptive skills",
"     </li>",
"     <li>",
"      Decrease nonfunctional or negative behaviors",
"     </li>",
"     <li>",
"      Promote academic functioning and cognition",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practical and ethical factors have made it challenging to evaluate intervention programs for ASD in randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/5\">",
"     5",
"    </a>",
"    ]. The literature on behavioral interventions for ASD is mixed but stresses the importance of early intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/3,6,7\">",
"     3,6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/54/872?source=see_link&amp;anchor=H4#H4\">",
"     \"Autism spectrum disorders in children and adolescents: Overview of management\", section on 'Early intervention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systematic reviews of small randomized trials and nonrandomized controlled trials have found that certain behavioral and education treatment strategies are associated with improvements in the core symptoms of ASD (behavior, language skills, and peer interaction) and IQ (intelligence test scores) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/6-20\">",
"     6-20",
"    </a>",
"    ]. However, the methodologic limitations of the individual studies make it difficult to be certain about the effectiveness of particular programs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/8,18,20\">",
"     8,18,20",
"    </a>",
"    ]. Methodologic limitations include the lack of outcome measures that are sensitive to changes in autism symptomatology and the inability to measure or control pretreatment factors, such as environmental context, other treatments, comorbid conditions, etc [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/5\">",
"     5",
"    </a>",
"    ]. Questions remain regarding the optimal age at initiation of treatment, language and cognitive skills necessary for certain treatment modalities, intensity of treatment (ie, number of hours per week), magnitude and type of benefit, and whether certain programs are better than others for certain children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/6,18,21-25\">",
"     6,18,21-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The National Research Council, one of the four agencies that make up the National Academies including the Institute of Medicine, recommends that educational services begin as soon as a child is suspected of having an ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/6\">",
"     6",
"    </a>",
"    ]. The services should include a minimum of 25 hours a week, 12 months per year, in which the child is engaged in systematically planned, and developmentally appropriate educational activity toward identified objectives. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Attributes of successful programs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most research has focused on the treatment of preschool and school-aged children. There is little information about treatment of ASD in adolescents and children younger than two years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Programs for toddlers'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Programs for older children and adolescents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Attributes of successful programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the lack of evidence from randomized controlled trials, there is growing evidence from observational studies and systematic reviews and a general consensus in the professional community that children with ASD should participate in therapeutic programs as early as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/2,3,6,7\">",
"     2,3,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Core features of successful autism educational programs identified in observational studies and systematic reviews include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/2,3,6,7,25\">",
"     2,3,6,7,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A high staff-to-student ratio (1:1 or 1:2)",
"     </li>",
"     <li>",
"      Individualized programming for each child",
"     </li>",
"     <li>",
"      Teachers with special expertise in working with children with autism",
"     </li>",
"     <li>",
"      A minimum of 25 hours per week of services",
"     </li>",
"     <li>",
"      Ongoing program evaluation and adjustment",
"     </li>",
"     <li>",
"      A curriculum emphasizing attention, imitation, communication, play, and social interaction",
"     </li>",
"     <li>",
"      A highly supportive teaching environment",
"     </li>",
"     <li>",
"      Predictability and structure",
"     </li>",
"     <li>",
"      Functional analysis of behavior problems",
"     </li>",
"     <li>",
"      Transition planning",
"     </li>",
"     <li>",
"      Family involvement",
"     </li>",
"     <li>",
"      Close monitoring and modification as the child's needs change",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The components of the educational program for an individual child with ASD will vary depending upon the child's chronologic age, developmental level, specific strengths and weaknesses, and family needs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/6\">",
"     6",
"    </a>",
"    ]. However, minimal intensity (ie, 25 hours per week) is critical to effective intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/2,6\">",
"     2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To better understand the child's learning environment and program, the pediatric healthcare provider can ask the following questions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How many days a week does the child attend and how much time does he or she spend in each setting?",
"     </li>",
"     <li>",
"      How many students and providers are in each setting?",
"     </li>",
"     <li>",
"      What therapies is the child receiving? For how long? Are the therapies provided individually or in group settings?",
"     </li>",
"     <li>",
"      Are there any home-based therapies?",
"     </li>",
"     <li>",
"      Who is providing the therapies? Who is overseeing the program? What are their qualifications?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The responses to these questions, in conjunction with information about the child's functioning, can be used to help families determine if the program is appropriate. A tool for evaluating the quality of Individual Education Programs for children with ASD that incorporates the requirements of the Individuals with Disabilities Education Act and the National Research Council&rsquo;s recommendations for children with autism is available in the full text of reference [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Classroom environment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision regarding classroom placement should be guided by the child's individualized goals and objectives and the supports that are necessary to achieve them [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/3\">",
"     3",
"    </a>",
"    ]. Different schools may have different models. The goal is to promote functioning and, if appropriate, transition to a regular classroom with support.",
"   </p>",
"   <p>",
"    Children who require a lot of support may be placed in a small classroom with a high teacher-to-student ratio and other children with similar behavioral profiles. They may receive all of their therapies in the classroom or be taken to a small therapy room. They may spend the entire day in the small classroom or part of the day in a classroom with more typically developing peers. If they spend part of the day with typically developing peers, they may require part- or full-time support from an aide or behavioral therapist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INTERVENTIONAL MODELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with autism spectrum disorders (ASD) generally require a combination of therapies and interventions to address their individual constellation of symptoms. Approaches can be broadly categorized according to conceptual models as behavioral (eg, Applied Behavior Analysis [ABA]), Structured Teaching (eg, the Treatment and Education of Autistic and related Communication-handicapped CHildren [TEACCH]), or",
"    <span class=\"nowrap\">",
"     developmental/relationship-based",
"    </span>",
"    (eg, Floortime). However, the types of interventions provided within these programs often overlap. Integrative programs use a combination of strategies within the treatment program (eg, Social Communication, Emotional Regulation, Transactional Support [SCERTS]). Parental involvement is an important aspect of the treatment program. Some therapies may be provided in the home, and parent training may be part of the intervention.",
"   </p>",
"   <p>",
"    A systematic review found insufficient evidence to suggest that any particular interventional model is superior to another [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/2\">",
"     2",
"    </a>",
"    ]. However, there is moderate evidence that greater intensity (in hours per week) and greater duration (in months) of treatment lead to better outcomes.",
"   </p>",
"   <p>",
"    Some of the commonly used therapies in treatment programs for children with ASD are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Intensive behavioral interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensive behavioral interventions seek to target the defining symptoms of autism spectrum disorders (ASD) (",
"    <a class=\"graphic graphic_table graphicRef72403 \" href=\"UTD.htm?29/6/29804\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/3,14\">",
"     3,14",
"    </a>",
"    ]. They are based upon the principles of behavior modification. One such intensive behavioral intervention, Applied Behavior Analysis (ABA), seeks to reinforce desirable behaviors and decrease undesirable behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/15\">",
"     15",
"    </a>",
"    ]. The goals of ABA are to teach new skills and generalize learned skills by breaking them down into their simplest elements. The skills are taught through repeated reward-based trials.",
"   </p>",
"   <p>",
"    To maximize success, intensive behavioral programs should have a low student-to-therapist ratio. They may be delivered in a variety of settings (eg, home, self-contained classroom, inclusive classroom, community) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/14,28\">",
"     14,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of specific intensive behavior intervention programs include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discrete trial training (DTT), which is the most structured form of intensive behavior therapy; it was developed by Ivar Lovaas.",
"     </li>",
"     <li>",
"      Contemporary ABA programs, which occur in more naturalistic settings; they include pivotal response training (PRT), language paradigms, and incidental teaching.",
"     </li>",
"     <li>",
"      Early intensive behavioral intervention (EIBI).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The range of behavioral treatment models for which there is evidence of efficacy in ASD is described in greater detail in the Table (",
"    <a class=\"graphic graphic_table graphicRef54198 \" href=\"UTD.htm?39/28/40396\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Effectiveness &ndash; Intensive behavioral intervention programs have a larger body of supportive evidence than other types of interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/4,29\">",
"     4,29",
"    </a>",
"    ]. One reason for this is that ABA methodology requires collection and analysis of detailed data about the child's response to therapy.",
"   </p>",
"   <p>",
"    Intensive behavioral intervention programs for ASD have been evaluated in systematic reviews of randomized trials and cohort studies, most of which had methodologic limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/2,9-16,18,20\">",
"     2,9-16,18,20",
"    </a>",
"    ]. With evidence of benefit from several well-controlled studies, the National Autism Center's National Standards Report, a systematic review of the peer-reviewed behavioral and educational literature (1957-2007) considers intensive behavioral intervention to be an \"established\" treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intensive behavior programs may improve core symptoms of ASD but should not be expected to lead to normal function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/9,10,13-15,18\">",
"     9,10,13-15,18",
"    </a>",
"    ]. The studies revealing the most gains for intensive behavior programs included a high level of intervention (eg, 30 to 40 hours per week of intensive one-on-one services for two or more years and starting before the age of five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/9,30\">",
"     9,30",
"    </a>",
"    ]. However, the evidence is insufficient to provide a general recommendation that all children with ASD require this level of intervention. The most significant improvements generally are seen within the first 12 months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/11\">",
"     11",
"    </a>",
"    ]. Pretreatment variables that are associated with improved outcomes include the presence of joint attention, functional play skills, higher cognitive abilities, and decreased severity of autism symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although research is ongoing, it is unclear whether one type of intensive behavioral intervention is better than another, how to determine which children with ASD will respond maximally to intensive behavioral interventions, and whether intensive behavior programs should be recommended over other types of treatment programs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/9,11,16,18\">",
"     9,11,16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with other interventions &ndash; Although ABA methods appear to be efficacious when compared with control interventions (eg, special education), it is not clear that ABA is superior to other behavioral therapy methods [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/9\">",
"     9",
"    </a>",
"    ]. There are very few studies comparing ABA with other treatment models, and those studies have methodologic limitations. Those performed comparing ABA with a Developmental Individual Difference Relationship-based Model (Floortime) and TEACCH found no difference in efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'TEACCH/Structured Teaching method'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'Developmental and relationship models'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    ABA for older children &ndash; There is some controversy about the use of ABA for older children, and there are few studies to guide recommendations for this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/3\">",
"     3",
"    </a>",
"    ]. The studies tend to be smaller both in duration and in numbers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/30\">",
"     30",
"    </a>",
"    ]. Children requiring ABA at an older age may be more impaired than children who no longer require ABA. In such children, ABA may used to target specific needs, rather than broad deficits, limiting the generalizability of study results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     TEACCH/Structured Teaching method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TEACCH method uses Structured Teaching to help individuals overcome areas of weakness. The goal is to modify the environment and to improve skills. This model incorporates the therapist as generalist (meaning that the therapist understands the whole child and does not specialize in one developmental discipline), is individualized to the student, and includes family involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The TEACCH method focuses on (",
"    <a class=\"external\" href=\"file://teacch.com/about-us-1/what-is-teacch\">",
"     file://teacch.com/about-us-1/what-is-teacch",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Understanding the culture of autism",
"     </li>",
"     <li>",
"      Using an individualized person- and family-centered plan",
"     </li>",
"     <li>",
"      Organizing the physical environment",
"     </li>",
"     <li>",
"      A predictable sequence of activities",
"     </li>",
"     <li>",
"      Visual schedules",
"     </li>",
"     <li>",
"      Routines with flexibility",
"     </li>",
"     <li>",
"      Structured",
"      <span class=\"nowrap\">",
"       work/activity",
"      </span>",
"      systems",
"     </li>",
"     <li>",
"      Visually structured activities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonrandomized studies comparing TEACCH with no intervention have noted improvements in fine motor skills, gross motor skills, cognitive functioning, social adaptive functioning, and communication skills [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/9,36-38\">",
"     9,36-38",
"    </a>",
"    ]. The 2011 Agency for Healthcare Research and Quality (AHRQ) systematic review of four studies of TEACCH published after 2000 found some evidence of benefit in cognitive and motor function but that the body of evidence was insufficient to estimate the magnitude of the effect [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/39\">",
"     39",
"    </a>",
"    ]; the document is available at:",
"    <a class=\"external\" href=\"file://www.effectivehealthcare.ahrq.gov/\">",
"     www.effectivehealthcare.ahrq.gov",
"    </a>",
"    . This conclusion is similar to that of earlier systematic reviews, although one categorized TEACCH as \"likely to be beneficial\", based upon consensus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/12,14\">",
"     12,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Developmental and relationship models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental and relationship-based models focus on teaching skills that are essential to development (eg, social communication, emotional relationships, cognitive abilities) that were not learned adequately at the expected age. Some commonly used developmental models are described in the Table (",
"    <a class=\"graphic graphic_table graphicRef70816 \" href=\"UTD.htm?12/8/12428\">",
"     table 3",
"    </a>",
"    ). They include the Denver model; Developmental Individual Difference Relationship-based approach (DIR or Floortime); Relationship-Development Intervention (RDI); and Responsive Teaching (RT).",
"   </p>",
"   <p>",
"    Developmental therapies often are used in clinical practice. However, the current evidence is inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/9,12,14\">",
"     9,12,14",
"    </a>",
"    ]. The variety of approaches to developmental therapies makes it difficult to interpret, compare, and generalize results. A 2008 systemic review found evidence of benefit for some developmental approaches, as illustrated below [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Milieu therapy was associated with improvement in cognitive skills, overall course, and communication and play skills [",
"      <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Responsive teaching was associated with improvements in quality of social communication and expressive language [",
"      <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The More Than Words&reg; program was associated with positive outcomes in facilitative strategies and vocabulary, but failed to show gains in other areas [",
"      <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Integrative models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some programs use an integrative approach that combines more than one interventional model. The SCERTS program is an example, although it is sometimes classified as a relationship-based model. The SCERTS program provides individualized, collaborative programming that addresses social communication deficits and interfering behaviors to help the child increase his or her competence and independence using various strategies supported in the literature.",
"   </p>",
"   <p>",
"    The Early Start Denver Model (ESDM) uses a combination of intensive ABA programming and developmental- and relationship-based approaches, and includes parents as therapists. A randomized trial comparing the ESDM program with interventions commonly available in the community demonstrated significant language, cognitive, and adaptive functioning gains in 48 children over a two-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/44\">",
"     44",
"    </a>",
"    ]. Although this trial suggests that this particular combination of ABA and relationship-developmental model is efficacious in young children, it is not clear that the results can be generalized to other specific models or combinations of models [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Parental role",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parental and family involvement is an important aspect of the treatment program for children with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/14\">",
"     14",
"    </a>",
"    ]. Some therapies may be provided in the home, and parent training may be part of the intervention. Parent-mediated interventions may help families interact with their child, promote development, and increase parental satisfaction, empowerment, and mental health [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/15,45\">",
"     15,45",
"    </a>",
"    ]. However, which parental interventions maximize outcomes is unknown. Parent-mediated intervention programs must be individualized to the child and changes made based on the child's progress. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Attributes of successful programs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Small randomized and nonrandomized studies have noted increased reciprocal social interaction and improved generalization and maintenance of behavior changes with parent training [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. However, systematic reviews of parent-mediated interventions found the evidence inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Interventions for specific behaviors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral interventions may be used to target specific behaviors (eg, sleep disturbance, failure to initiate social contact with peers, self-injury) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Before initiating a behavioral intervention for a specific behavior, the possibility that the behavior is related to a particular skill deficit or sensory problem should be evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of 251 studies of targeted behavioral interventions found that focal behavioral interventions consistently result in positive behavioral outcomes across a wide range of targets, including aberrant behaviors (eg, self-injury, aggression), language skills, daily living skills, social skills, etc [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/46\">",
"     46",
"    </a>",
"    ]. The National Autism Center's National Standards Report considers targeted behavioral interventions to be an \"established\" treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2011 AHRQ review of studies published after 2000 found several studies suggesting that CBT-based interventions were effective in reducing anxiety symptoms in high-functioning individuals with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/47\">",
"     47",
"    </a>",
"    ]; the document is available at:",
"    <a class=\"external\" href=\"file://www.effectivehealthcare.ahrq.gov/\">",
"     www.effectivehealthcare.ahrq.gov",
"    </a>",
"    . The AHRQ systematic review also found a few studies suggesting the utility of parent training for improving behavioral outcomes in general and of adding parent training to medication interventions (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    ) for children with challenging behaviors. However, the studies were small, relied on parent report and used varying intervention models. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER INTERVENTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Communication interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Communication-, speech-, and language-based interventions seek to improve core deficits in social and functional communication skills (",
"    <a class=\"graphic graphic_table graphicRef72403 \" href=\"UTD.htm?29/6/29804\">",
"     table 1",
"    </a>",
"    ). Interventions to promote communication skills are essential to improvement in overall functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/15\">",
"     15",
"    </a>",
"    ]. The specific goals of communication interventions vary depending upon the child's level of function.",
"   </p>",
"   <p>",
"    Children with autism spectrum disorders (ASD) benefit most from language interventions that span settings and are incorporated into their daily routines [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/15\">",
"     15",
"    </a>",
"    ]. Many therapists in clinical practice use a total communication approach to promote verbal language skills and enhance overall communication skills. The communication program may include a variety of interventions, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Traditional speech and language interventions",
"     </li>",
"     <li>",
"      Behaviorally based strategies to encourage language",
"     </li>",
"     <li>",
"      Augmentative communication strategies (eg, picture exchange system, gestures, sign language, electronic communication systems)",
"     </li>",
"     <li>",
"      Visual supports (eg, visual schedules, choice boards)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is insufficient evidence to support a specific methodology for improvement of communication skills in children with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/9,14\">",
"     9,14",
"    </a>",
"    ]. Systematic reviews have found individual controlled trials of computer-assisted instruction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/48-50\">",
"     48-50",
"    </a>",
"    ] and sign language training [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/51,52\">",
"     51,52",
"    </a>",
"    ] that suggested improvement in some areas, but could draw no overall conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/9,14\">",
"     9,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of augmentative communication strategies for individuals who are nonverbal or have diminished language skills can be helpful in promoting communication and decreasing frustration related to communication deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. The use of a specific augmentative communication system called PECS, or Picture Exchange Communication System (a system which an individual is taught to use pictures to communicate), is common in clinical practice. It can be helpful in improving communication initiation. Systematic reviews of the effectiveness of PECS have generally found it to be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/2,12,14,56\">",
"     2,12,14,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parents may be concerned that use of augmentative strategies inhibits the development of communication and language skills, but this is not the case [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/3\">",
"     3",
"    </a>",
"    ]. There is some evidence to suggest that children with ASD may be more stimulated to learn speech if they already have an understanding of symbolic communication [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/55,57,58\">",
"     55,57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Social skills instruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficits in social function are one of the core deficits of autism spectrum disorders (",
"    <a class=\"graphic graphic_table graphicRef72403 \" href=\"UTD.htm?29/6/29804\">",
"     table 1",
"    </a>",
"    ), and social skills instruction is an important component of management. Although additional studies are necessary, a 2012 meta-analysis of five randomized trials (196 participants) found some evidence that participation in social skills groups improved overall social competence and friendship quality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2009 National Autism Center's National Standards Report identified four therapies that directly target social skills for which there is evidence of benefit from several well-controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/14\">",
"     14",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Joint attention interventions (eg, pointing to objects, showing, etc)",
"     </li>",
"     <li>",
"      Modeling (both real-life and video-based modeling)",
"     </li>",
"     <li>",
"      Peer training package (including, but not limited to peer networks, peer initiation training, and peer-mediated social interventions)",
"     </li>",
"     <li>",
"      Story-based intervention package (including the Socials Stories&trade; approach) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/60\">",
"       60",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interventions are described in the Table (",
"    <a class=\"graphic graphic_table graphicRef54198 \" href=\"UTD.htm?39/28/40396\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Interventions that included the social skills package (eg, social and pragmatic groups, which often are used clinically with success) were categorized as \"emerging\" (defined by having few studies variably demonstrating a beneficial effect) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/14\">",
"     14",
"    </a>",
"    ]. This is consistent with the findings of other systematic reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/12,61\">",
"     12,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized trial, supplementation of a comprehensive intervention program with a curriculum targeting social behavior (imitation, joint attention, and affect sharing) was effective in improving the frequency of socially engaged imitation (imitation paired with eye contact) in toddlers with ASD (from a mean of 17 percent at baseline to 42 percent after the intervention) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/62\">",
"     62",
"    </a>",
"    ]. This improved social behavior was generalized to unfamiliar contexts and maintained six months after the intervention was discontinued.",
"   </p>",
"   <p>",
"    Comorbid emotional or behavioral problems may influence outcomes of social skills interventions. In an observational study, after a 10-week social skills training program, parent-reported social-skills improved among children with ASD and children with ASD and comorbid anxiety, but not among children with ASD and comorbid",
"    <span class=\"nowrap\">",
"     attention-deficit/hyperactivity",
"    </span>",
"    disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Social skills programs for higher-functioning children with ASD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41801?source=see_link&amp;anchor=H7#H7\">",
"     \"Asperger disorder: Management and prognosis in children and adolescents\", section on 'Social skills'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Occupational therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Traditional OT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with ASD commonly present with deficits in adaptive functioning and fine motor skills that affect academic and everyday functioning. Occupational therapy is often used to address these deficits.",
"   </p>",
"   <p>",
"    In young children with ASD, occupational therapy usually focuses on enhancing sensory processing, sensorimotor and social-behavioral performance, self-care (eg, dressing, hygiene), and participation in play [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/64\">",
"     64",
"    </a>",
"    ]. In older children the focus of occupational therapy may include social and behavioral performance and transition to work and independence in the community.",
"   </p>",
"   <p>",
"    There is little research regarding traditional occupational therapy for children with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/3,65\">",
"     3,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Sensory integration therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The theory of sensory integration disorder or dysfunction is based upon the hypothesis that various sensory experiences (eg, vestibular, proprioceptive, gravitational, tactile, visual, and auditory) help to guide development [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/66\">",
"     66",
"    </a>",
"    ]. Within this hypothesis, aberrations in sensory integration are thought to result in disorganization of the central nervous system that manifests as developmental and behavioral abnormalities known as sensory integration dysfunction. As part of this theory, sensory integration dysfunction is treated through the introduction of intensive sensory inputs using specific equipment and techniques. Such treatment typically is provided by occupational therapists.",
"   </p>",
"   <p>",
"    Sensory integration therapy is often used for children with ASD because many of their behaviors are thought to be related to deficiencies in the sensory system. However, the validity of the sensory integration model and sensory integration therapy are controversial, with strong supporters on both sides [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/67-70\">",
"     67-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systematic reviews and meta-analysis have inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/12,64-66,71-74\">",
"     12,64-66,71-74",
"    </a>",
"    ]. There are many studies; most of them are small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/75-77\">",
"     75-77",
"    </a>",
"    ], and the lack of standard diagnostic criteria, treatment, and outcome measures makes interpretation difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/67,69,74\">",
"     67,69,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little information about the potential harms of sensory integration therapy. However, many of the interventions that are used in sensory integration therapy also are used in traditional occupational therapy treatment without adverse effect [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of sensory integration therapy in ASD is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/14,66\">",
"     14,66",
"    </a>",
"    ]. The American Academy of Pediatrics recommends that treatment programs focus on behavioral and educational interventions as described above [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/3\">",
"     3",
"    </a>",
"    ]. However, sensory integration therapy may be included as part of a comprehensive program that focuses on behavioral and educational interventions to calm the child, reinforce desired behaviors, or help with transitions between activities [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/3,66\">",
"     3,66",
"    </a>",
"    ]. Continued use of sensory integration should be based upon the treatment response in the individual child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGRAMS FOR TODDLERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As awareness of autism and autism spectrum disorders (ASD) increases and the diagnosis is made in younger children, interventions for toddlers are essential.",
"   </p>",
"   <p>",
"    Many of the strategies that are used to address the deficits in autism in preschool children may or may not be appropriate for toddlers or children with significant cognitive impairment who have not attained certain skills (eg, understanding of cause and effect, establishment of joint attention). In addition, the learning style of children younger than two years and the environments in which they learn are different from those of preschool children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the published studies regarding ASD in toddlers are descriptive [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/26\">",
"     26",
"    </a>",
"    ]. Research in this age group is ongoing, and interventional studies are beginning to be published. One study that includes younger children provided some evidence suggesting a role for intensive behavioral interventions in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/44\">",
"     44",
"    </a>",
"    ]. However, the most appropriate interventions for toddlers with ASD have not yet been determined.",
"   </p>",
"   <p>",
"    Outside of the research setting, ASD-specific interventions for children younger than two years are not widely available. However, early intervention services, including speech and language interventions, are strongly recommended for toddlers with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/26\">",
"     26",
"    </a>",
"    ]. Interventions for toddlers should focus on [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Natural learning environments",
"     </li>",
"     <li>",
"      Child initiative and sensory-motor exploration",
"     </li>",
"     <li>",
"      Development of nonverbal intentional communicative acts",
"     </li>",
"     <li>",
"      Reciprocal play with social partners",
"     </li>",
"     <li>",
"      Enriched language environments",
"     </li>",
"     <li>",
"      Environments that provide opportunities for the toddlers to have an active role in learning",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PROGRAMS FOR OLDER CHILDREN AND ADOLESCENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little published research evaluating comprehensive educational programs for older children and adolescents on the autism spectrum [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/3\">",
"     3",
"    </a>",
"    ]. However, there is empirical support for the use of certain strategies, particularly those based on Applied Behavior Analysis or general behavioral principles, to increase and maintain desirable behaviors, reduce maladaptive behaviors, teach new skills, and generalize behaviors to new environments or situations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/3,46,78\">",
"     3,46,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Educational interventions for adolescents should continue to include the core attributes of successful programs. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Attributes of successful programs'",
"    </a>",
"    above.) The program should focus on achieving social competence, emotional and behavioral regulation, educational success, and the functional adaptive skills necessary for independence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Transition planning",
"    </span>",
"    &nbsp;&mdash;&nbsp;By age 16 years, the individualized education program (IEP) for a child with autism spectrum disorder (ASD) should include a plan for transition from child- to adult-oriented activities, but the process of transition planning should begin much sooner, as early as age 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/1/4122/abstract/3\">",
"     3",
"    </a>",
"    ]. Comprehensive transition planning involves the student, parents, teachers, medical home, and community agencies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27737?source=see_link&amp;anchor=H18#H18\">",
"     \"Children with special health care needs\", section on 'Transition planning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals with autism spectrum disorders (ASD) have varying degrees of impairment in social and behavioral function (",
"      <a class=\"graphic graphic_table graphicRef72403 \" href=\"UTD.htm?29/6/29804\">",
"       table 1",
"      </a>",
"      ). Behavioral and educational interventions targeting core symptoms should be tailored to the child's specific needs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overarching goals of treatment are to maximize functioning, move the child toward independence, and improve the quality of life. Specific goals are to improve core symptoms and adaptive skills, decrease negative behaviors, and promote academic functioning and cognition. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Goals of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Practical and ethical factors have made it challenging to evaluate intervention programs for individuals with ASD in randomized controlled trials. Systematic reviews of behavioral and educational interventions for children with ASD suggest that earlier and more intensive therapies are associated with better outcomes. However, the evidence is insufficient to endorse any particular therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Expert reviews of treatment programs for ASD have identified the following core attributes of successful programs:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A high staff-to-student ratio of 1:1 or 1:2",
"     </li>",
"     <li>",
"      Individualized programming for each child",
"     </li>",
"     <li>",
"      Teachers with special expertise in working with children with autism",
"     </li>",
"     <li>",
"      A minimum of 25 hours per week of services",
"     </li>",
"     <li>",
"      Ongoing program evaluation and adjustment",
"     </li>",
"     <li>",
"      A curriculum emphasizing attention, imitation, communication, play, and social interaction",
"     </li>",
"     <li>",
"      A highly supportive teaching environment",
"     </li>",
"     <li>",
"      Predictability and structure",
"     </li>",
"     <li>",
"      Functional analysis of behavior problems",
"     </li>",
"     <li>",
"      Transition planning",
"     </li>",
"     <li>",
"      Family involvement",
"     </li>",
"     <li>",
"      Close monitoring and modification as a child's needs change",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Attributes of successful programs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interventional models for treatment may include intensive behavioral interventions (based upon the principles of Applied Behavior Analysis), Structured Teaching (including the Treatment and Education of Autistic and related Communication-handicapped CHildren [TEACCH] model),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       developmental/relationship-based",
"      </span>",
"      models (such as Developmental Individual Difference [DIR or Floortime]), and models that integrate various approaches. The evidence is insufficient to recommend one of these models over another. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Interventional models'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parent-mediated interventions may help families interact with their child, promote development, and increase parental satisfaction, empowerment, and mental health. However, which parental interventions maximize outcomes is unknown. In addition to providing direct interventions, general parental involvement in the treatment program is essential and should include parent training and collaboration. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Parental role'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with ASD benefit most from language interventions that span settings and are incorporated into their daily routines. There is insufficient evidence to support a specific methodology (eg, traditional speech and language interventions, behaviorally based strategies, augmentative communication strategies, visual support), and a variety of methods may be used. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Communication interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interventions that address social skills deficit that have evidence of benefit from well-controlled studies include interventions that address joint attention, modeling, peer training, and story-based interventions. There is less evidence to support social and pragmatic groups, although these are used in clinical practice with success. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Social skills instruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Traditional occupational therapy is often used to address deficits in adaptive functioning and fine motor skills. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Traditional OT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sensory integration therapy for children with ASD is controversial, and the evidence regarding its benefits is inconsistent. It may be warranted for specific indications (eg, to calm the child, reinforce desired behaviors, or help with transitions) within a comprehensive behavioral and educational program. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Sensory integration therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some of the strategies that are used to address the deficits in autism in preschool children may not be appropriate for toddlers or children with significant cognitive impairment, but early intensive therapy is recommended. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Programs for toddlers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Programs for older children and adolescents should focus on achieving social competence, emotional and behavioral regulation, and the functional adaptive skills necessary for independence. They should continue to include the core attributes of successful programs, including a plan for transition to adulthood. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Programs for older children and adolescents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Attributes of successful programs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Pervasive Developmental Disorders. In: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR&reg;)., American Psychiatric Association, Washington, DC  p.70.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/2\">",
"      Maglione MA, Gans D, Das L, et al. Nonmedical interventions for children with ASD: recommended guidelines and further research needs. Pediatrics 2012; 130 Suppl 2:S169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/3\">",
"      Myers SM, Johnson CP, American Academy of Pediatrics Council on Children With Disabilities. Management of children with autism spectrum disorders. Pediatrics 2007; 120:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/4\">",
"      Myers SM. Management of autism spectrum disorders in primary care. Pediatr Ann 2009; 38:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/5\">",
"      Spence SJ, Thurm A. Testing autism interventions: trials and tribulations. Lancet 2010; 375:2124.",
"     </a>",
"    </li>",
"    <li>",
"     National Research Council, Committee on Educational Interventions for Children with Autism. Educating Children with Autism, Lord C, McGee JP (Eds), National Academy Press, Washington, DC 2001.",
"    </li>",
"    <li>",
"     New York State Department of Health Early Intervention Program. Clinical practice guideline: The guideline technical report: Autism/Pervasive developmental disorders assessment and intervention for young children (age 0-3 years). Publication No. 4217, Albany, NY 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/8\">",
"      Seida JK, Ospina MB, Karkhaneh M, et al. Systematic reviews of psychosocial interventions for autism: an umbrella review. Dev Med Child Neurol 2009; 51:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/9\">",
"      Ospina MB, Krebs Seida J, Clark B, et al. Behavioural and developmental interventions for autism spectrum disorder: a clinical systematic review. PLoS One 2008; 3:e3755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/10\">",
"      Spreckley M, Boyd R. Efficacy of applied behavioral intervention in preschool children with autism for improving cognitive, language, and adaptive behavior: a systematic review and meta-analysis. J Pediatr 2009; 154:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/11\">",
"      Howlin P, Magiati I, Charman T. Systematic review of early intensive behavioral interventions for children with autism. Am J Intellect Dev Disabil 2009; 114:23.",
"     </a>",
"    </li>",
"    <li>",
"     Parr J. Autism. In: Clinical Evidence Handbook, BMJ Publishing Group, London 2008. p.69.",
"    </li>",
"    <li>",
"     Bassett K, Green CJ, Kazanjian A. Autism and Lovaas treatment: A systematic review of effectiveness evidence. Office of Health Technology Assessment, Centre for Health Services and Policy Research (BCOHTA); 2000. Available at: www.chspr.ubc.ca/node/351 (Accessed on May 18, 2010).",
"    </li>",
"    <li>",
"     The National Autism Center's National Standards Report. National Autism Center, Randolph, MA, 2009. Available at: www.nationalautismcenter.org/pdf/NAC%20Standards%20Report.pdf (Accessed on May 18, 2010).",
"    </li>",
"    <li>",
"     Scottish Intercollegiate Guidelines Network. Assessment, diagnosis and clinical interventions for children and young people with autism spectrum disorders. A national clinical guideline. Scottish Intercollegiate Guidelines Network, Edinburgh 2007. www.sign.ac.uk/guidelines/fulltext/98/index.html (Accessed on November 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/16\">",
"      Reichow B, Wolery M. Comprehensive synthesis of early intensive behavioral interventions for young children with autism based on the UCLA young autism project model. J Autism Dev Disord 2009; 39:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/17\">",
"      McConachie H, Diggle T. Parent implemented early intervention for young children with autism spectrum disorder: a systematic review. J Eval Clin Pract 2007; 13:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/18\">",
"      Warren Z, McPheeters ML, Sathe N, et al. A systematic review of early intensive intervention for autism spectrum disorders. Pediatrics 2011; 127:e1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/19\">",
"      Kasari C, Gulsrud A, Freeman S, et al. Longitudinal follow-up of children with autism receiving targeted interventions on joint attention and play. J Am Acad Child Adolesc Psychiatry 2012; 51:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/20\">",
"      Reichow B, Barton EE, Boyd BA, Hume K. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012; 10:CD009260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/21\">",
"      Baird G, Charman T, Cox A, et al. Current topic: Screening and surveillance for autism and pervasive developmental disorders. Arch Dis Child 2001; 84:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/22\">",
"      Rutter M. Autism: its recognition, early diagnosis, and service implications. J Dev Behav Pediatr 2006; 27:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/23\">",
"      Howlin P. Practitioner review: psychological and educational treatments for autism. J Child Psychol Psychiatry 1998; 39:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/24\">",
"      Rogers SJ. Empirically supported comprehensive treatments for young children with autism. J Clin Child Psychol 1998; 27:168.",
"     </a>",
"    </li>",
"    <li>",
"     Dawson G, Osterling J. Early intervention in autism: effectiveness and common elements of current approaches. In: The Effectiveness of Early Intervention: Second Generation Research, Guralnick MJ (Ed), Paul Brookes, Baltimore 1997. p.307.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/26\">",
"      Zwaigenbaum L, Bryson S, Lord C, et al. Clinical assessment and management of toddlers with suspected autism spectrum disorder: insights from studies of high-risk infants. Pediatrics 2009; 123:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/27\">",
"      Ruble LA, McGrew J, Dalrymple N, Jung LA. Examining the quality of IEPs for young children with autism. J Autism Dev Disord 2010; 40:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/28\">",
"      Levy SE, Mandell DS, Schultz RT. Autism. Lancet 2009; 374:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/29\">",
"      Rogers SJ, Vismara LA. Evidence-based comprehensive treatments for early autism. J Clin Child Adolesc Psychol 2008; 37:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/30\">",
"      Granpeesheh D, Tarbox J, Dixon DR. Applied behavior analytic interventions for children with autism: a description and review of treatment research. Ann Clin Psychiatry 2009; 21:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/31\">",
"      Gillberg C, Steffenburg S. Outcome and prognostic factors in infantile autism and similar conditions: a population-based study of 46 cases followed through puberty. J Autism Dev Disord 1987; 17:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/32\">",
"      Sigman M, McGovern CW. Improvement in cognitive and language skills from preschool to adolescence in autism. J Autism Dev Disord 2005; 35:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/33\">",
"      Stevens MC, Fein DA, Dunn M, et al. Subgroups of children with autism by cluster analysis: a longitudinal examination. J Am Acad Child Adolesc Psychiatry 2000; 39:346.",
"     </a>",
"    </li>",
"    <li>",
"     Hilton JC. Communication skills of young children diagnosed with autism: comparative effectiveness of applied behavior analysis and developmental, individual-difference, relationship-based interventions (dissertation). James Madison University, Harrisonburg, VA 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/35\">",
"      Farrell P, Trigonaki N, Webster D. An exploratory evaluation of two early intervention programmes for young children with autism. Educ Child Psychol 2005; 22:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/36\">",
"      Ozonoff S, Cathcart K. Effectiveness of a home program intervention for young children with autism. J Autism Dev Disord 1998; 28:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/37\">",
"      Panerai S, Ferrante L, Zingale M. Benefits of the Treatment and Education of Autistic and Communication Handicapped Children (TEACCH) programme as compared with a non-specific approach. J Intellect Disabil Res 2002; 46:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/38\">",
"      Tsang SK, Shek DT, Lam LL, et al. Brief report: application of the TEACCH program on Chinese pre-school children with autism--Does culture make a difference? J Autism Dev Disord 2007; 37:390.",
"     </a>",
"    </li>",
"    <li>",
"     Warren Z, Veenstra-VanderWeele J, Stone W, et al. Therapies for children with autism spectrum disorders. AHRQ Publication No.11-EHC029-EF, p.106, Agency for Healthcare Research and Quality; Rockville, MD 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/40\">",
"      Macalpine ML. Play in autism: the power of microdevelopment. Dissert ABst Int B: Sciences and Engineering 1999; 59:5593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/41\">",
"      Yoder P, Stone WL. A randomized comparison of the effect of two prelinguistic communication interventions on the acquisition of spoken communication in preschoolers with ASD. J Speech Lang Hear Res 2006; 49:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/42\">",
"      Aldred C, Green J, Adams C. A new social communication intervention for children with autism: pilot randomised controlled treatment study suggesting effectiveness. J Child Psychol Psychiatry 2004; 45:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/43\">",
"      McConachie H, Randle V, Hammal D, Le Couteur A. A controlled trial of a training course for parents of children with suspected autism spectrum disorder. J Pediatr 2005; 147:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/44\">",
"      Dawson G, Rogers S, Munson J, et al. Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model. Pediatrics 2010; 125:e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/45\">",
"      Green J, Charman T, McConachie H, et al. Parent-mediated communication-focused treatment in children with autism (PACT): a randomised controlled trial. Lancet 2010; 375:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/46\">",
"      Matson JL, Benavidez DA, Compton LS, et al. Behavioral treatment of autistic persons: a review of research from 1980 to the present. Res Dev Disabil 1996; 17:433.",
"     </a>",
"    </li>",
"    <li>",
"     Warren Z, Veenstra-VanderWeele J, Stone W, et al. Therapies for children with autism spectrum disorders. AHRQ Publication No. 11-EHC029, p.104, Agency for Healthcare Research and Quality; Rockville, MD 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/48\">",
"      Golan O, Baron-Cohen S. Systemizing empathy: teaching adults with Asperger syndrome or high-functioning autism to recognize complex emotions using interactive multimedia. Dev Psychopathol 2006; 18:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/49\">",
"      Silver M, Oakes P. Evaluation of a new computer intervention to teach people with autism or Asperger syndrome to recognize and predict emotions in others. Autism 2001; 5:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/50\">",
"      Moore M, Calvert S. Brief report: vocabulary acquisition for children with autism: teacher or computer instruction. J Autism Dev Disord 2000; 30:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/51\">",
"      Oxman J, Konstantareas MM, Liebovitz-Bojm SF. Simultaneous communication training and vocal responding in nonverbal autistic and autistic-like children. Int J Rehabil Res 1979; 2:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/52\">",
"      Yoder PJ, Layton TL. Speech following sign language training in autistic children with minimal verbal language. J Autism Dev Disord 1988; 18:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/53\">",
"      Goldstein H. Communication intervention for children with autism: a review of treatment efficacy. J Autism Dev Disord 2002; 32:373.",
"     </a>",
"    </li>",
"    <li>",
"     Paul R, Sutherland D. Enhancing early language in children with autism spectrum disorders. In: Handbook of Autism and Pervasive Developmental Disorders, 3rd ed, Volkmar FR, Paul R, Klin A, Cohen D (Eds), John Wiley &amp; Sons, Hoboken, NJ 2005. p.946.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/55\">",
"      Millar DC, Light JC, Schlosser RW. The impact of augmentative and alternative communication intervention on the speech production of individuals with developmental disabilities: a research review. J Speech Lang Hear Res 2006; 49:248.",
"     </a>",
"    </li>",
"    <li>",
"     Warren Z, Veenstra-VanderWeele J, Stone W, et al. for children with autism spectrum disorders. AHRQ Publication No.11-EHC029-ER, p.110, Agency for Healthcare Research and Quality; Rockville, MD 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/57\">",
"      Bondy A, Frost L. The Picture Exchange Communication System. Behav Modif 2001; 25:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/58\">",
"      Layton TL. Language training with autistic children using four different modes of presentation. J Commun Disord 1988; 21:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/59\">",
"      Reichow B, Steiner AM, Volkmar F. Social skills groups for people aged 6 to 21 with autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012; 7:CD008511.",
"     </a>",
"    </li>",
"    <li>",
"     The Gray Center for Social Learning and Understanding. Available at: www.thegraycenter.org (Accessed on February 19, 2010).",
"    </li>",
"    <li>",
"     Warren Z, Veenstra-VanderWeele J, Stone W, et al. Therapies for children with autism spectrum disorders. AHRQ Publication No.11-EHC029-ER, p.102, Agency for Healthcare Research and Quality; Rockville, MD 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/62\">",
"      Landa RJ, Holman KC, O'Neill AH, Stuart EA. Intervention targeting development of socially synchronous engagement in toddlers with autism spectrum disorder: a randomized controlled trial. J Child Psychol Psychiatry 2011; 52:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/63\">",
"      Antshel KM, Polacek C, McMahon M, et al. Comorbid ADHD and anxiety affect social skills group intervention treatment efficacy in children with autism spectrum disorders. J Dev Behav Pediatr 2011; 32:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/64\">",
"      Case-Smith J, Arbesman M. Evidence-based review of interventions for autism used in or of relevance to occupational therapy. Am J Occup Ther 2008; 62:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/65\">",
"      Dawson G, Watling R. Interventions to facilitate auditory, visual, and motor integration in autism: a review of the evidence. J Autism Dev Disord 2000; 30:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/66\">",
"      Section On Complementary And Integrative Medicine, Council on Children with Disabilities, American Academy of Pediatrics, et al. Sensory integration therapies for children with developmental and behavioral disorders. Pediatrics 2012; 129:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/67\">",
"      Williames LD, Erdie-Lalena CR. Complementary, holistic, and integrative medicine: sensory integration. Pediatr Rev 2009; 30:e91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/68\">",
"      Baranek GT. Efficacy of sensory and motor interventions for children with autism. J Autism Dev Disord 2002; 32:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/69\">",
"      Rogers SJ, Ozonoff S. Annotation: what do we know about sensory dysfunction in autism? A critical review of the empirical evidence. J Child Psychol Psychiatry 2005; 46:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/70\">",
"      Schaaf RC, Miller LJ. Occupational therapy using a sensory integrative approach for children with developmental disabilities. Ment Retard Dev Disabil Res Rev 2005; 11:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/71\">",
"      Vargas S, Camilli G. A meta-analysis of research on sensory integration treatment. Am J Occup Ther 1999; 53:189.",
"     </a>",
"    </li>",
"    <li>",
"     Tochel C. Sensory or auditory integration therapy for children with autistic spectrum disorders. In: STEER: Succint and Timely Evaluated Evidence Reviews. Bazian Ltd (Eds). Wessex Institute for Health Research and Development, University of Southampton and Bazian Ltd., London 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/73\">",
"      Hoehn TP, Baumeister AA. A critique of the application of sensory integration therapy to children with learning disabilities. J Learn Disabil 1994; 27:338.",
"     </a>",
"    </li>",
"    <li>",
"     Warren Z, Veenstra-VanderWeele J, Stone W, et al. Therapies for children with autism spectrum disorders. AHRQ Publication No.11-EHC029-ER, p.10, Agency for Healthcare Research and Quality; Rockville, MD 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/75\">",
"      Ayres AJ, Tickle LS. Hyper-responsivity to touch and vestibular stimuli as a predictor of positive response to sensory integration procedures by autistic children. Am J Occup Ther 1980; 34:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/76\">",
"      Case-Smith J, Bryan T. The effects of occupational therapy with sensory integration emphasis on preschool-age children with autism. Am J Occup Ther 1999; 53:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/1/4122/abstract/77\">",
"      Linderman TM, Stewart KB. Sensory integrative-based occupational therapy and functional outcomes in young children with pervasive developmental disorders: a single-subject study. Am J Occup Ther 1999; 53:207.",
"     </a>",
"    </li>",
"    <li>",
"     Harris SL, Handleman JS, Jennett HK. Models of educational intervention for students with autism: home, center, and school-based programming. In: Handbook of Autism and Pervasive Developmental Disorders, 3rd ed, Volkmar FR, Klin PR, Cohen D (Eds), John Wiley &amp; Sons, Hoboken, NJ 2005. p.882.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 607 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_1_4122=[""].join("\n");
var outline_f4_1_4122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Goals of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Attributes of successful programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Classroom environment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INTERVENTIONAL MODELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Intensive behavioral interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TEACCH/Structured Teaching method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Developmental and relationship models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Integrative models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Parental role",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Interventions for specific behaviors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Communication interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Social skills instruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Occupational therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Traditional OT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Sensory integration therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGRAMS FOR TODDLERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PROGRAMS FOR OLDER CHILDREN AND ADOLESCENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Transition planning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/607\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/607|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/6/29804\" title=\"table 1\">",
"      DSM IV criteria autism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/28/40396\" title=\"table 2\">",
"      NAC established therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/8/12428\" title=\"table 3\">",
"      Developmental models ASD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41801?source=related_link\">",
"      Asperger disorder: Management and prognosis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16234?source=related_link\">",
"      Autism spectrum disorders in children and adolescents: Complementary and alternative therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/54/872?source=related_link\">",
"      Autism spectrum disorders in children and adolescents: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35562?source=related_link\">",
"      Autism spectrum disorders in children and adolescents: Pharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27737?source=related_link\">",
"      Children with special health care needs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=related_link\">",
"      Clinical features of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=related_link\">",
"      Diagnosis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=related_link\">",
"      Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_1_4123="Causes of prerenal pediatric acute kidney injury";
var content_f4_1_4123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of prerenal pediatric acute kidney injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Etiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased intravascular volume",
"       </td>",
"       <td>",
"        Dehydration, hemorrhage, diuretics, burns, shock, nephrotic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased cardiac function",
"       </td>",
"       <td>",
"        Heart failure, arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral vasodilatation",
"       </td>",
"       <td>",
"        Sepsis, anaphylaxis, antihypertensive medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal vasoconstriction",
"       </td>",
"       <td>",
"        Sepsis, nonsteroidal antiinflammatory drugs, ACE inhibitor",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     ACE: angiotensin converting enzyme.",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_1_4123=[""].join("\n");
var outline_f4_1_4123=null;
var title_f4_1_4124="Chronologic appearance and characteristics of organisms in burns";
var content_f4_1_4124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chronologic appearance and characteristics of organisms in burns",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organism, chronology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Commensal skin organisms (gram positive) result in early colonization of burns",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Streptococcus and Staphylococcus species primarily",
"         </li>",
"         <li>",
"          Other sources are upper respiratory tract and environment",
"         </li>",
"         <li>",
"          Topical antimicrobials help decrease colonization",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gram-negative species dominant &gt;5 days",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          2 to 4 days post-burn, gram-negative bacteria colonize wound",
"         </li>",
"         <li>",
"          Patient skin, upper respiratory tract, gastrointestinal tract, and hospital environment are typical sources",
"         </li>",
"         <li>",
"          Pseudomonas aeruginoasa, Acinetobacter baumannii, E. Coli, Klebsiella pneumoniae, Enterobacter cloacae.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If gram-negative cover is initiated, yeast often appears",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Yeast and fungi colonization follows",
"         </li>",
"         <li>",
"          Majority are Candida&nbsp;species, other fungi are increasing in frequency",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Finally, more resistant bacteria and fungi invade the wound",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          MRSA, VRE, multi-drug-resistant Pseudomonas and Acinetobacter species, and fungi",
"         </li>",
"         <li>",
"          Usually secondary to broad-spectrum antibiotics, or inadequate host response or therapeutic measures (excision burn, topical and systemic antibiotics)",
"         </li>",
"         <li>",
"          Transition from colonization to invasion",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MRSA:&nbsp; methicillin-resistant Staphylococcus aureus, VRE: vancomycin-resistant Enterococcus",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_1_4124=[""].join("\n");
var outline_f4_1_4124=null;
var title_f4_1_4125="Amyloid precursor proteins I";
var content_f4_1_4125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Protein precursor of amyloid deposits-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Protein class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Precursor protein (abbreviation)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Amyloid type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        High density apolipoproteins",
"       </td>",
"       <td>",
"        (Apo) serum AA",
"       </td>",
"       <td>",
"        AA",
"       </td>",
"       <td>",
"        Associated with amyloid complicating chronic infections or inflammatory diseases, and some heredofamilial periodic fever syndromes, such as FMF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apolipoprotein A-I (ApoAI)",
"       </td>",
"       <td>",
"        AApoAI",
"       </td>",
"       <td>",
"        Age-related amyloid occurring in the aortic intima, and some hereditary neuropathic or cardiopathic amyloidoses",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apolipoprotein A-II (ApoAII)",
"       </td>",
"       <td>",
"        AApoAII",
"       </td>",
"       <td>",
"        Some hereditary nephropathic amyloidoses",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Immunoglobulin (Ig) gene superfamily",
"       </td>",
"       <td>",
"        Ig L chain/Ig H chains (IgL/IgH)",
"       </td>",
"       <td>",
"        AL/AH",
"       </td>",
"       <td>",
"        Primary and myeloma-associated amyloidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta-2 microglobulin",
"       </td>",
"       <td>",
"        A&beta;2m",
"       </td>",
"       <td>",
"        Dialysis amyloidosis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Neuroendocrine",
"       </td>",
"       <td>",
"        (Pro)Calcitonin",
"       </td>",
"       <td>",
"        ACal",
"       </td>",
"       <td>",
"        Amyloid complicating C-cell thyroid tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Islet amyloid",
"       </td>",
"       <td>",
"        AIAPP",
"       </td>",
"       <td>",
"        Islet cell amyloid in Insulinomas, type II diabetes mellitus, and aging",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrial natriuretic peptide",
"       </td>",
"       <td>",
"        AANF",
"       </td>",
"       <td>",
"        Isolated atrial amyloidosis of aging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolactin/Apro",
"       </td>",
"       <td>",
"        APro",
"       </td>",
"       <td>",
"        Prolactinomas/aging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin",
"       </td>",
"       <td>",
"        Alns",
"       </td>",
"       <td>",
"        Local amyloid complicating use of the insulin pump",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Cytoskeleton-related",
"       </td>",
"       <td>",
"        Gelsolin",
"       </td>",
"       <td>",
"        AGel",
"       </td>",
"       <td>",
"        Hereditary neuropathic amyloid associated with corneal lattice dystrophy and cutis laxa (Meretoja syndrome)",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keratin",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        Cutaneous amyloid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keratoepithelin",
"       </td>",
"       <td>",
"        AKer",
"       </td>",
"       <td>",
"        Hereditary granular, lattice, and avellino corneal dystrophies",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Does not yet have nomenclature designated.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Mucchiano GI, Haggqvist B, Sletten K, Westermark P, J Pathol 2001; 193:270.",
"       </li>",
"       <li>",
"        de Sousa MM, Vital C, Ostler D, et al, Am J Pathol 2000; 156:1911.",
"       </li>",
"       <li>",
"        Benson MD, Liepnieks JJ, Yazaki M, et al, Genomics 2001; 72:272.",
"       </li>",
"       <li>",
"        Hoppener JW, Ahren B, Lips CJ. N Engl J Med 2000; 343:411.",
"       </li>",
"       <li>",
"        Kiuru S, Amyloid 1998; 5:55.",
"       </li>",
"       <li>",
"        Klintworth GK. Front Biosci 2003; 8:d687.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_1_4125=[""].join("\n");
var outline_f4_1_4125=null;
var title_f4_1_4126="Contents: Psychotic disorders";
var content_f4_1_4126=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?41/24/42381\">",
"       Psychiatry",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Psychotic disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Psychotic disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Antipsychotic medications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/24/7562\">",
"           First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/40/6793\">",
"           Guidelines for prescribing clozapine in schizophrenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/9/30871\">",
"           Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/10/15530\">",
"           Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/4/3145\">",
"           Delusional parasitosis: Epidemiology, clinical presentation, assessment and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/58/28583\">",
"           Overview of psychosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/39/17014\">",
"           Postpartum psychosis: Epidemiology, clinical manifestations, and assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/34/1575\">",
"           Treatment of delusional parasitosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/62/29670\">",
"           Treatment of postpartum psychosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Schizophrenia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/3/2105\">",
"           Anxiety in schizophrenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/21/25944\">",
"           Depression in schizophrenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/35/29241\">",
"           Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/45/44760\">",
"           Pharmacotherapy for schizophrenia: Side effect management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/44/8904\">",
"           Psychosocial interventions for schizophrenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/15/1270\">",
"           Psychosocial interventions for severe mental illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/47/34552\">",
"           Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/37/20057\">",
"           Schizophrenia: Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-F91FB7E9BE-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f4_1_4126=[""].join("\n");
var outline_f4_1_4126=null;
var title_f4_1_4127="Bleeding esoph varix Endosc";
var content_f4_1_4127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bleeding esophageal varix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A jet of active bleeding is visible from an esophageal varix in a patient with cirrhosis. Bleeding from esophageal varices can be massive.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rome Jutabha, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_1_4127=[""].join("\n");
var outline_f4_1_4127=null;
